Biomarkers for treatment outcome in newly diagnosed epilepsy by Auce, P
1 
 
UNIVERSITY OF LIVERPOOL 
Biomarkers for 
treatment outcome in 
newly diagnosed 
epilepsy 
Thesis submitted in accordance with the requirements of the 
University of Liverpool for the degree of Doctor in Philosophy by 
Pauls Auce 
 
 
 
 
September 2016 
  
2 
 
Table of contents 
  
Table of contents ................................................................................................................... 2 
Abbreviations ........................................................................................................................ 8 
Abstract .............................................................................................................................. 10 
Declaration .......................................................................................................................... 11 
Acknowledgments ............................................................................................................... 12 
Oral and poster presentationss ........................................................................................... 13 
1.0. Introduction.................................................................................................................. 14 
1.1.0. Epilepsy overview ...................................................................................................... 14 
1.2.0. Clinical features of newly diagnosed epilepsy .......................................................... 17 
1.3.0. Prognostic factors related to newly diagnosed epilepsy .......................................... 19 
1.3.1. Gender ....................................................................................................................... 20 
1.3.2. Age of onset .............................................................................................................. 22 
1.3.3. Time from first seizure to diagnosis .......................................................................... 25 
1.3.4. Neurological sequelae / abnormal exam .................................................................. 26 
1.3.5. Seizure type ............................................................................................................... 27 
1.3.6. Epilepsy syndrome .................................................................................................... 30 
1.3.7. Aetiology ................................................................................................................... 31 
1.3.8. Total number of pre-treatment seizures .................................................................. 32 
1.3.9. Imaging CT/MRI ......................................................................................................... 33 
  
3 
 
1.3.10. Electroencephalography ......................................................................................... 37 
1.3.11. Febrile seizures ........................................................................................................ 38 
1.3.12. Family history of epilepsy ....................................................................................... 39 
1.3.13. Treatment history ................................................................................................... 41 
1.3.14. Learning Disabilities ................................................................................................ 42 
1.3.2 Prognostic research .................................................................................................... 43 
1.4.0. Description of important cohorts ............................................................................. 45 
1.4.1. Department of Veterans Affairs multicentre studies (VA – 118 and VA – 264) ....... 45 
1.4.2. Glasgow ..................................................................................................................... 46 
1.4.3. The Italian Collaborative Group for the Study of Epilepsy........................................ 47 
1.4.4. The National General Practice Study of Epilepsy (NGPSE) ....................................... 48 
1.4.5. SANAD study ............................................................................................................. 49 
1.4.6. Rochester, Minnesota study ..................................................................................... 50 
1.5.0. Pharmacology of epilepsy and impact of genetic variation ...................................... 51 
1.5.1. Drug efflux transporters ............................................................................................ 52 
1.5.2. Sodium channels ....................................................................................................... 57 
1.5.3. Gamma-aminobutyric acid system ........................................................................... 59 
1.5.4. Hepatic metabolism .................................................................................................. 60 
1.5.5. Adverse events .......................................................................................................... 62 
1.6. Newly diagnosed epilepsy and GWAS .......................................................................... 63 
  
4 
 
1.7. Methodological aspects ............................................................................................... 64 
2.0. Aims and objectives of this work ................................................................................. 67 
3.0. Methods ....................................................................................................................... 69 
3.1. General overview of EpiPGX project ............................................................................ 69 
3.2. Ethical aspects .............................................................................................................. 74 
3.3. EpiPGX Work Package 2: Detailed description............................................................. 74 
3.3.1. Sample size ................................................................................................................ 74 
3.3.2. Cohort assembly ........................................................................................................ 74 
3.3.3. Data collection and phenotyping .............................................................................. 75 
3.3.4. Phenotype definitions and their application ............................................................ 76 
3.3.4. Data transfer ............................................................................................................. 82 
3.4. Statistical and genetic analysis ..................................................................................... 86 
3.4.1. Phenotype derivation ................................................................................................ 86 
3.4.2. Statistical analysis of clinical factors associated with treatment outcome .............. 88 
3.4.3. Assessment of impact of study methodology ........................................................... 89 
3.4.4. Genotyping ................................................................................................................ 91 
3.4.5. GWAS QC and imputation ......................................................................................... 92 
4.0. Results .......................................................................................................................... 96 
4.1. Descriptive statistics ..................................................................................................... 96 
4.1.1. Remission .................................................................................................................. 97 
  
5 
 
4.1.2. Age at diagnosis ...................................................................................................... 100 
4.1.3. Gender ..................................................................................................................... 102 
4.1.4. Epilepsy type ........................................................................................................... 104 
4.1.5. Pre-treatment seizure count ................................................................................... 107 
4.1.6. Seizure type ............................................................................................................. 111 
4.1.7. Investigations .......................................................................................................... 114 
4.1.8. Family history .......................................................................................................... 115 
4.1.9. Neurological examination / sequelae ..................................................................... 117 
4.1.10. Febrile convulsions ................................................................................................ 117 
4.1.11. Learning disabilities ............................................................................................... 118 
4.1.12. Time from first seizure to first AED ....................................................................... 119 
4.1.13. First well-tolerated anti-epileptic drug ................................................................. 121 
4.2. Logistic regression ...................................................................................................... 123 
4.3. Cox regression ............................................................................................................ 129 
4.4. Impact of methodology .............................................................................................. 136 
4.4.1. Cohort ...................................................................................................................... 136 
4.4.2. Effect of method of case ascertainment ................................................................. 137 
4.4.3. Period of observation .............................................................................................. 138 
4.4.4. Duration of remission .............................................................................................. 141 
4.4.5. Assessment of effect of definition of remission ..................................................... 142 
  
6 
 
4.4.6. Impact of data transformation and upload ............................................................ 143 
4.5. Genome-wide association analysis ............................................................................ 145 
4.5.1. Description of GWAS ............................................................................................... 145 
4.5.2. Sample size calculation ........................................................................................... 145 
4.5.3. Results of GWAS ...................................................................................................... 147 
5.0. Discussion ................................................................................................................... 163 
5.1. Study of clinical factors .............................................................................................. 163 
5.1.1. Remission ................................................................................................................ 163 
5.1.2. Age at diagnosis ...................................................................................................... 165 
5.1.3. Gender ..................................................................................................................... 166 
5.1.4. Epilepsy type ........................................................................................................... 166 
5.1.5. Neurological examination / sequelae ..................................................................... 167 
5.1.6. Time from first seizure to first AED ......................................................................... 168 
5.1.7. Investigations .......................................................................................................... 168 
5.1.8. Pre – treatment seizure count ................................................................................ 169 
5.1.9. Seizure type ............................................................................................................. 170 
5.1.10. First well-tolerated antiepileptic drug .................................................................. 171 
5.2. Logistic and Cox regression ........................................................................................ 172 
5.3. Methodology .............................................................................................................. 174 
5.3.1. Origin of cohort and method of case ascertainment .............................................. 174 
  
7 
 
5.3.2. Length of observation ............................................................................................. 176 
5.3.3. Duration of remission .............................................................................................. 177 
5.3.4. Impact of data transfer ........................................................................................... 178 
5.4. Genome based biomarkers for treatment response in newly diagnosed epilepsy ... 181 
5.4.1. Phenotypes .............................................................................................................. 181 
5.4.2. Role of adjustment for clinical and non-clinical factors in genomic studies .......... 182 
5.4.3. Sample size .............................................................................................................. 183 
5.4.4. Results of GWAS ...................................................................................................... 183 
5.5. Limitations of the study and suggestions regarding future research ........................ 184 
6.0. Conclusions................................................................................................................. 189 
References ......................................................................................................................... 191 
Appendix 1......................................................................................................................... 212 
Appendix 2......................................................................................................................... 233 
Appendix 3......................................................................................................................... 239 
Appendix 4......................................................................................................................... 249 
Appendix 5......................................................................................................................... 253 
Appendix 6......................................................................................................................... 264 
Appendix 7......................................................................................................................... 279 
  
  
  
8 
 
Abbreviations 
ABCB1 ATP-Binding Cassette Subfamily B Member 1 
ABCC1 ATP Binding Cassette Subfamily C Member 1 
ABCC2 ATP Binding Cassette Subfamily C Member 2 
AED Antiepileptic Drug 
Australia TheRoyal Melbourne Hospital / The University of Melbourne 
cohort 
CAROLE A multicenter, prospective, and observational study (CAROLE; 
i.e., Coordination Active du Réseau Observatoire Longitudinal 
de l'Epilepsie) of patients with newly diagnosed unprovoked 
seizures 
CBZ Carbamazepine 
CI Confidence Interval 
CLCN-2 Chloride Voltage-Gated Channel 2 
CPS Complex Partial Seizure 
CT Computerised Tomography 
CYP2C9 Cytochrome P450 Family 2 Subfamily C Member 9 
EEG Electroencephalography 
EKUT Eberhard-Karls-Universität Tübingen 
EPHX1 Epoxide Hydrolase 1 
EpiPGX Epilepsy Pharmacogenomics: delivering biomarkers for clinical 
use 
GABA Gamma-Aminobutyric Acid 
Glasgow Epilepsy Unit, Western Infirmary / University of Glasgow cohort 
GWAS Genome-Wide Association Study 
ILAE International league against epilepsy 
IQR Interquartile Range 
JME Juvenile Myoclonic Epilepsy 
LCSB Luxembourg Centre for Systems Biomedicine, University of 
Luxembourg  
MAF Minor allele frequency 
MESS Multicentre Study of Early Epilepsy and Single Seizures 
MRI Magnetic Resonance Imaging 
NGPSE National General Practice Survey of Epilepsy 
NICE National Institute for Health and Care Excellence 
P-gp P-glycoprotein 
RCSI Royal College of Surgeons in Ireland 
  
9 
 
RCT Randomized Clinical Trial 
rsid Reference SNP cluster ID 
SANAD Standard Versus New Antiepileptic Drug trial  
SCN1A Sodium Voltage-Gated Channel Alpha Subunit 1 
SCN2A Sodium Voltage-Gated Channel Alpha Subunit 2 
SCN3A Sodium Voltage-Gated Channel Alpha Subunit 3 
SCN8A Sodium Voltage-Gated Channel Alpha Subunit 8 
SGTC Secondarily Generalized Tonic-Clonic seizure 
SMEI Severe Myoclonic Epilepsy of Infancy 
SNP Single Nucleotide Polymorphism 
UCL University College London cohort 
ULB Hôpital Erasme, Université Libre de Bruxelles cohort 
ULIV University of Liverpool cohort 
VA Veterans Affairs Healthcare System 
VPA Valproate 
WP2 EpiPGX Work package 2 
  
  
10 
 
Abstract 
Introduction and aims 
Epilepsy is a common neurological condition and around 25% of patients are resistant to 
treatment with currently available drugs (Brodie et al., 2012). Currently there is only a 
limited ability to predict treatment outcome and no genome based biomarkers for 
treatment efficacy. The main aim for this thesis was to investigate clinical and genome 
based biomarkers for treatment response in newly diagnosed epilepsy as well as explore 
methodological aspects related to the assembly of a large scale international research 
cohort. 
Methods 
An EU-funded project entitled “Epilepsy Pharmacogenomics: delivering biomarkers for 
clinical use (EpiPGX)” was undertaken by a pan-European research consortium to 
explore genome-based biomarkers that could be used to individualize treatment of 
epilepsy. University of Liverpool led work on newly diagnosed epilepsy. Work presented 
in this thesis is solely based on this project. Cases with newly diagnosed epilepsy were 
either de-novo phenotyped or data was transferred from existing clinical databases. 
Analysis of clinical covariates using logistic and Cox regression, and a subsequent GWAS 
were performed. Methodological and data transfer quality aspects were assessed 
separately using descriptive statistics and Cohen's kappa and Lin’s coefficients. 
Results and Conclusion 
The following clinical factors were significantly associated with twelve month remission 
after application of first well tolerated antiepileptic drug: age at diagnosis, abnormal 
neurological examination, GTCs-only, epilepsy type, number of seizures before the 
treatment, MRI and EEG results. Heterogeneity of outcomes between cohorts, effect of 
mode of cases ascertainment was also demonstrated. Data quality assessment showed 
that simple variables can be robustly transferred between data bases whereas more 
complicated variables have a potential for introduction of bias. A GWAS was carried out 
on newly diagnosed cases with focal epilepsy and failed to identify any SNPs significantly 
associated with treatment outcome.  
Clinical factors associated with treatment outcome potentially can be useful in daily 
clinical practice when assessing patients with newly diagnosed epilepsy. Large scale 
multi-centre studies utilizing historical retrospective data are possible but prospective 
recruitment should be preferred. Sound methodology and quality assurance methods 
should be applied in future epilepsy pharmacogenetic research particularly involving 
large multi-centre cohorts. 
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1.0. Introduction 
 
1.1.0. Epilepsy overview 
Epilepsy is characterized by the recurrence of unprovoked seizures caused by 
excessive electrical discharges generated by hyper – synchronous and hyperexcitable 
neuronal aggregates or networks. Current clinical definition requires at least two 
unprovoked seizures 24 hours apart or a single seizure and risk of recurrence at least 
60%, or diagnosis of a specific epilepsy syndrome (Fisher et al., 2014).   
Prevalence of active epilepsy in Europe has been estimated to range between 3.3 – 
7.8 per 1000 inhabitants (Forsgren et al., 2005). It not only has a significant social and 
health effect on the affected individual, but also has a significant economic burden to 
society costing around 13.8 billion euros per year for the whole Europe (Olesen et al., 
2012). Seizure control is by far the main aim of epilepsy treatment. At the moment, 
modern medical science has no means of achieving full seizure remission in all patients 
with epilepsy. Already back in 1881 in his book “Epilepsy and other chronic convulsive 
diseases: their causes, symptoms & treatment” Gowers described a relatively good 
prognosis for epilepsy with around 70% of patients experiencing “arrest” of their 
seizures when treated with bromides (Gowers, 1885). In a later hospital-based study 
comprised from mixed patient population reported in 1965 by Rodin and co-authors two 
year seizure freedom were observed only in 32.2 % (n=29) and a five year seizure 
freedom in 16.6 % (n=15) of their patients. When authors compared their results with 
earlier studies they concluded that available newer anticonvulsants, have failed to 
improve the long term seizure control (Rodin et al., 1965). This difference might be 
explained by differences in the case ascertainment. A later study from United Kingdom 
recruiting patients with a definite epilepsy from general practice between 1984 and 
1987 showed a five year terminal remission on 9 years’ follow up in the 54 % of subjects 
(Cockerell et al., 1995). A more recent study of newly diagnosed cases demonstrated 
that 68 % patients were seizure free at their last visit and 52 % had ten year continuous 
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remission by the end of the study (Brodie et al., 2012). In conclusion treatment results 
for newly diagnosed epilepsy have not changed much with the time despite increasing 
numbers of AED (Antiepileptic Drugs) available over the last 20 years (Schmidt and 
Sillanpää, 2012, Shorvon and Luciano, 2007).  
 Importance of achieving full seizure freedom should not be underestimated. Seizure 
freedom not only reduces social stigma and lifts specific restrictions on daily activities, 
but also lowers mortality (Ridsdale et al., 2011, Salanova et al., 2002). Efficacy of 
treatment is just one side of the coin; there is also a tolerability aspect to the treatment. 
A survey looking at the impact of the disease from the patient’s perspective, ranked by 
patients themselves, demonstrated that fewer side effects was one of their top 
priorities (Fisher et al., 2000). Currently ability to reliably predict both the efficacy and 
occurrence of most side effects is limited. There are great hopes that better 
understanding of genetics of epilepsy and drug response will provide us with such tools 
in future as well as expand our understanding of disease process itself thus potentially 
aiding in the quest for new treatment options. 
Epilepsy is a highly heterogeneous disorder; with a complex syndrome classification 
relying on variety of factors like seizure type, age at onset, imaging and EEG results. With 
the evolution of genome based technology, genetic factors are due to play a more 
prominent role in the classification (Thomas and Berkovic, 2014). It has already been 
shown that common variants collectively might have a significant effect on phenotypic 
variation in epilepsy (Speed et al., 2014b).  
AEDs at the moment are the mainstay of treatment, hence it is important to develop 
better understanding of factors related to treatment efficacy. Treatment outcome 
modelling in newly diagnosed epilepsy based on the Standard Versus New Antiepileptic 
Drug study (SANAD), utilising routine and recognised clinical factors, only have limited 
ability to predict outcomes (Bonnett et al., 2012, Bonnett et al., 2014a, Bonnett et al., 
2014b). This fact opens the question if there are any additional factors determining 
treatment results? In newly diagnosed epilepsy, response to the initial treatment is a 
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predicting factor for development of further drug resistance and only a limited number 
of patients later develop drug resistance after initially responding (Kwan and Brodie, 
2000, Brodie et al., 2012). This pattern could potentially indicate that treatment 
response in newly diagnosed epilepsy is an important part of the general epilepsy 
phenotype. More recently, data from a prospective genome – wide association study 
(GWAS) has shown that no common variant explains more than 4.4% variation of 
outcome suggesting that it is influenced by multiple and complex genetic factors and 
that biological pathways should be investigated (Speed et al., 2014a). Genome based 
biomarkers in the future will likely play a role in prognosticating treatment outcome in 
epilepsy, but it is unlikely it will be a single test, but rather integration of large individual 
genomic data encompassing relevant pathways with clinical predictors. 
Pharmacogenetics as a term was first time coined by Vogel back in 1959.  It “is 
defined as the study of variability in drug responses attributed to hereditary factors in 
different populations” (Roses, 2001). Response is not only efficacy of applied treatment, 
but also occurrence of any adverse effects.  
At the moment, as pharmacogenetics in epilepsy is largely limited to preventative 
testing for a few serious cutaneous adverse reactions to carbamazepine (CBZ), there are 
no genetic markers predicting AED efficacy It has been reliably demonstrated that pre – 
treatment testing for HLA-B*1502 allele in an appropriate ethnic group  is associated 
with significant reduction of Stevens–Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) (Chen et al., 2011). In the meantime it has also been shown that the 
introduction of genetic screening alone is insufficient to reduce rates of SJS and TEN as 
prescribers would substitute carbamazepine with other aromatic AEDs which do not 
require genetic testing. This emphasizes the important role of education and 
dissemination of information. (Chen et al., 2014b).  
Utilization of genetic markers to predict treatment results is part of a wider concept 
of precision medicine. Precision medicine aims to tailor targeted treatment based on all 
factors that distinguish a given patient from others with a similar presentation (Jameson 
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and Longo, 2015). A first example of this approach applied to epilepsy is Migrating 
Partial Seizures of Infancy (MPSI) due to KCNT1 mutation and its treatment with 
quinidine.  MPSI has a heterogeneous genetic background, but mutations in KCNT1 are 
the most common underlying known genetic cause; a case report has shown that 
quinidine, a partial agonist of KCNT1 but not an established anticonvulsant, could 
potentially be a valuable treatment option in those cases (Milligan et al., 2014, Bearden 
et al., 2014). After an initial case report and basic science exploration of concepts, 
further larger studies are required to substantiate initial reports. 
1.2.0. Clinical features of newly diagnosed epilepsy 
 
Epilepsy is a clinical diagnosis and relies less on para–clinical disciplines like imaging 
and neurophysiology. National Institute for Health and Care Excellence (NICE) has 
advised that patients should be seen by a specialist and diagnosis is based on a 
constellation consisting of a description of attacks and other symptoms present, while 
EEG and neuroimaging serve as supplementary methods (NICE, 2012).  However, both 
neuroimaging and EEG play an important role in stratifying the risk of recurrence after 
the first seizure and in the case of relevant detected abnormalities might add enough 
supportive weight to allow a diagnosis of epilepsy after only one seizure (Fisher et al., 
2014, Krumholz et al., 2015). Probably the most important role of neuroimaging (CT or 
MRI) is to elucidate underlying structural lesions. From the pharmacological treatment 
selection point of view results of neuroimaging have no direct effect on the selection of 
the anticonvulsant, but if there is an identified structural abnormality it might have to be 
approached separately, depending on the type. EEG has a role in defining epileptic 
syndrome and hence might influence selection of an anticonvulsant. Figure 1 
summarizes clinical approach to patient presenting with first seizure. 
Initial treatment is a monotherapy with a single AED, in case of focal onset seizures it 
is either carbamazepine, lamotrigine or levetiracetam, whereas in generalised epilepsy 
valproate or lamotrigine (NICE, 2012, Network, 2015). 
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Figure 1. Flowchart illustrating clinical approach in case of first seizure. 
First seizure 
 Establish that the event was epileptic in nature. 
Paroxysmal events of loss of consciousness due to other 
causes (eg. syncope) are excluded from further steps. 
 History and examination 
 Collateral eyewitness history 
 Imaging studies (MRI or CT) 
o Aim to elucidate structural lesion potentially 
related to seizure or lesion requiring separate 
management (eg. neoplastic lesion) 
 EEG 
 Other tests as clinically required 
Appraisal of results of 
investigations and clinical 
data 
Risk of recurrence More than 60 % 
Offer to start treatment 
with AED 
Less than 60 % 
Observation, treatment 
offered after second seizure 
Investigations 
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1.3.0. Prognostic factors related to newly diagnosed epilepsy 
 
Historically several clinical factors have been investigated for their links with 
treatment outcome in newly diagnosed epilepsy. The need to adjust analysis for clinical 
covariates in GWAS pharmacogenetic studies is neither clear nor well assessed. A recent 
large pharmacogenetic study elected to carry out two versions of analysis; in one the 
authors adjusted for clinical covariates whereas in the other, they did not (Speed et al., 
2014a). The authors reasoned that if genetic factors influenced prognosis via clinical 
factors then adjustment might lead to failure to detect association, whereas lack of 
adjustment might reduce power. This study did not identify any associated (Single 
Nucleotide Polymorphisms) SNPs with GWAS significance, but all three loci with 
suggestive evidence had a similar effect size in both adjusted and unadjusted analysis. 
They suggested that association was therefore not mediated via clinical factors.  
Based on data from previous analyses carried by Bonnett et al (Bonnett et al., 2012, 
Bonnett et al., 2014b) on the SANAD trial dataset, the following covariates have been 
selected for more in-depth description: 
 Gender 
 Febrile seizures 
 Family history of epilepsy 
 Imaging 
 Treatment history 
 Age at onset 
 Time from first seizure to diagnosis 
 Neurological examination 
 Total number of pre – treatment seizures 
 EEG 
 Seizure type 
 Epilepsy syndrome 
 Aetiology 
 Learning disabilities  
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1.3.1. Gender 
Several epidemiological studies have shown a gender difference in the incidence of 
epilepsy; with males being affected more than females (Benn et al., 2008, Christensen et 
al., 2007, Lavados et al., 1992, Hauser et al., 1993). However, a systematic review and 
meta-analysis carried out by Kotsopoulos et al demonstrated showed no statistically 
significant difference in the incidence of epilepsy between genders, albeit with males 
having a slightly higher incidence (Kotsopoulos et al., 2002). Differences between gender 
in relation to epilepsy syndromes have been also reported. A study from Denmark based 
on the International League Against Epilepsy (ILAE) 1989 classification showed no overall 
difference in localization related epilepsies, but generalized epilepsy was observed more 
frequently in females (Christensen et al., 2005). The most frequent subtype of the 
localization related epilepsy was cryptogenic temporal lobe epilepsy which was more 
often observed in females, but males suffered more from the symptomatic localization 
related epilepsy. Juvenile myoclonic and juvenile absence epilepsy were more common 
in females. 
Newly diagnosed epilepsy in general has a good prognosis with majority of patients 
experiencing prolonged periods of remission (Cockerell et al., 1995, Collaborative Group 
for the Study of, 1992). A landmark longitudinal study from Rochester, Minnesota 
utilizing a record linkage system from Mayo Clinic included 618 local residents of the 
county diagnosed with epilepsy between 1935 and 1974. Annegers et al observed that 
newly diagnosed epilepsy had a better prognosis for long-term remission than expected. 
One of the covariates assessed by the study was gender; females had slightly better 
remission rates than males initially, but in a long term differences were minimal 
(Annegers et al., 1979). Several later studies have failed to show any significant role of 
gender in relation to remission in newly diagnosed epilepsy (Beghi and Tognoni, 1988, 
Shorvon and Reynolds, 1982, MacDonald et al., 2000). Similarly, a prospective hospital 
based cohort of newly-diagnosed patients from Glasgow demonstrated no association of 
gender with the development of treatment resistant epilepsy (Hitiris et al., 2007). A 
study specifically investigating treatment outcomes for the newly-diagnosed patients in 
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the geriatric population also showed no significant difference in outcomes in relation to 
gender (Besocke et al., 2013). In the case of generalized epilepsies, a study from 
Glasgow showed that gender had no association with treatment outcome in non-
paediatric newly-diagnosed idiopathic epilepsy (Mohanraj and Brodie, 2007).  
Treatment outcome in newly-diagnosed epilepsy does not have a uniform and binary 
pattern. It has several different patterns: early or delayed remission, intermittent 
relapses and remissions, or continued persistence of seizures (Brodie et al., 2012). In a 
predominantly adult retrospective study from two tertiary epilepsy centres in Italy, 
specifically investigating prognostic factors for early versus late remission in patients 
with newly-diagnosed epilepsy, about 10 % of patients had a late remission and the only 
predictive factor for it in a multivariate analysis was more than 6 partial seizures before 
starting treatment; gender did not have any significance (Del Felice et al., 2010). 
The SANAD trial is by far the largest multicentre randomised open-label controlled 
study in epilepsy. Arm A recruited mostly newly–diagnosed patients for whom the 
clinician deemed carbamazepine to be the first-line treatment. Thus an overall majority 
of patients had focal epilepsy (Marson et al., 2007a). A post hoc subgroup analysis based 
on the focal epilepsy arm (arm A) utilizing multivariable regression modelling identified 
several significant risk factors for time to treatment failure and 12 month remission. 
Bonnett et al demonstrated that females were more likely to fail due to unacceptable 
adverse effects, but no significant gender difference was seen for failure due to 
inadequate seizure control; men had a longer time to 12 month remission, but were 
marginally more likely to achieve a remission. (Bonnett et al., 2012). SANAD arm B was a 
separate un-blinded randomised multicentre study, which investigated effectiveness of 
valproate, lamotrigine and topiramate for generalised and unclassifiable epilepsy 
(Marson et al., 2007b). Contrary to similar analysis carried out in arm A, prognostic 
modelling showed that gender had no significant association with time to 12 and 24 
month remission in generalised and unclassifiable epilepsy (Bonnett et al., 2014b). 
According to a further prognostic model involving the whole SANAD dataset, and looking 
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at the time to 12 month remission after failing the first anticonvulsant, men were again 
more likely to achieve 12 month remission (Bonnett et al., 2014a).  
In summary, data from the literature are not straight-forward and that may be due to 
variety of reasons, particularly reporting bias and heterogeneity of disease and 
population studied. Gender likely has a small role, at best, in determining treatment 
outcome in newly diagnosed epilepsy. 
1.3.2. Age of onset 
In the developed world incidence of epilepsy has two peaks, one in early life and the 
other one in the elderly population; there are also some suggestions of a change in 
temporal trends over the time with reduction of the incidence in childhood and a rise of 
epilepsy numbers in the older age group (Neligan et al., 2012). Age groups differ by 
more characteristic epileptic syndromes and prevalent aetiology. Elderly patients with 
late onset epilepsy tend to have more symptomatic localization related and less 
idiopathic generalized epilepsy. Tumours and cerebrovascular disease are more 
common aetiologies of elderly onset epilepsy, whereas hippocampal sclerosis is 
observed less commonly than in both younger patients and elderly patients with early 
onset (Stefan et al., 2014). Hippocampal sclerosis (HS) has been shown to have worse 
treatment outcome compared to other causes of symptomatic focal epilepsy including 
post stroke epilepsy (Stephen et al., 2001).  
Current literature regarding age of onset and treatment outcome in newly diagnosed 
epilepsy is contradictory. Some studies have observed no effect or a weak effect of age 
on treatment outcome (Shafer et al., 1988, Collaborative Group for the Study of, 1992, 
Cockerell et al., 1997, MacDonald et al., 2000). As already described earlier those studies 
have a variety of limitations, for example NGPSE included both treated and untreated 
cases whereas some patients in the major multicentre collaborative study from Italy 
(Collaborative Group for the Study of, 1992) were started on treatment after a first 
seizure if clinician felt treatment was required. Several hospital based cohorts have 
failed to demonstrate associations between age and treatment outcome in newly 
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diagnosed epilepsy (Elwes et al., 1984, Gasparini et al., 2013, Zhang et al., 2013, Shorvon 
and Reynolds, 1982, Su et al., 2013). These studies are heterogeneous by both 
population and their objectives. Furthermore, they have rather small sample size and 
they are not all prospective. Additionally, these studies have a wide time frame when 
they were conducted, thus anticonvulsant selection and treatment strategies might 
differ.  
It has been suggested by Glasgow group that both elderly and young people have a 
more favourable response (Mohanraj and Brodie, 2006). Moreover in the case of newly 
diagnosed idiopathic generalized epilepsy in a non-paediatric setting, age has no 
influence on treatment outcome (Mohanraj and Brodie, 2007). Post hoc modelling 
based on SANAD study has suggested that older age has in general better prognosis in 
focal epilepsy (Bonnett et al., 2012) although this relationship is rather a complex. For 
time to 12 month remission in focal epilepsy, age showed a U-shaped relationship, with 
younger and older patients tending to respond more favourable. For time to failure, 
older patients had a higher chance to fail due to unacceptable adverse events and less 
due to inadequate seizure control. Younger patients had higher chance for treatment 
failure due to lack of effect and less due to poor tolerability (Bonnett et al., 2012). In a 
similar analysis based on SANAD arm B, where valproate was the standard of treatment, 
age had no predictive role either for time to remission or treatment failure (Bonnett et 
al., 2014b). The elderly also had better prospects for remission on a second AED after 
failure of the first drug (Bonnett et al., 2014a).  
Observations from studies conducted specifically in elderly population also have 
shown in general good prognosis (Stephen et al., 2006, Besocke et al., 2013). Stephen et 
al demonstrated in general favourable outcome in a hospital based study with 62% of 
elderly patients becoming seizure free on a first drug and complete seizure freedom 
obtained in 79% of patients (Stephen et al., 2006). Similarly favourable outcome results 
were reported in a different study from Argentina, although additionally they suggested 
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that elderly patients might be more prone to medication adverse effects (Besocke et al., 
2013).  
A complex picture can be observed in the case of paediatric epilepsy where studies 
have shown different effects of age. These range from a significant association of 
younger age with a worse course of epilepsy (Geerts et al., 2010), to no difference if age 
of onset is above or below 6 years in regards of terminal remission of epilepsy (Sillanpää 
et al., 2014) or onset age 5 to 9 being significantly associated with 2 year remission (Berg 
et al., 2001).  
Studies in newly diagnosed epilepsy are different from ones looking at established 
epilepsy. One of the differences is duration of disease at the moment of inclusion in the 
study and history of exposure to anticonvulsants. Age at onset of the condition is one of 
the factors from natural history that influences length of the treatment time with 
younger patients potentially having longer duration of epilepsy.   
A study consisting of a mixture of newly diagnosed and established epilepsy cases 
showed that duration of epilepsy had a negative effect on response to newly 
administered AEDs (Schiller and Najjar, 2008). As already shown earlier, epilepsy has a 
complex course and often it involves mixtures of remissions and relapses even in the 
case of intractable disease. Duration of intractability has been shown to be negatively 
linked to chances of remission in this group, but had no association with potential for 
relapse in previously drug resistant patients that had entered remission (Callaghan et al., 
2011). A similar hospital-based retrospective study involving patients with treatment 
resistant epilepsy showed that age of onset is not a significant predictor for treatment 
outcome (Selwa et al., 2003). In this study patients were young and from a very specific 
patient population who had been evaluated for epilepsy surgery, but found out not to 
be candidates for it. Thus, they were, by definition, treatment resistant but otherwise 
relatively young and healthy. In another hospital based surgical cohort study that 
assessed time to failure of the second anticonvulsant, younger age was shown to be 
strongly associated with longer latency period and past history of remission; age at 
  
25 
 
onset was also an independent factor associated with hippocampal atrophy, thus 
demonstrating the complex interaction between covariates (Berg et al., 2003). Research 
based on different cohorts of patients with mesial temporal lobe sclerosis also has 
controversial results; several studies have suggested early disease onset is linked to 
worse outcome (Kim et al., 1999, Varoglu et al., 2009, Sànchez et al., 2014) but at the 
same time, it has also been reported as associated with good seizure outcome (Kumlien 
et al., 2002).  
As a covariate, age at onset has broad interactions with other factors such as epilepsy 
syndrome, seizure type, treatment duration, tolerability of drugs (comorbid conditions 
and their treatments), as well as specific disease aetiologies. Furthermore, age at onset 
can either be measured at the onset of first or second seizure or at the formal diagnosis. 
For example, a higher pre –treatment seizure frequency could potentially lead to earlier 
diagnosis and treatment, whereas some patients with rare seizures and low pre –
treatment density might be diagnosed later in life. In summary, older age at onset of 
epilepsy confers better prognosis for treatment responsiveness. 
1.3.3. Time from first seizure to diagnosis 
Time from first seizure to diagnosis is influenced by several factors, some of which 
are related to epilepsy while others to health and social care as well as to the individual. 
For example, diagnostic delay might be due to over-reliance on investigations rather 
than accepting that epilepsy is a clinical diagnosis. A study exploring diagnostic delay for 
early onset childhood epilepsy showed that some cases were delayed due to over-
reliance on the EEG (Berg et al., 2014). Thus, one can speculate that an abnormal EEG in 
childhood might lead to earlier treatment and shorter time between first seizure and 
treatment, while a normal EEG could potentially lead to a more ‘watching and waiting’ 
approach. There is also some overlap of clinical factors predicting earlier second seizure 
thus potentially a shorter time to diagnosis. Some of them are also potentially 
associated with treatment outcome once treatment has been started. The Multicentre 
Study of Early Epilepsy and Single Seizures (MESS) demonstrated that abnormal EEG, 
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neurological disorder and a higher number of seizures before randomisation were all 
significant factors predicting recurrent seizures (Kim et al., 2006a). In general, time from 
first seizure till diagnosis of epilepsy is very variable; it can be a single day in some cases, 
up to several decades. CAROLE study showed that roughly 59 % of patients will be 
diagnosed within the first year, 12 % in the second year and as many as 15 % more than 
five years after the initial seizure (Jallon et al., 2001).  
Several studies have found no association between the time from the first seizure to 
diagnosis and either remission or treatment outcome in newly diagnosed epilepsy 
(MacDonald et al., 2000, Collaborative Group for the Study of, 1992, Park et al., 2014, 
Sillanpää, 1993). In a hospital based cohort of newly diagnosed epilepsy, duration of pre 
– treatment epilepsy was associated with a development of treatment resistance in the 
univariate analysis, but lost its significance in multivariate analysis (Hitiris et al., 2007).  
Time from the first seizure to diagnosis is closely related to time from first seizure to 
randomization, which has been assessed in post hoc analysis based on SANAD trial data. 
Results of this analysis showed that it has a role in the case of focal epilepsy. A longer 
duration between the first seizure and randomisation increases chances of remission 
but more seizures before treatment reduces it (Bonnett et al., 2012).  
1.3.4. Neurological sequelae / abnormal exam 
Neurological examination is performed in epilepsy with a goal to identify the 
sequeleae of previous neurological insults, or an on-going CNS disorder, for example 
brain tumour. However, damage of the central nervous system does not always produce 
focal neurological signs, and focal neurological signs do not always have a clear 
explanation. In epilepsy, a significant proportion of patients (10 – 15 %) has abnormal 
neurological examination (Okuma and Kumashiro, 1981, Heller et al., 1995, 
Collaborative Group for the Study of, 1992). It has also been demonstrated that 
neurological examination does not always pick up serious causes of seizures. A study 
from Finland has shown positive correlation between examination and changes on the 
CT, but not all patients with tumours had focal signs (Reinikainen et al., 1987). In 
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epilepsy research, there is a risk that hospital-based cohorts over-represent the 
proportion of patients with focal neurological signs or learning disabilities, particularly in 
historical studies where a significant proportion of patients was institutionalised. 
Furthermore, in cases of abnormal neurological examination one should bear in mind 
the link between it and underlying CNS disorder. Several studies have reported 
neurological symptoms as a negative predictor for remission in epilepsy (Okuma and 
Kumashiro, 1981, Sillanpää, 1993, Elwes et al., 1984) or in some cases as a combination 
of neurological and psychiatric handicap (Shorvon and Reynolds, 1982). In contrast, 
there are also several studies failing to demonstrate a significant association in this 
respect (Turnbull et al., 1985, Collaborative Group for the Study of, 1992, Lossius et al., 
1999). It has been shown that neurological examination is not a prognostic factor for 
early- versus delayed-onset remission (Del Felice et al., 2010) or the development of 
treatment resistant epilepsy (Hitiris et al., 2007). Nevertheless, a covariate combining 
both learning disability and neurological deficit has been shown to be a significant 
predictive factor for time to 12 month remission for both focal and 
generalised/unclassified epilepsy (Bonnett et al., 2012, Bonnett et al., 2014b). In 
summary, neurological insult as a predictive factor probably reflects underlying brain 
pathology and singles out symptomatic from cryptogenic epilepsy. 
1.3.5. Seizure type 
Pre-treatment seizure type as a clinical predictor for treatment outcome has been 
assessed by several studies. Seizure type can be broadly classified into generalised and 
partial (focal). Both generalised and partial seizures are then further sub classified into 
smaller categories. Seizure classification according to ILAE 1981 Classification has been 
summarised in table 1 (1981). 
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Table 1. Summary of  ILAE 1981 classification of seizures (Bancaud et al., 1981). 
Seizure type Notes 
Partial seizures 
Simple partial seizure Consciousness is not impaired 
Complex partial seizure Consciousness is impaired, sometimes 
might start as simple partial seizure 
Partial seizure evolving into 
secondary generalised seizure 
Can evolve from both simple and 
complex partial seizure 
Generalised (convulsive and non-convulsive) 
Absence seizures Might only have impairment of 
consciousness, or with additional mild 
tonic, clonic or autonomic components. 
Ictal EEG usually regular bilateral, 
symmetrical 3 Hz spike and wave 
complexes. 
Atypical absence Changes in tone are more pronounced, 
onset might not be as abrupt as in typical 
absence seizure. Ictal EEG is more 
heterogeneous.  
Myoclonic seizures Single or multiple myoclonic jerks. 
Clonic seizures Clonic jerks without tonic component 
Tonic seizures Rigid violent muscular contractions 
involving torso or limbs 
Tonic-clonic seizures Grand mal seizures. Tonic phase 
followed by clonic. Can be primarily or 
secondarily generalised. 
Atonic (astatic) seizures Sudden diminution of muscle tone, 
might be fragmentary 
Unclassified epileptic seizures All seizures that cannot be classified  
  
 Partial seizures have been shown by several studies to be a negative predictor for 
remission (Annegers et al., 1979, Shorvon and Reynolds, 1982, Elwes et al., 1984, 
Turnbull et al., 1985). A combined large VA study including patients with symptomatic 
localization-related epilepsy demonstrated that in this patient group, those with 
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generalized tonic-clonic seizures alone have the best prognosis for remission, complex 
partial seizures alone the worst and with all others somewhere in-between (Mattson et 
al., 1996). Contrary to their earlier report, a later and more extended study from 
Rochester County, Minnesota showed that never having had a generalized tonic-clonic 
seizure is a positive predictor (Shafer et al., 1988). A mixed seizure type also has been 
associated with poorer treatment responsiveness (Zhang et al., 2013, Su et al., 2013, 
Beghi and Tognoni, 1988).  
Post-hoc analysis done on the SANAD trial data showed that in the case of focal 
epilepsy overall treatment failure is more likely if the subject experiences simple or 
complex partial seizures alone compared to those with additional secondary generalised 
tonic-clonic seizures. This link is significant for failure due to adverse events but not due 
to inadequate seizure control (Bonnett et al., 2012). Similar analysis done on patients 
with generalised or unclassified epilepsy showed that the presence of myoclonic or 
absence seizures is a negative predictor for 12 or 24 month remission, and that patients 
with absence seizures or a mixed seizure type (including absence or myoclonic seizures 
with generalized tonic-clonic seizures) are more likely to have treatment failure due to 
inadequate seizure control (Bonnett et al., 2014b). A further analysis of the SANAD data 
from patients who failed their first AED demonstrated that occurrence of tonic-clonic 
seizures while on treatment was a negative predictive factor for a subsequent remission. 
Likewise, patients with focal seizures before starting treatment had less chance of 
remission than those with secondary generalized seizures (Bonnett et al., 2014a). 
 On the other hand, there are several studies covering different patient groups that 
have failed to demonstrate any significant association of treatment outcome with pre – 
treatment seizure type (Mohanraj and Brodie, 2007, Park et al., 2014, Gasparini et al., 
2013, Berg et al., 2001, Besocke et al., 2013, MacDonald et al., 2000). 
Seizure type as a covariate can influence and is influenced by other factors like 
epilepsy syndrome and aetiology. Some seizure types are more intrusive and could 
prompt patients to seek medical attention earlier hence leading to earlier diagnosis and 
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lower pre – treatment seizure frequency. In short, expressing generalised tonic-clonic 
seizures only or as the predominant seizure type probably has a positive association 
with treatment outcome.  
1.3.6. Epilepsy syndrome 
Certain epilepsy syndromes are more prominent or occur almost exclusively during 
certain periods of life. Some childhood epilepsy syndromes like benign rolandic or 
occipital epilepsy has invariably very favourable prognosis with almost all patients 
entering into remission, whereas Lennox – Gastaut and West syndromes have a poor 
prognosis (Berg et al., 2001, Sillanpää et al., 2014). Age has an effect on the incidence of 
the epilepsy syndrome, with generalised epilepsies being more common than partial 
during the first five years of life, a roughly equivalent incidence during the adolescent 
years, and partial epilepsy taking over after age of 24. Interestingly there are also 
differences by gender (Hauser et al., 1993).  
Several studies have demonstrated a lack of significant association between epilepsy 
syndrome and treatment outcome (Sillanpää and Schmidt, 2009, Park et al., 2014, 
Collaborative Group for the Study of, 1992). In newly diagnosed focal epilepsy, the lobe 
of origin also has been shown to have no association with response to the first 
anticonvulsant (Bonnett et al., 2012). Furthermore, there are no significant differences 
between cryptogenic and symptomatic focal epilepsies in terms of treatment outcome, 
although there are differences based on aetiology (Mohanraj and Brodie, 2005a).  
On the other hand, there are also several studies demonstrating a link between 
syndrome and treatment outcome, as outlined below. In a paediatric population, 
idiopathic epilepsy syndromes have higher remission rates (Berg et al., 2001, Sillanpää et 
al., 2014). Similarly, in adults, idiopathic generalised epilepsy has been reported to have 
higher response rates than cryptogenic or symptomatic generalised epilepsies 
(Mohanraj and Brodie, 2006). Juvenile myoclonic epilepsy makes up around 5 – 10 % of 
all epilepsy and is the most common form of idiopathic generalised epilepsy (Camfield et 
al., 2013). Reported remission rates vary between studies, ranging from 17 % to 88 % 
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(Kleveland and Engelsen, 1998, Panayiotopoulos et al., 1994, Camfield and Camfield, 
2009, Penry et al., 1989, Geithner et al., 2012, Siren et al., 2002).  This wide range is 
probably related to study design, the definition of remission and a relatively small 
sample size in many studies. It has also been demonstrated that different seizure types 
have different remission rates (Kleveland and Engelsen, 1998).  
Classification of epilepsy syndromes has changed several times hence it might be 
hard to compare older studies with newer ones. Epilepsy syndrome itself is intrinsically 
linked to the seizure type, aetiology, age at onset, EEG findings and genetic factors. All of 
these covariates are probably associated with the treatment outcome in their own right. 
In general, certain distinctive childhood syndromes have a very strong predictive effect, 
whereas in adults this effect might be less pronounced.  
1.3.7. Aetiology 
Aetiology can be linked to other co – variates, such as age, results of investigations, 
neurological deficit and epilepsy syndrome. For example, in the case of age at onset, 
cerebrovascular and neurodegenerative disorders are more often observed in the 
elderly, whereas congenital causes are more often observed in the younger patient 
group (Hauser et al., 1993). Due to the evolution of diagnostic capabilities, knowledge 
about genetic causes of epilepsy, and improved classification of aetiology, comparison 
between older and newer studies is becoming complicated. Furthermore, aetiological 
categories are often lumped together and different studies also employ different 
diagnostic criteria and investigation protocols making further comparison difficult. 
Neurological dysfunction identified at birth has been associated with poorer 
prognosis (Annegers et al., 1979), whereas absence of early brain damage is associated 
with more favourable outcomes (Shafer et al., 1988). Likewise, remote symptomatic or 
merged similar categories as a non-idiopathic aetiology in paediatric population has 
been shown to have a worse treatment prognosis (Berg et al., 2001, Geerts et al., 2010). 
In adults with newly diagnosed focal epilepsy, cerebral atrophy and cerebrovascular 
disease are associated with more remissions than post-traumatic epilepsy. Interestingly, 
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primary brain tumours, cortical malformations and vascular lesions do not have a 
particularly worse treatment outcome than other aetiologies (Mohanraj and Brodie, 
2005a). However, studies in patients with established epilepsy due to hippocampal 
sclerosis have shown a poor treatment response (Semah et al., 1998, Stephen et al., 
2001, Hui et al., 2007). Then again, several studies covering different populations with 
regard to age and status of diagnosis at the time of inclusion, and using mostly 
condensed and simplified aetiological classifications, have shown no association with 
treatment outcome (Besocke et al., 2013, Su et al., 2013, Sillanpää and Schmidt, 2009, 
Collaborative Group for the Study of, 1992, Zhang et al., 2013, MacDonald et al., 2000).  
In summary, the relationship between aetiology and treatment outcome is complex 
and will change in future as our knowledge about causes of epilepsy expands. With the 
development of genetic and imaging technologies, aetiology might increasingly guide us 
in the selection of the correct treatment approach. 
 
1.3.8. Total number of pre-treatment seizures 
Research based on patients undergoing ambulatory and video-EEG monitoring has 
shown that significant numbers of patients are not aware of their seizures and under-
report seizure numbers. This applies to both adults (Blum et al., 1996, Hoppe et al., 
2007, Kerling et al., 2006, Tatum et al., 2001) and children, where parents have been 
shown to under-report seizure numbers (Akman et al., 2009).  
Several studies have demonstrated that total number of pre – treatment seizures is 
associated with treatment outcome. The National General Practice Study of Epilepsy 
(NGPSE) showed that the strongest predictive factor for all types of remission is the 
number of seizures in the first 6 months after the index seizure (MacDonald et al., 2000). 
A similar association was also demonstrated for the number of seizures prior to the 
index seizure. This effect is not linear and those with ten or more seizures before the 
index seizure have a better chance of remission. A further aspect arising from the NGPSE 
was the concept of “seizure density”, which is closely related to seizure frequency.  
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Similar results have been demonstrated by several other observational studies of 
newly diagnosed epilepsy, showing that a higher number of seizures before treatment is 
associated with worse treatment outcome (Shorvon and Reynolds, 1982, Elwes et al., 
1984, Beghi and Tognoni, 1988, Collaborative Group for the Study of, 1992, Di Mascio et 
al., 1986, Stephen et al., 2006, Kwan and Brodie, 2000). Higher pre-treatment seizure 
count has also been associated with relapse of seizures in newly diagnosed epilepsy (Su 
et al., 2013).  
Prognostic modelling based on the SANAD data has shown that in focal epilepsy, a 
higher total number of seizures before treatment is associated with treatment failure 
and also is a negative prognostic factor for time to 12 month remission (Bonnett et al., 
2012). Similarly, in generalized epilepsy, the total number of tonic-clonic seizures was 
negatively associated with time to 12 and 24 month remission, but not with treatment 
failure (Bonnett et al., 2014b). Despite these observations, several studies have 
suggested that there is no association between treatment outcomes and number of pre-
treatment seizures (Gasparini et al., 2013, Zhang et al., 2013, Park et al., 2014, Turnbull 
et al., 1985, Hitiris et al., 2007). 
Pre – treatment seizure count is influenced by several factors. In some idiopathic 
generalized epilepsy syndromes, for example juvenile myoclonic epilepsy, total seizure 
number can be very high due to either absence or myoclonic seizures or both. This could 
explain the absence of a linear relationship in the NGPSE study. This covariate is related 
to epilepsy syndrome, as well as to localization of the epileptogenic zone and dominant 
seizure type. In conclusion, total pre-treatment seizure number probably is a clinical 
covariate associated with a treatment outcome.  
1.3.9. Imaging CT/MRI 
Neuroimaging has an important role in the assessment of patients with seizures and 
also in the management of epilepsy. Magnetic resonance imaging (MRI) is the preferred 
method to elucidate structural causes of the disease (NICE, 2004). Computed 
tomography (CT) is inferior to cranial MRI. In a study from Australia involving 300 
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consecutive patients from the first seizure clinic, computerised tomography (CT) failed 
to identify roughly one half of tumours detected by MRI (7 out of 15) as well as 
detecting lesions in less than one half of the cases (12 out of 28) (King et al., 1998). This 
fact has implications when assembling retrospective patient cohorts where some 
patients might have had CT and others MRI.  A further large study involving adults 
referred to the first seizure clinic for an assessment, detected potentially epileptogenic 
lesions in 23% of MRI scanned individuals (Hakami et al., 2013).  Authors observed 
statistically significant differences in the frequency of lesions between patients who 
were diagnosed as having an epileptic seizure and those with non-epileptic events (28% 
vs. 8% p <0.001). This emphasises the fact that newly diagnosed seizures, although 
closely related, are not the same as newly diagnosed epilepsy as some patients with 
non-epileptic events still had abnormal imaging.  
In a paediatric study of newly diagnosed epilepsy, close to 13% of imaged cases had a 
significant abnormality (Berg et al., 2000). Due to differences in the aetiology at various 
ages those results are not directly comparable, but nevertheless they demonstrate the 
importance of imaging in newly diagnosed epilepsy.  
As discussed previously, MRI produces better diagnostic yield than CT, but imaging 
protocols and reporting is of importance as well. MRI carried out according to a specific 
epilepsy protocol and reported by radiologists experienced in epilepsy field has a better 
diagnostic output (McBride et al., 1998, von Oertzen et al., 2002). This potentially adds 
an extra layer of variability in cohorts where imaging studies are assessed locally by a 
mixture of general and neuroradiologists utilizing a variety of imaging protocols.  
The number of studies assessing imaging in relation to treatment outcomes in newly 
diagnosed epilepsy is limited. The first study including imaging was from King’s College 
hospital, conducted by Elwes et al, which recruited patients in the period between 1974 
and 1979. It combined learning disabilities, focal neurological signs and abnormal CT 
scan under a variable termed ‘neurological handicap’. This was shown to be one of the 
factors linked to worse treatment prognosis (Elwes et al., 1984). A study assessing only 
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initial response after the first 6 months of treatment in newly diagnosed epilepsy 
demonstrated no differences between responders and non – responders for the 
presence of structural lesions on MRI (Park et al., 2014). Lack of association of imaging 
with treatment outcome in newly diagnosed epilepsy has been shown both in adults 
(Zhang et al., 2013, Su et al., 2013) and in the elderly (Stephen et al., 2006). It also had 
no influence on prediction of early or late remission (Del Felice et al., 2010).  
In the SANAD focal epilepsy arm, abnormal imaging studies were reported in 26% of 
patients and in a further subgroup analysis, imaging results were included in a 
multivariable prognostic model for time to 12 month remission with a hazard ratio of 
0.88 but a wide 95% confidence interval of 0.76 – 1.03 (Bonnett et al., 2012). This could 
probably be explained by a complex interaction with other covariates. In the unclassified 
and generalised epilepsy arm of SANAD 5% of patients had an abnormal scan, with 
imaging results considered but not included in final prognostic models for time to 12 
month remission and time to treatment failure (Bonnett et al., 2014b). An older hospital 
based cohort consisting of established epilepsy showed no link between CT imaging and 
recurrence of seizures (Lossius et al., 1999).  
The nature of brain lesions is usually assessed by one of the imaging methods, most 
commonly MRI. In newly diagnosed, localization-related symptomatic epilepsy, it has 
been shown that cerebral atrophy and cerebrovascular disease had a better treatment 
outcome, while traumatic brain injury had worse results than patients with other 
symptomatic epilepsies (Mohanraj and Brodie, 2005a). 
 The Glasgow group has demonstrated earlier that mesial temporal sclerosis has a 
worse treatment outcome prognosis in newly diagnosed epilepsy than other common 
causes of symptomatic focal epilepsy (Stephen et al., 2001). In contrast, a different study 
based in a tertiary hospital setting, with the majority of cases being established epilepsy, 
showed an influence of MRI detected lesions on the intractability of partial epilepsy. The 
authors observed that patients with MRI detected lesions had a significantly less 
frequent remission (25% versus 42% seizure free, p < 0.001). Furthermore, hippocampal 
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sclerosis, dual pathology and cortical dysgenesis had the poorest outcomes, while 
tumours, vascular malformations and old strokes fared best (Semah et al., 1998). These 
studies are clearly different, one utilized newly diagnosed cases while the other one 
focused on established epilepsy and thus they cannot be directly compared. 
Interestingly the relationship between hippocampal sclerosis (HS) on MRI and treatment 
outcomes in patients with already established epilepsy is also not simple or 
straightforward. Some studies have shown that HS is a predictor of poor prognosis for 
treatment outcome (Semah et al., 1998, Van Paesschen et al., 1997, Pittau et al., 2009). 
Poor outcomes nevertheless have not been confirmed by all studies, for example Kim et 
al showed that one quarter of patients with a mesial temporal sclerosis (MTS) achieved 
remission and 37% had an improvement in seizure control with a medical treatment 
(Kim et al., 1999). MTS has also been observed in patients with sporadic benign 
temporal lobe epilepsy illustrating the complexity of this relationship (Kobayashi et al., 
2001, Labate et al., 2006). Hippocampal atrophy is a part of mesial temporal lobe 
sclerosis but, so far, not all studies have demonstrated its clear association with 
treatment outcome (Andrade-Valença et al., 2003, Mohanraj and Brodie, 2005a). 
Interestingly, in a volumetric MRI study the pattern for grey matter atrophy for 
treatment resistant and relapsing-remitting epilepsy was similar, but different from 
responders (Bilevicius et al., 2010). The pharmacoresistant group had a lower age of 
onset and higher initial seizure frequency. Age of onset had previously been 
demonstrated to be strongly associated with time to intractability, and together with a 
history of febrile seizures, it was also shown to be associated with hippocampal atrophy 
(Berg et al., 2003). 
 In summary, results of imaging studies are not clear-cut predictors of treatment 
outcome. There are varieties of potential explanations like heterogeneous patient 
populations plus the majority of studies are hospital-based and retrospective and there 
are differences in acquisition of imaging and in its interpretation. Furthermore, imaging 
as a predictor might not be fully independent, but might bear some relationship to 
aetiology of epilepsy. There is a need for a prospective study of new and sophisticated 
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methods of neuroimaging and treatment response in newly diagnosed epilepsy. Such a 
study has been proposed by a research group in Halifax (Pohlmann-Eden et al., 2013). 
1.3.10. Electroencephalography 
Electroencephalography (EEG) is a valuable tool for diagnosis and classification of 
epileptic syndrome and localization of the ictal onset zone in the case of surgery.  
Epileptiform changes on the EEG performed after new onset seizures are observed in 12 
to 50 % of adults (Wirrell, 2010). There is a correlation between focal abnormalities on 
the EEG and neuroimaging though it is not absolute (Reinikainen et al., 1987). Some of 
the idiopathic generalised epilepsy syndromes have specific EEG changes, which 
influences treatment choices (Panayiotopoulos, 2005). In addition some seizure types 
are more likely to have abnormal EEG, like absences and myoclonic seizures (Carpay et 
al., 1997). Timing of EEG can also influence the chance of detecting epileptiform 
abnormalities, with earlier EEG after seizure having a higher likelihood of abnormal 
findings (King et al., 1998). A higher number of seizures during the preceding 12 months 
also increased the probability of capturing an abnormal EEG. (Sundaram et al., 1990) 
Those factors and their relationship with epileptic syndrome itself, where EEG often is 
an integral part, should be taken into account when assessing EEG as a treatment 
outcome predictor.  
EEG as a treatment outcome predictor has been assessed by multiple studies; results 
so far have been controversial. Several studies covering a variety of different 
populations have shown no association (Elwes et al., 1984, Beghi and Tognoni, 1988, 
Stephen et al., 2006, Turnbull et al., 1985, Zhang et al., 2013, Mohanraj and Brodie, 
2007). In contrast, several others have shown a link between EEG and treatment 
outcome (Su et al., 2013, Bonnett et al., 2014b, Bonnett et al., 2012, Shafer et al., 1988). 
A study done by Shafer et al based on Rochester project showed that absence of 
generalised epileptiform activity was associated with the higher probability to achieve 
five year remission (Shafer et al., 1988).  Similarly in a prognostic modelling based on 
SANAD presence of epileptiform abnormality was a significant factor for time to 
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treatment failure but not for remission (Bonnett et al., 2012, Bonnett et al., 2014b). Su 
et al demonstrated that epileptiform EEG before onset of treatment is associated with 
relapse of seizures in patients with newly diagnosed epilepsy (Su et al., 2013). 
Interestingly epileptiform EEG during the treatment did not have such association. 
In summary, it is not clear if epileptiform abnormalities on EEG are predictive of 
treatment outcome. It may well be that specific seizure type and epileptic syndrome are 
associated with certain EEG changes, which themselves have prognostic value rather 
than the EEG itself. 
1.3.11. Febrile seizures 
Febrile seizures are defined as seizures occurring in a febrile child aged 6 to 60 
months without a previous history of afebrile seizures and in the absence of intracranial 
infection or metabolic disturbances (Steering Committee on Quality Improvement 
Management, 2008). The risk of development of afebrile seizures in later life is slightly 
increased and has been estimated to be between 2-7% (Chungath and Shorvon, 2008). 
Interestingly, a large population based cohort from Denmark showed that this risk is 
higher in those with a family history of epilepsy, cerebral palsy and low Apgar scores at 5 
minutes (Vestergaard et al., 2007). 
Association of febrile seizures with treatment outcomes in newly diagnosed epilepsy 
has not been investigated as extensively as other covariates. A study from Glasgow 
involving 780 patients with newly diagnosed epilepsy treated in the same hospital-based 
outpatient clinic demonstrated an association of febrile seizures with worse treatment 
outcome (Hitiris et al., 2007). Not surprisingly, similar results were obtained from 
another study which was based on the same clinical cohort of newly diagnosed adults 
from Glasgow, but specifically looking at treatment outcomes for idiopathic generalized 
epilepsy syndromes in a non-paediatric setting (Mohanraj and Brodie, 2007). A Dutch 
study assessing the course and outcome of childhood epilepsy showed similar results 
(Geerts et al., 2010). This study included 413 subjects with the mean age of onset of 5.5 
years (median 5.1; range 1 month – 15.5 years) and in whom history of febrile seizures 
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was one of the predictors of intractability. The role of febrile seizures as a prognostic 
factor was also assessed in the post – hoc subgroup analysis based on the data from 
SANAD trial. Although it failed to reach statistical significance, it was included in the final 
prognostic model for time to 24 month remission in subjects with generalised and 
unclassified epilepsy (Bonnett et al., 2014b). Febrile seizures have also been shown to be 
associated with drug resistant mesial temporal lobe epilepsy, while MTS in the same 
study was more likely to be intractable (Pittau et al., 2009). This study was based in a 
hospital tertiary care setting, case recruitment used both prospective and retrospective 
methods, and patients were not newly diagnosed. Berg et al, in a large, multicentre, 
pre–surgical, hospital-based study, demonstrated that history of febrile seizures and age 
at onset had independent effects on finding hippocampal atrophy on MRI, and that all 
three factors were associated with time to intractability. Multivariate analysis showed 
that age at onset provided the largest explanatory value and the authors suggested that 
all three variables are inter–related (Berg et al., 2003). In the meantime, a hospital-
based retrospective study from Italy investigating factors related to long-term remission 
in newly diagnosed, cryptogenic focal epilepsy showed that individual history of febrile 
seizure had no association with the outcome (Gasparini et al., 2013).  
1.3.12. Family history of epilepsy 
First degree relatives of a proband with epilepsy have an increased incidence of 
epilepsy; the risk is higher for idiopathic generalized epilepsy, but is also present in the 
case of focal epilepsy (Peljto et al., 2014). Inclusion of data on family history in epilepsy 
studies largely depends on self – reporting or occasionally from interviewing relatives. It 
has been shown that this information has a relatively good precision for siblings and 
offspring, but not for parents (Ottman et al., 2011).  
Several studies have included family history in their assessment, but not all have 
reported results. A heterogeneous group of studies involving newly diagnosed epilepsy 
from both community and hospital-based clinics have shown no association with 
treatment outcome (Shafer et al., 1988, Su et al., 2013, Beghi and Tognoni, 1988, 
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Shorvon and Reynolds, 1982, Zhang et al., 2013), while a few studies have demonstrated 
a link with poorer prognosis (Elwes et al., 1984, Hitiris et al., 2007). Interestingly, family 
history showed no association with treatment outcome in newly diagnosed generalized 
epilepsy syndromes in an adult population (Mohanraj and Brodie, 2007). Similar results 
have been demonstrated in juvenile myoclonic epilepsy, the commonest syndrome of 
idiopathic generalized epilepsy (Gelisse et al., 2001). It also appears that family history 
has no significant influence on the occurrence of either early or late remission (Del 
Felice et al., 2010). In the case of newly diagnosed cryptogenic epilepsy, results of a 
retrospective hospital-based cohort have suggested association between positive family 
history and long term remission (Gasparini et al., 2013). In contrast, mesial temporal 
lobe epilepsy studies have failed to show any significant role of family history (Pittau et 
al., 2009, Sànchez et al., 2014, Varoglu et al., 2009). The presence or absence of a first 
degree relative with epilepsy was also considered in a post – hoc subgroup analysis of 
the SANAD study data and it was included in a prognostic model for time to 12 month 
remission in generalised and unclassified epilepsy (Bonnett et al., 2012, Bonnett et al., 
2014b).It was demonstrated that presence of the first degree relative with epilepsy is 
negatively associated with the time to 12 month remission (HR = 0.69; 95% CI 0.54 to 
0.89). 
The majority of participants in studies exploring family history as a predictor of 
prognosis are adults with adult-onset epilepsies. Epilepsy syndromes characteristic for 
childhood are often different in their natural history from typical syndromes 
encountered in adults. However, a more extensive review about paediatric epilepsy is 
outside of the scope of this chapter. In general, the relationship between family history 
and paediatric epilepsy is complex. Two studies assessing young children showed no 
association of family history with treatment intractability (Wirrell et al., 2012, Wirrell et 
al., 2013), but a large cohort of prospectively followed children have shown a negative 
association between family history and 2 year remission (Berg et al., 2001). 
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1.3.13. Treatment history 
History of previous treatment is not a relevant predicting factor for treatment 
outcome in the case of newly diagnosed epilepsy as there is no previous treatment. 
However, it is valuable to explore it in more detail as it has a role in the case of 
established epilepsy. Furthermore, all patients with newly diagnosed epilepsy will 
develop a unique treatment history in due course, which will thus play a role in 
predicting outcome for more distant future.  
It has been shown that, in newly diagnosed epilepsy, in the case of failure due to lack 
of efficacy of the first anticonvulsant, response to subsequent treatment decreases with 
every subsequent failure (Mohanraj and Brodie, 2006, Kwan and Brodie, 2000, Zhang et 
al., 2013). Studies have demonstrated several patterns of response. It has been 
proposed that some patients will go into remission, with some in indefinite or terminal 
remission and others relapsing later, some patients experience a relapsing and remitting 
course, and the remainder are treatment resistant from the outset (Brodie et al., 2012). 
Remission can be either early or delayed and in both cases patients who enter remission 
can later relapse and develop intractable epilepsy (Del Felice et al., 2010, Zhang et al., 
2013, Brodie et al., 2012). It is the generally accepted view that intractable epilepsy 
harbours a worse long-term prognosis. Even in this group, a number of patients will 
enter into seizure remission, although a substantial number of them will subsequently 
relapse (Callaghan et al., 2011, Schiller, 2009). In both of these studies, previous 
treatment history was highlighted as a negative predictive factor. Schiller demonstrated 
that it is associated with seizure relapse and development of drug resistance (Schiller, 
2009), while Callaghan et al additionally looked for predicting factors of relapse and 
showed that focal epilepsy is associated with reduced likelihood of relapse (Callaghan et 
al., 2011).  
A study investigating treatment outcomes in established mesial temporal sclerosis 
showed that a noticeable proportion of patients still will experience some form of 
remission on pharmacological treatment (72 % in surgical group versus 23 % in non-
surgical); responders had a lower number of previously used treatment schedules and 
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an earlier age at onset of the disease  (Kumlien et al., 2002). Interestingly, a small 
community-based paediatric study involving only 77 patients with newly diagnosed 
temporal lobe epilepsy did not observe an effect of remission within the first two years 
on longer term outcome, although they did report a strong association between MRI 
lesions and the persistence of seizures (Spooner et al., 2006). These two studies are not 
comparable as one is a hospital-based adult pre-surgical series, while the other is a 
community-based paediatric study.  
In the case of newly diagnosed epilepsy, the situation is more complicated as there is 
no previous treatment history, but some potentially useful prognostic information can 
be obtained from the initial months of the first adequate and appropriate treatment 
schedule. A recent post-hoc analysis of patient data from five double-blind, active 
control drug studies (three in newly diagnosed epilepsy) that assessed efficacy of 
oxcarbazepine against several mainstay AEDs showed that being seizure free after the 
first six months of treatment is strongly associated with being seizure free for further six 
months (Schmidt, 2007). 
1.3.14. Learning Disabilities  
Epilepsy is a commonly seen comorbid condition in children with learning disabilities; 
prevalence rate varies from 6 % in children with mild to 50 % in case of profound 
learning disability (Lhatoo and Sander, 2001). Only a few studies have reported on 
learning disabilities in adult newly diagnosed epilepsies. A study from China which 
included a mixed adult and paediatric population has shown that learning disability is 
not associated with treatment response in newly diagnosed epilepsy (Zhang et al., 
2013). A further study from Glasgow, also including a mixed population but 
predominantly adults, similarly showed that presence of learning disability is not 
associated with development of pharmacoresistant epilepsy (Hitiris et al., 2007). 
However, in contrast, a study involving patients with both newly diagnosed and 
established epilepsy from China showed a significant association of learning disabilities 
with refractory epilepsy (Hui et al., 2007). Interestingly, earlier studies in newly 
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diagnosed epilepsy that explored the broad concept of ‘neuropsychiatric handicap’ also 
showed association with treatment failure (Shorvon and Reynolds, 1982, Elwes et al., 
1984). It has similarly been demonstrated that prognosis for remission is poorer for 
patients with associated neurological dysfunction from birth (Annegers et al., 1979).  
In summary, learning disability as a prognostic factor has been studied relatively 
infrequently. This clinical group is very heterogeneous both in the way that the LD 
diagnosis is made and also in aetiological aspects influencing the response to treatment 
(Lhatoo and Sander, 2001). Both learning disabilities and epilepsy might be a non-
specific symptom for a specific genetic syndrome and in future with evolution of 
understanding of background genetics; precision based medicine could aid in a better 
treatment selection.  
 
1.3.2 Prognostic research 
Prognostic factor is present in the population with the given condition and is 
associated with the clinical outcome which can also be a response to a treatment (Riley 
et al., 2013). Prognostic factors are not always causally related to the condition (Moons 
et al., 2009). Stratified medicine on the other hand is targeting the intervention 
according to a shared risk common to the patient subpopulation (Hingorani et al., 2013).  
Prognostic research has been carried out in the epilepsy field. For example, 
prognostic modelling has been applied to ascertain the risk of relapse after withdrawal 
from treatment in the case of remission, the recurrence of further seizures after the first 
seizure or treatment outcome after the application of the first AED in the case of newly 
diagnosed epilepsy (Group, 1993, Kim et al., 2006a, Bonnett et al., 2012, Bonnett et al., 
2014b).  
The general quality of prognostic research in medicine has been described as 
insufficient, which often limits their clinical application or reproducibility (Riley et al., 
2003, Bouwmeester et al., 2012, Hemingway et al., 2009). Several important limitations 
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of current research have been suggested by Riley et al, like publication and reporting 
biases, poor study design and statistical analysis and lack of external validation (Riley et 
al., 2013). Prognostic research often relies on a retrospective design, which has several 
attractive features like a long observation time to collect a substantial number of events 
of interest but at the expense of data quality (Altman and Riley, 2005, Moons et al., 
2009). On the other hand, it has significant limitations like, the lack of a pre-specified 
design, unclear inclusion criteria, lack of standardization and incompleteness of data. A 
prospective approach helps in reducing data dredging and type 1 errors, hence it is a 
preferred design (Riley et al., 2013).  
A further important issue is data quality, and it has been suggested that factors with 
known inter-observer variability might be less suitable (Moons et al., 2012). Other 
potentially significant problems are the dichotomising of continuous co-variates and the 
assumption of their linearity as well as assumption that the data missingness is a 
random event (Moons et al., 2012, Riley et al., 2013). This could potentially be an issue 
in the case of newly diagnosed epilepsy with pre-treatment seizure frequency.  
Sample size can also be an issue, with some studies being inadequately powered or 
having no reported sample size calculation (Hemingway et al., 2009, Bouwmeester et al., 
2012). Small sample size can lead to over-fitted models particularly in cases where 
predictor selection is based on a relatively small significance level (Moons et al., 2012). 
The establishment of new prospective clinical cohorts with an adequate sample size 
has been suggested as a way of improving the quality of prognostic research (Riley et al., 
2013). Furthermore it is important that prognostic models are externally validated and 
updated and that the performance of new factors are assessed (Steyerberg et al., 2013).  
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1.4.0. Description of important cohorts 
In this section, a brief description of the most important research cohorts of newly-
diagnosed epilepsy will be provided; these are often cited in other relevant chapters. 
Furthermore, results described in this thesis are compared with them. It should also be 
stated that a significant proportion of the EpiPGX research cohort was derived from two 
of these pre-existing cohorts – those from SANAD and Glasgow. 
Several studies involving large size cohorts with newly diagnosed epilepsy have 
assessed the effect of multiple covariates on treatment outcome or natural history. 
Some of them like SANAD and the Veterans Affairs multicentre studies were initially set 
up as clinical trials, but data were later used for analysis of association or prognostic 
modelling. All but two cohorts (NGPSE and Rochester study) were hospital based and all 
had a prospective follow up. Twelve month remission rates in all cohorts were reported 
to be  between 50% to 80%, depending on study methodology, concordantly indicating a 
favourable prognosis for newly diagnosed epilepsy (Annegers et al., 1979, Collaborative 
Group for the Study of, 1992, MacDonald et al., 2000, Marson et al., 2007a, Marson et 
al., 2007b, Brodie et al., 2012, Speed et al., 2014a). 
 
1.4.1. Department of Veterans Affairs multicentre studies (VA – 118 and 
VA – 264) 
Both VA – 118 and VA – 264 studies were conducted using a very similar 
methodology, by the same research group, and mostly utilizing the VA healthcare 
setting. Inclusion criteria for both studies were newly diagnosed epilepsy in adults with 
partial onset seizures and/or secondarily generalised tonic-clonic seizures. Patients with 
previously documented treatment (if appropriate and adequate), severe learning 
disabilities, progressive neurological conditions, substance abuse and poor compliance 
were excluded. V-118 was conducted from 1978 to 1984, compared carbamazepine, 
phenobarbital, phenytoin and primidone, and recruited 622 adults in total. Overall, it 
showed superiority of carbamazepine and phenytoin over the other two drugs (Mattson 
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et al., 1985). V-264 utilized the same criteria, with 480 patients recruited between 1985 
and 1991. This study compared valproate and carbamazepine and showed better results 
for carbamazepine in controlling complex partial seizures (CPS), but similar efficacy with 
regards to secondarily generalized tonic-clonic seizures (SGTC) (Mattson et al., 1992). A 
further post-hoc analysis of both studies showed that patients with SGTC had better 
prognosis than those with CPS alone (Mattson et al., 1996). Both studies had 
shortcomings, particularly due to the environment in which they were conducted, which 
led to significant selection bias. The proportion of enrolled women in both studies was 
around only 10%. Similarly, only around 10% of patients were not from VA Hospitals and 
up to 40% of patients had previous exposure to AEDs (Mattson et al., 1992, Mattson et 
al., 1985). Due to the specific population that VA healthcare serves, there is a potential 
for further selection bias by over-representation of focal post traumatic epilepsy (34% 
and 31% respectively) among veterans. On the other hand, both VA studies were 
multicentre, randomized and double-blind, with a prospective follow up and had a 
significant sample size. 
 
1.4.2. Glasgow 
The epilepsy research group in Glasgow has, over a long time, contributed 
significantly to knowledge about the pharmacological treatment of epilepsy. Its newly 
diagnosed patient cohort is drawn from a single hospital-based epilepsy unit and 
includes both adults and adolescents. Care for patients with epilepsy in the region is 
provided either by the Institute of Neurological Sciences at the Southern General 
Hospital, with expertise in diagnostics and epilepsy surgery, or the Epilepsy Research 
Unit at the Western Infirmary, which specialises in drug therapy. Hence, the catchment 
area of the epilepsy unit includes all of the Greater Glasgow area and the west of 
Scotland. The unit serves not only newly diagnosed patients, but also patients with an 
established diagnosis of epilepsy. 
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Although the Epilepsy Research Unit itself was based at the Western Infirmary, it was 
close to a community-based epilepsy practice. At certain time periods, the unit has 
provided additional specialised services like adolescent, pre-conception and learning 
disability & epilepsy clinics. The main source of referrals to this research cohort was 
from general practitioners, with less than 10% of patients referred from hospital A&E 
departments. Patients were followed up prospectively and reviewed regularly until 
seizure free for one year (Mohanraj and Brodie, 2005b). The unit also actively 
participated in regulatory trials and that was often reflected in recruitment of patients 
and in their treatment histories. 
At the last analysis, the newly diagnosed cohort from Glasgow consisted of 1098 
treatment naïve patients and was well balanced from a gender perspective with 52% (n 
= 575) males. Seizure freedom on the first AED in this cohort was observed in 50% of 
patients (Brodie et al., 2012). In addition to pharmacological and epidemiological 
studies, this cohort has participated in several genetic studies of newly diagnosed 
epilepsy (Sills et al., 2005, Makmor-Bakry et al., 2009, Szoeke et al., 2009). The sub-
cohort for genetic studies is a mixture of regular patients from the unit with established 
epilepsy and patients enrolled into regulatory trials for newly diagnosed epilepsy 
conducted by the unit (Shazadi et al., 2014). Follow up for this cohort is mixed 
prospective and retrospective. This cohort contributes significantly to the research 
described in this thesis and the entire genetic sub-cohort has been phenotyped as part 
of this project.  
1.4.3. The Italian Collaborative Group for the Study of Epilepsy 
This was a multicentre, prospective observational study of patients with newly 
diagnosed epilepsy seen in 14 Italian hospitals and university centres. The majority of 
hospitals involved in the study were from northern Italy (n = 7), followed by central Italy 
(n=5) and the south of Italy (n =2). It started recruiting patients in 1982 and finished in 
1985. Treatment was started at the time of recruitment or no earlier than three months 
before it. The study had a prospective design with regular follow up visits. Unselected 
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drugs at the standard dose for that time as a monotherapy were used. Cases where 
AEDs were prescribed as polytherapy or as prophylaxis were excluded (Beghi and 
Tognoni, 1988). Life table methods and Cox proportional hazards modelling were used 
for statistical processing of data. There were 280 patients included the study; 18% of 
them had experienced only a single seizure but the physician deemed it necessary to 
start treatment. The majority of patients had localisation related epilepsy (52.5%), 
followed by generalised (38.5%) and undetermined (6.8%) epilepsy. Phenobarbital was 
prescribed most often, followed by carbamazepine, valproate and phenytoin. The 
authors reported 1 year remission at 1 year follow-up in 62% of their patients and also 
demonstrated a negative association of pre-treatment seizure number with remission 
rates as well as a relationship between seizure relapses during the first year of follow-up 
and the subsequent risk of developing intractable epilepsy (Collaborative Group for the 
Study of, 1992).  
1.4.4. The National General Practice Study of Epilepsy (NGPSE) 
NGPSE study was a community-based prospective cohort study in general practice. It 
utilized the unique primary care system of the UK National Health Service where general 
practitioners (GPs) serve as gate-keepers to specialist medicine. Case identification ran 
from 1984 to 1987 and included 275 general practices. GPs were asked to include all 
cases with suspected or definite new diagnoses of epileptic seizures. The index seizure 
leading to inclusion in the study was not always was the first seizure. The study also 
included cases with symptomatic and febrile seizures. Exclusion criteria were a previous 
diagnosis of epilepsy and onset within the neonatal period. Data was collected from 
both GP practices and hospitals. Patients were not reviewed directly by the authors of 
the study but cases were classified by a panel based on information collected. In total, 
there were 1195 patients recruited, of whom 104 (9 %) were excluded (Sander et al., 
1990). 
 From this group, 792 patients with definite or probable epileptic seizures were 
identified. Patients were followed up prospectively by collecting information from their 
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GPs, with a median follow up period of 7.2 years (MacDonald et al., 2000). The study 
demonstrated a relatively good prognosis for epilepsy with 68% achieving 5 year 
remission and pre-treatment seizure frequency was shown to be the most important 
factor associated with treatment response (MacDonald et al., 2000, Cockerell et al., 
1997).  This study was not designed to assess effectiveness of individual treatments. 
 
1.4.5. SANAD study 
The SANAD study is the largest ever randomised clinical trial in newly diagnosed 
epilepsy. Patients were stratified based on an initial clinical decision; if they were 
considered to have focal epilepsy, in which case carbamazepine was the preferred drug 
(arm A), or if they were suspected to have generalised or unclassified epilepsy, in which 
case valproate was the preferred drug (arm B). Patient recruitment lasted from 
December 1999 till August 2004 (Marson et al., 2007a, Marson et al., 2007b). Study 
design was pragmatic and resembled regular clinical practice. Hence, if the clinician felt 
that treatment was required it was started before investigations were carried out. The 
study was un-blinded. Two or more clinically definite unprovoked seizures were 
required before recruitment and the study also accommodated patients who were 
previously treated with inadequate AEDs or who had relapsed after earlier drug 
withdrawal. Patients with provoked seizures and known progressive neurological 
disorders were excluded. A further post-hoc analysis using predictive modelling was 
carried out by Bonnett et al (Bonnett et al., 2012, Bonnett et al., 2014a, Bonnett et al., 
2014b). 
In total, there were 1721 patients included in SANAD arm A; 378 randomised to 
carbamazepine; 377 to gabapentin; 378 to lamotrigine; 210 to oxcarbazepine; and 378 
to topiramate. Of these, 82% were previously untreated and 10% of cases were later 
considered to have generalised or unclassified epilepsy (Marson et al., 2007a, Marson et 
al., 2007). SANAD arm B included 716 patients who were randomised either to 
lamotrigine (n = 239), valproate (n = 238) or topiramate (n = 239). Of these, 87.7% were 
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previously untreated (Marson et al., 2007, Marson et al., 2007b). Arm A showed that 
Lamotrigine is clinically superior to Carbamazepine for treatment of focal epilepsy, 
whereas arm B confirmed the superiority of valproate for the treatment of generalised 
and unclassified epilepsy (Marson et al., 2007b, Marson et al., 2007a). Furthermore 
extensive prognostic modelling for newly diagnosed epilepsy based on the SANAD 
cohort was carried out by Bonnett et al which have been reviewed in relevant sections 
of this thesis (Bonnett et al., 2014b, Bonnett et al., 2012). 
 DNA from ~40% of patients participating in SANAD was collected and has been used 
in previous genomic studies (Leschziner et al., 2006, Speed et al., 2014a). Like the 
Glasgow cohort, the SANAD study was a major contributor to the EpiPGX cohort of 
newly diagnosed epilepsy described in this thesis. 
 
1.4.6. Rochester, Minnesota study 
This was a longitudinal, observational study utilizing the record linkage system of the 
Mayo Clinic. Residents of Rochester, Minnesota with a diagnosis of epilepsy were 
identified from hospital records and their cases screened by single neurologist. Cases 
were identified between 1935 and 1984. Afterwards, patients were followed up using 
their medical records or via follow up enquiries (Hauser et al., 1993). This study was 
observational and patients were not always on treatment. Furthermore, the inclusion 
period covered a very long time span. That allowed the observation of temporal trends, 
but together with a lack of information on individual treatment schedules, this would 
potentially limit the ability to draw conclusions about individual drug efficacy.    
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1.5.0. Pharmacology of epilepsy and impact of genetic variation  
 
Selection of the first anticonvulsant is a complex process and involves clinical factors 
as well as balancing patient’s perspectives. Clinical factors like epilepsy syndrome or 
dominant seizure type, comorbid conditions, age, gender, family planning and potential 
drug interactions as well as costs and patient preferences all play an important role in 
this process. Future development of genetic knowledge will hopefully aid the process of 
accurate classification of epilepsy syndrome and help tailor treatment more effectively. 
Drug pharmacology can be separated into two main groups, pharmacokinetics 
(dealing with absorption and distribution of the drug) and pharmacodynamics (targets of 
the drug). Anti-epileptic drugs have a complex pharmacology as their targets are CNS-
based and therefore require the drugs to penetrate the blood-brain barrier. 
Furthermore, their targets are not necessarily specific to the epileptic process, hence 
there is a risk for adverse reactions. 
 There are several main theories trying to explain drug resistance in epilepsy. One of 
them – the drug transporter hypothesis - postulates that up-regulation of active efflux 
transporters is induced by a progressive increase in seizures, which in turn leads to a 
lower localised anticonvulsant concentration in the brain, rendering the drugs 
ineffective (Löscher and Potschka, 2002, Kwan and Brodie, 2005). It has also been 
proposed that epilepsy could be treatment resistant due to an intrinsic severity of the 
disease itself (Rogawski and Johnson, 2008, Rogawski, 2013). This approach has been 
substantiated by some epidemiological observations, particularly that a higher number 
of seizures (hence severity) before treatment is associated with a worse treatment 
outcome. Treatment resistance then would be an intrinsic property of the epilepsy and 
would be related to the same factors that are important in epilepsy severity (Rogawski 
and Johnson, 2008, Rogawski, 2013). Lastly, the drug target theory postulates that drug 
resistance is due to either acquired or genetic alteration of drug targets (Remy and Beck, 
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2006). All of these theories have some flaws and most likely treatment failure is due to 
multiple pathological mechanisms (Regesta and Tanganelli, 1999).  
1.5.1. Drug efflux transporters 
This section will focus on drug transporters located at the blood-brain barrier and 
predominantly on key members of the ATP binding cassette (ABC) family, such as P-
glycoprotein (P-gp) and multidrug resistance associated proteins one (MRP1) and two 
(MRP2). The RLIP76 transporter also will be considered although this is not part of the 
ABC family. 
P-gp was first described in 1976 by Juliano and Ling and as it altered drug 
permeability it was named permeability glycoprotein, or P-glycoprotein (Juliano and 
Ling, 1976). One of the sites where it is expressed is human capillary blood vessels at the 
blood-brain barrier (Cordon-Cardo et al., 1989). Increased expression of P-gp has been 
demonstrated in brain specimens removed from patients during surgery for intractable 
epilepsy (Tishler et al., 1995, Marchi et al., 2004, Dombrowski et al., 2001). Increased 
expression of MRP1 and MRP2 has also been associated with epileptic seizures (Miller, 
2010). These proteins function as active efflux pumps, transporting a variety of 
substrates across cell membranes against their concentration gradient (Kerb et al., 
2001). It has been proposed that over-expression of drug efflux transporters in the 
epileptogenic zone could lead to lower local concentrations of AEDs and thus failure to 
respond to treatment (Tishler et al., 1995, Sisodiya et al., 2002). For P-gp to effectively 
explain drug resistance, the majority of available AEDs should be substrates for 
transport. Research so far has produced conflicting results. There are suggestions that 
many commonly used AEDs are either definite or probable P-gp substrates (Zhang et al., 
2012) but other research has demonstrated only limited affinity of AEDs (Löscher and 
Sills, 2007, Dickens et al., 2013, Anderson and Shen, 2007). 
Polymorphisms in the ABCB1 (ATP-Binding Cassette Subfamily B Member 1) gene that 
encodes P-gp have been extensively studied in relation to treatment resistance in 
epilepsy. One of the most studied single-nucleotide polymorphisms (SNPs) in ABCB1 is 
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the synonymous 3435C>T SNP (rs1045642) located in exon 26 (Hoffmeyer et al., 2000). 
It was first described by Hoffmeyer et al in 2000, who demonstrated that volunteers 
expressing the T-allele have higher digoxin plasma level compared with those carrying 
the C-allele. 
The first study exploring this variant in pharmacoresistant epilepsy showed an 
association with the CC genotype (Siddiqui et al., 2003), although later studies have 
reported controversial results covering multiple possible outcomes. A string of studies 
covering diverse ethnic backgrounds failed to show an association between CC genotype 
and intractable epilepsy in adults (Sills et al., 2005) (Kim et al., 2006b), as well as in 
paediatric cases (Vahab et al., 2009) (Dong et al., 2011). A Malaysian study investigating 
response to monotherapy with either CBZ or valproate (VPA) also did not show any 
association (Haerian et al., 2011a), nor did an additional study comparing CBZ blood 
levels or dose/concentration ratios (Ozgon et al., 2008). Similarly, there was no 
association between CBZ and PHT dosing and the ABCB1 3435C>T genetic polymorphism 
(Tate et al., 2005).  
Two prospective studies exploring the link between this genetic polymorphism and 
treatment response in newly diagnosed epilepsy also did not yield any significant 
association (Szoeke et al., 2009, Leschziner et al., 2006). On the other hand, several 
studies have shown an association between CC genotype and drug resistant epilepsy 
(Siddiqui et al., 2003, Soranzo et al., 2004), although the patient cohort partially 
overlapped in these studies. Similar results have been reported from a study examining 
drug resistant and responsive patients with temporal lobe epilepsy (Zimprich et al., 
2004). This study exclusively enrolled treatment resistant patients undergoing pre-
surgical evaluation, with healthy volunteers used as controls. A study from Taiwan also 
demonstrated a positive association of the 3435C>T polymorphism with drug intractable 
epilepsy (Hung et al., 2007). This study defined drug resistance as the occurrence of 10 
or more seizures per year in patients who had tried two or more appropriate AEDs at 
maximal tolerated dose, while drug responsiveness was defined as the absence of 
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seizures for two years. Such a definition excludes a number of subjects in-between those 
categories, thus it is not fully representative of the epilepsy population. A study from 
China has interestingly reported an association between drug intractable epilepsy and 
the TT genotype of 3435C>T (Kwan et al., 2007), likewise Seo et al have reported similar 
results for CBZ monotherapy in Japanese patients (Seo et al., 2006). Thus, one can 
conclude that conflicting results are not confined to one ethnic group.  
The 3435C>T polymorphism is not the only SNP studied; other ABCB1 polymorphisms 
also have been investigated, most notably 2677T/A>G and 1236C>T. The number of 
these studies is smaller, but nevertheless results show similar controversies. In the case 
of 2677T/A>G, several studies have failed to find an association with drug resistance 
(Vahab et al., 2009, Kim et al., 2006b, Kim et al., 2009a, Shahwan et al., 2007, Von 
Stülpnagel et al., 2009), although a handful of reports are positive (Kumari et al., 2011a, 
Kwan et al., 2009). The situation is similar with 1236C>T and most studies do not report 
an association (Grover et al., 2010, Haerian et al., 2011b, Kumari et al., 2011a, Kim et al., 
2009b, Qu et al., 2012). Several meta-analyses have also been carried out, although, 
again, the results are not uniform. Some showed no association between 3435C>T 
polymorphism and drug resistance (Haerian et al., 2010, Haerian et al., 2011c, 
Bournissen et al., 2009), whereas others showed a weak association in Caucasians only 
but no association overall (Li et al., 2015b, Li et al., 2015a, Lv et al., 2014). When 
assessed separately, the ABCB1 C1236T / G2677T / C3435T haplotype showed no 
association with drug resistance even when stratified by ethnicity and the same study 
also showed a lack of association for ABCB1 C1236T and G2677T with drug resistance 
when analysed separately (Li et al., 2015a). One systematic review reported that 
heterogeneity is mainly derived from six positive studies (Haerian et al., 2010).  
All of these studies investigating the drug transporter hypothesis report somehow 
conflicting results. There is more than one explanation for this situation. The main 
problems are related to either study design, phenotype definitions, or sample size. For 
example, none of the above studies reported initial sample size calculations or an 
  
55 
 
assessment to determine whether there was sufficient power to detect genetic 
association. Sample size in these studies was very variable, ranging from 60 patients to 
685 patients, and most are significantly underpowered. Lack of unified and clear 
phenotype definitions is also an issue; a patient classified as drug resistant in one study 
could be classified as drug responsive in another (Kasperaviciute and Sisodiya, 2009). 
Definitions for drug resistance and response across different studies often identified 
very different patient groups. In some cases, generalized epilepsy was more prevalent in 
the drug responsive group and focal epilepsy, or those with co-morbid learning 
disabilities, was overrepresented in the intractable group. Several studies have reported 
demographic data only partially or not at all. Other potential bias is the fact that cohorts 
are often assembled from patients under the care of the tertiary level hospitals, that 
routinely deal with multi-drug resistant patients. Added to that, follow-up time is very 
variable, ranging from 3 months to 2 years, which might also contribute to 
heterogeneity (Li et al., 2015a).  
Available data about ABCC1 (ATP Binding Cassette Subfamily C Member 1; multidrug 
resistance-associated protein; MRP1) and ABCC2 (ATP Binding Cassette Subfamily C 
Member 2; MRP2) is not as extensive as for P-gp.  Literature about AEDs transported by 
both MRP transporters is limited. Luna-Tortós et al reported that neither 
carbamazepine, valproate, levetiracetam, phenytoin, lamotrigine nor phenobarbital is 
transported by MRP1 or MRP2 (Luna-Tortós et al., 2010). Compared to P-gp, the link 
between genetic polymorphism in MRP genes and drug response has been investigated 
in a very limited fashion. Only a few studies have investigated ABCC1 polymorphisms 
with regards to epilepsy treatment response. A study from India investigated ABC 
transporter genetic polymorphisms in relation to treatment response and included 
ABCB1 and both ABCC1 and ABCC2 (Grover et al., 2012). It reported a statistically 
significant association between ABCC2 promoter polymorphisms 1549G>A and 1019A>G 
and recurrent seizures in females despite using a highly conservative approach (i.e. 
Bonferroni method) to correct for multiple testing. Follow up period in this study was 
just 12 months, of which two months were assigned to achieve steady drug 
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concentration and 10 months to assess response. The authors initially enrolled 400 
patients, but by the end of the study the dropout rate was 46% (184). This represents a 
significant drop out rate for a short study and undermines its power, as well as raising 
questions about potential attrition bias and the validity of results. Furthermore, it is 
doubtful if 10 months is sufficient follow up length to evaluate treatment response. In a 
Caucasian paediatric and adolescent cohort, the ABCC2 24T variant was reported to be 
significantly over-represented among non-responders (Ufer et al., 2009a). Symptomatic 
epilepsy was also over-represented in the non-responder group compared to 
responders. Meanwhile, a later study on childhood epilepsy from the same authors 
failed to replicate their previous finding (Ufer et al., 2011). Any link between the ABCC2 
24T variant and drug resistance has not been confirmed in several adult studies (Seo et 
al., 2008, Zimprich et al., 2012), although some positive results also have been reported 
(Qu et al., 2012). Meta-analysis of available studies has shown conflicting results. One 
showed no statistically significant association for the most common SNPs whereas two 
others reported that ABCC2 G1249A might have a decreased risk of treatment resistance 
(Wang et al., 2015, Chen et al., 2014a, Grover and Kukreti, 2013). With regard to newly 
diagnosed epilepsy, it has been shown that ABCC2 polymorphisms have no association 
with treatment response to carbamazepine and furthermore, the authors showed that 
the drug is not a substrate of this transporter (Radisch et al., 2014). 
RLIP76 is a non ABC family multi-specific transporter that has been found at the 
blood-brain barrier in surgically removed epileptic foci  (Awasthi et al., 2005). In 2007, a 
study carried out by Soranzo et al showed that in both epileptic and control brain tissue 
RLIP76 was not endothelial. Furthermore, they genotyped six tagging SNPs in drug 
resistant and drug responsive groups and showed no association with phenotype 
(Soranzo et al., 2007). Later studies investigating common RLIP76 polymorphisms in 
epilepsy, including in newly diagnosed cases, failed to identify any influence on drug 
response (Leschziner et al., 2007, Manguoğlu et al., 2011). 
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In conclusion, it is unlikely that genetic polymorphisms in drug efflux transporters 
play a major role determining treatment outcomes.  
 
1.5.2. Sodium channels 
Voltage gated sodium channels have been extensively studied for their role in 
neurology, and particularly in epilepsy. In an adult human brain there are four main 
sodium channel subtypes, NaV1.1, NaV1.2, NaV1.3, and NaV1.6, encoded by the Sodium 
Voltage-Gated Channel Alpha Subunit 1 (SCN1A), Sodium Voltage-Gated Channel Alpha 
Subunit 2 (SCN2A), Sodium Voltage-Gated Channel Alpha Subunit 3 (SCN3A), and Sodium 
Voltage-Gated Channel Alpha Subunit 8 (SCN8A) genes, respectively (Noebels et al., 
2012). Mutations in these genes create a wide array of epileptic syndromes ranging from 
benign familial neonatal seizures to catastrophic epileptic encephalopathies, such as 
severe myoclonic epilepsy of infancy (SMEI). However, only 1 – 2 % of idiopathic 
epilepsies seems to be monogenic (Weber and Lerche, 2008). In terms of 
pharmacogenetics, SMEI is particularly important. There have been observations that 
AEDs with sodium channel properties, such as lamotrigine and carbamazepine (Rogawski 
and Loscher, 2004), can exacerbate seizures in patients with SMEI (Horn et al., 1986, 
Guerrini et al., 1998). It has now been postulated that selective impairment of sodium 
channels in GABAergic inhibitory neurons might be the underlying mechanism for SMEI 
(Noebels et al., 2012).  
Genome based biomarkers have been extensively investigated as predictive factors 
for treatment response and dosage parameters of AEDs with a main action on sodium 
channels.  An association between SCNA1 IVS5–91 G>A and response to sodium channel 
blocking AEDs has been shown in Japanese and Han Chinese populations (Abe et al., 
2008, Ma et al., 2014). Further studies have demonstrated an association between this 
polymorphism and clinically effective and/or maximal-tolerated doses of CBZ (Zhou et 
al., 2012, Hung et al., 2012, Tate et al., 2005), phenytoin (Tate et al., 2006, Tate et al., 
2005) and oxcarbazepine (Ma et al., 2015). The methodology in some of these studies is 
  
58 
 
questionable, for example Zhou et al reported a significant association but apparently 
failed to correct their analysis for multiple testing, which would have resulted in the loss 
of statistical significance. As with the efflux transporter studies reviewed above, there 
are at least as many studies showing no link between the IVS5–91 G>A polymorphism 
and drug resistance (Sánchez et al., 2010, Kumari et al., 2013) or CBZ dosage (Zimprich 
et al., 2008).  
Other SCN1A polymorphisms that have been investigated include 3166 A>G and 603-
91G>A, both without association (Sanchez et al., 2010) (Manna et al., 2011). The 
situation with A3184G is interesting as there are two studies from the same institution 
with opposing results (Kumari et al., 2011a, Lakhan et al., 2009). The SCN2A 56G>A 
polymorphism has been associated with drug resistant epilepsy in a northern Indian 
population (Lakhan et al., 2009) and this is one of the few studies that has performed a 
sample size calculation. A study from Taiwan investigated multiple SNPs and found 
association between SCN2A IVS7-32A>G and resistance to AED treatment in a Han 
Chinese population. The authors of this study created a subgroup in their cohort of 
patients who were treated exclusively with sodium channel blocking AEDs but the 
association in this subgroup was no stronger than that seen in general. (Kwan et al., 
2008). Two multi-centre cohort studies involving patients from Malaysia and Hong Kong 
have failed to demonstrate any association between treatment outcome and common 
SCN1A, SCN2A, SCN3A polymorphisms, and two further meta-analyses have been 
similarly unsuccessful (Haerian et al., 2013, Haerian et al., 2012).  
Polymorphisms in sodium channel genes are unlikely to be a general biomarker for 
treatment response. Nevertheless, as sodium channel defects are causal in some 
epileptic syndromes, genetic testing and diagnosis might have implications for 
treatment selection. For example, in Dravet syndrome, the majority of patients will have 
a mutation in SCN1A and their treatment strategy might be different from other forms 
of early onset epilepsy (Dravet and Oguni, 2013). In conclusion, in selected patient 
populations there might be a role for testing mutations in sodium channel genes as a 
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part of the clinical work-up but otherwise these genes do not appear to harbour 
valuable biomarkers of treatment outcome in general. 
1.5.3. Gamma-aminobutyric acid system 
 
The GABAergic system is one of the main inhibitory systems in the brain and has been 
extensively studied in relation to almost all aspects of epilepsy. Mutations in genes 
encoding GABAergic system have been associated with generalised epilepsy, SMEI or 
febrile seizures (Baulac et al., 2001, Wallace et al., 2001, Cossette et al., 2002, Harkin et 
al., 2002, Audenaert et al., 2006, Johnston et al., 2014). Furthermore mechanism of 
action of some AED are via potentiation of GABAergic system (Kwan et al., 2001). This 
makes the GABAergic system an attractive target for pharmacogenomics research. 
Polymorphisms in Gamma-Aminobutyric Acid (GABA) related genes and treatment 
response in epilepsy has also been investigated, although not as extensively as P-gp or 
other potential drug targets. Several studies have investigated the potential link 
between genetic polymorphism in GABA receptor subunits and drug resistance. One 
such study evaluated GABRA1 IVS11 + 15 A > G and GABRG2 588C > T and reported an 
association of the G-allele of the GABRA1 with both susceptibility for epilepsy and drug 
resistance, but no association was observed for the GABRG2 588C>T variant (Kumari et 
al., 2010). A later study based on the same cohort investigated polymorphism in 
different GABA receptor subtypes. It showed no association for GABRA6 c. 1512 T>C, 
GABRB2 c. 1412 C>T, and GABRR2 c. IVS2C>G polymorphisms and drug resistance 
(Kumari et al., 2011b). An further study utilising mesial temporal lobe epilepsy due to 
hippocampal sclerosis as a prototype resistant epilepsy and Juvenile Myoclonic Epilepsy 
(JME) as responsive epilepsy showed no difference in GABAA receptor SNP distributions 
between the groups (Balan et al., 2013). Likewise, a study from Taiwan investigating 
SNPs in the α-subunit of the GABAA receptor showed no significant difference in 
individual genotype distributions between responsive and treatment resistant patients 
but interestingly, a logistic regression model adjusted for age, aetiology and epileptic 
syndrome suggested that the combination of GABRA1 (rs6883877 C>T), GABRA2 
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(rs511310 A>G) and GABRA3 (rs4828696 C>T) SNPs was associated with treatment 
outcome (Hung et al., 2013).  
In conclusion, as in the case of sodium channels, testing for genomic biomarkers 
related to the GABAergic system might ultimately have a role in a clinical practice, but as 
an aspect of diagnostic work-up rather than in the prediction of treatment outcome. 
 
1.5.4. Hepatic metabolism 
Some of the most commonly-used AED, like phenytoin, valproic acid, carbamazepine 
and lamotrigine, are entirely or at least partially metabolized in the liver. The most 
widely studied drug metabolising system is the cytochrome P450 (CYP) system. Several 
AEDs are substrates for CYP enzymes, including phenytoin which is metabolized 
extensively by Cytochrome P450 Family 2 Subfamily C Member 9 (CYP2C9) and CYP2C19 
(Klotz, 2007). Numerous studies have investigated efficacy, adverse effects and/or blood 
levels of this drug in relation to variability in the genes encoding these two enzymes. 
Studies examining PHT pharmacokinetics in the Japanese population have demonstrated 
a role of genetics in the metabolism of the drug (Odani et al., 1997, Hashimoto et al., 
1996). A study from the Netherlands involving 60 individuals with learning difficulties, 
covering ages between 16 to 74 years, showed an association between dose 
requirements of PHT and CYP2C19 genetic variants. However, only 13 of patients were 
on PHT monotherapy (van der Weide et al., 2001). A later investigation looking at dosing 
of CBZ and PHT reported an association between the CYP2C9*3 polymorphism and 
maximum dose of PHT. The PHT group had 281 patients and carbamazepine had 425, 
thus 185 patients had been on dual treatment with potential interaction between drugs 
(Tate et al., 2005). Furthermore, there are individual case reports of significant 
phenytoin toxicity occurring after emergency usage in CYP2C9 poor metabolizers 
(Dorado et al., 2013).  
The Pharmacogenetics Working Group of the Royal Dutch Association for the 
Advancement of Pharmacy conducted a systematic review on a list of common 
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medicines and the effect of genetic factors on their dosing requirements and afterwards 
issued nationwide recommendations. The advice for phenytoin is a 25% dose reduction 
in carriers of CYP2C9 common variants (*1/*2, *1/*3) and 50% reduction in carriers of 
less common but more dysfunctional alleles (*2/*2, *2/*3, *3/*3) (Swen et al., 2011).  
Phenobarbital also has been investigated in this respect and an association between 
dosage and CYP2C19 polymorphisms seen (Mamiya et al., 2000).  
Several studies have analysed CYP polymorphisms and response to treatment 
without regard to specific AEDs. A mixed paediatric and adolescent cohort from 
Germany was used to explore the link between several CYP2C8, CYP2C9, and CYP2C19 
polymorphisms and treatment outcome but arrived at inconsistent results and 
concluded that these SNPs have only minor impact on drug response (Ufer et al., 
2009b). Another mixed adult and paediatric cohort from Spain showed no association 
for drug responsiveness and genetic polymorphisms in CYP enzymes (Sanchez et al., 
2010). A study from India demonstrated that the CYP2C9 1075A>C (*3 variant) 
polymorphism shows significantly different genotype distributions in multi-drug 
resistant and drug-responsive patients (Kumari et al., 2011a). However, despite testing 
multiple polymorphisms, the authors failed to correct for multiple comparisons and 
once this is done, the results lose their statistical significance.  
Another enzyme involved in drug metabolism that has been investigated in 
pharmacogenetic studies is epoxide hydrolase (encoded by EPHX1). A Japanese study 
showed that several EPHX1 haplotypes are associated with altered CBZ metabolism 
(Nakajima et al., 2005). Furthermore, there are two studies that have evaluated CBZ 
dosage and EPHX1 genetic polymorphisms, both of them reporting association of 
genetic polymorphisms with CBZ maintenance dose (Hung et al., 2011, Makmor-Bakry et 
al., 2009).  
Polymorphisms in genes encoding enzymes belonging to UDP-
glucuronosyltransferase family have also been investigated, although far less often than 
others. There is a reported effect of the UGT1A4 L48V variant on LTG serum 
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concentration when used as monotherapy (Gulcebi et al., 2011). A further study used 
multivariate modelling and showed an association of UGT2B7 c.802T>C, together with 
SCN1A IVS5–91 G>A and EPHX1 c.337T>C, with concentration–dose ratios of CBZ (Hung 
et al., 2011). A similar investigation looking at VPA dose optimization indicated that SNPs 
in UGT1A6 and GRIN2B might be associated with concentration–dose ratios of VPA 
(Hung et al., 2011). 
In conclusion, the metabolism of phenytoin is most likely influenced by the genetic 
status of CYP2C9. Because of its complex pharmacokinetics, it probably plays a role in 
the development of neurotoxicity with this drug. However, generally speaking, genetic 
polymorphisms in metabolising enzymes have only a modest effect of AED 
pharmacokinetics. In the absence of a correlation between AED concentration and 
treatment response (Tomson et al., 2007), which explains why regular measurement of 
serum levels is not a widespread clinical practice, SNP genotyping is of limited value 
even where there is evidence of a link between genotype and dosing.  
1.5.5. Adverse events 
Five commonly used drugs for the treatment of epilepsy have labels that have been 
updated by the U.S. Food and Drug Administration (FDA) to include pharmacogenetic 
information. These are carbamazepine, valproic acid, clobazam, phenytoin and 
diazepam, although in the case of diazepam the FDA does not advise about genetic 
testing or genetic factors but simply informs about the role of CYP3A4 and CYP2C19 in 
its metabolism and in potential drug interactions. A study from Japan investigating 
recovery time after general anaesthesia when diazepam had been used as pre-
medication showed an influence of CYP2C19 genotype (Inomata et al., 2005). In the case 
of clobazam, the FDA advise changes in the starting dose and pace of titration for 
patients who are known to be CYP2C19 poor metabolizers . 
Carbamazepine and phenytoin are two commonly prescribed AEDs with known 
genome based markers associated with cutaneous hypersensitivity reactions. HLA-
B*15:02 has a strong association with CBZ-induced Stevens-Johnson syndrome in the 
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Asian population (Yip et al., 2012) and a moderate association with similar reactions 
induced by phenytoin (Cheung et al., 2013). Additionally, HLA-A*31:01 is associated with 
a broader phenotype of CBZ cutaneous hypersensitivity across multiple ethnicities (Yip 
et al., 2012, Amstutz et al., 2014). Recent pharmacogenetics research for both drugs has 
resulted in changes in labelling (U.S. Food and Drug Administration, 2011a),(2011b). 
Interestingly, lamotrigine, which is another widely used anticonvulsant associated with 
cutaneous hypersensitivity reactions, so far has no robust HLA association identified 
(Bloch et al., 2014). 
Valproic acid is contraindicated in persons with urea cycle disorders and there are 
recommendations that it is investigated further in patients who develop unexplained 
hyperammonemic encephalopathy (U.S. Food and Drug Adminstration, 2016). It also 
carries a risk of potential liver toxicity, particularly in patients with Alpers-Huttenlocher 
syndrome caused by a mutation in mtDNA replicase, polymerase gamma 1 (POLG) 
(Stewart et al., 2010, Saneto et al., 2010), although it has no formal warning in this 
regard.   
1.6. Newly diagnosed epilepsy and GWAS 
At the moment there is only one prospective pharmacogenomics study utilising 
GWAS for newly diagnosed epilepsy (Speed et al., 2014a). This study and the work 
described in this thesis shared common patient cohorts and methodological aspects. 
Speed et al analysed 1296 cases of newly diagnosed epilepsy, with the study cohort 
compromising SANAD patients and a prospectively followed cohort from Melbourne, 
Australia. Measured outcome was 12 months or longer seizure freedom and patients 
with incomplete follow-up were excluded from the study. Univariate analysis of clinical 
prognostic factors was performed on both sub-cohorts separately. Factors from the 
SANAD sub-cohort that were statistically significantly associated with the presence of 12 
months remission were later used in the GWAS analysis. GWAS was performed both 
with and without adjusting for relevant clinical covariates. The following factors were 
used for adjustment; age at starting treatment, number of seizures before treatment, 
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EEG result, epilepsy type, presence or absence of neurological impairment, and 
treatment with gabapentin. After QC procedures, the GWAS was performed on 889 
newly treated epilepsy patients who had complete follow-up data. This was just 68.6% 
of the total available cases and although the Melbourne sub-cohort lost more cases 
(61.8% included) than the SANAD sub-cohort (71.4% included), there was no difference 
in the proportions of responders (experiencing 12 month seizure freedom) and non-
responders between excluded and included patient groups. The GWAS was performed 
separately on each sub-cohort and a fixed-effect meta-analysis subsequently carried 
out.   
 To summarise the findings, no single SNP reached genome-wide significance, but 
three loci had suggestive evidence of association; two from the unadjusted analysis 
(rs492146 and rs72700966) and one from the adjusted analysis (rs143536437). The 
study was sufficiently powered to detect variants with the strong effect size, but was not 
intended to assess treatment response as a polygenetic trait. 
 
1.7. Methodological aspects 
As a rapidly evolving field, pharmacogenomics has not been spared from 
controversies and problems. As expected, there is significant room for growth and 
improvement. The situation when significant number of molecular genetic studies fail to 
fully follow the basic principles of clinical epidemiology is not new (Bogardus, 1999). A 
study evaluating methodological quality of pharmacogenetic studies using binary 
responses showed that significant number of studies have problems with design and 
methods. From 65 reviewed studies, only one reported a planned sample size and had 
performed a prior sample size calculation, only one third provided detailed information 
on design, and a small minority undertook any correction for multiple testing (Cobos et 
al., 2011).  
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Epilepsy pharmacogenomics is not excluded from the methodological problems that 
are seen in the rest of the field. In 2004, Neurology had two articles in the same edition 
on ABCB1 polymorphisms and treatment response that reported different results 
(Zimprich et al., 2004, Tan et al., 2004). In the accompanying editorial, Ott drew the 
conclusion that a positive result is likely due to a combination of low pre-test probability 
and insufficient sample size (Ott, 2004). A further problem is with heterogeneity in the 
definitions of treatment outcome. A paediatric epilepsy study applying six different 
definitions of intractability that had been employed in previous investigations found that 
the proportion of children counted drug resistant ranged between 9% - 24%, depending 
on the definition used (Berg and Kelly, 2006). This demonstrates that differences in 
outcome can be created simply by applying various different definitions. This could be a 
potentially important issue in the case of small and underpowered pharmacogenomics 
studies in epilepsy. It has already been demonstrated that remission rates vary 
significantly between studies. These differences have been explained by several factors, 
including case ascertainment (prospective studies having more recurrent seizures than 
retrospective), the proportion of patients included with a single seizure (higher 
proportion of remission in cohorts with more single seizure cases), age of the patients 
included, and duration of follow-up (Abimbola et al., 2011). Epidemiological studies 
provide further corroborative evidence of the importance of case definition. It has been 
shown that the incidence of epilepsy is affected depending on how epilepsy has been 
defined, with higher incidence reported when single unprovoked and acute 
symptomatic seizures are included (Banerjee et al., 2009).  
Case ascertainment is an important aspect of research design. Prospective study 
design is the gold standard in observational studies. If a case-control design is used, 
groups should only differ in respect of the outcome studied and controls should have a 
chance to develop the outcome of interest (Jorgensen and Williamson, 2008). Hence, 
using healthy controls is inappropriate as they have never been exposed either to 
treatment or to the disease itself.  
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A systematic review of prognostic factors for medically intractable epilepsy has 
shown that there is significant heterogeneity and bias towards hospital based studies 
(Wassenaar et al., 2013). On the other hand, randomized clinical trials are often 
designed for regulatory purposes, enrol highly selected patients and employ short 
follow-up periods that are consistent with short-term treatment exposure (Kwan and 
Sander, 2004).    
Most research in epilepsy pharmacogenetics thus far has concentrated on a simple 
monogenic explanation, hypothesizing that one mechanism explains drug intractability. 
This approach is questionable from a biological perspective. It is not clear how it fits with 
currently available epidemiological data showing that some patients experience a 
remitting-relapsing pattern to their disease course (Brodie et al., 2012, Sillanpaa and 
Schmidt, 2006). It is unlikely that such a pattern could be explained by simple 
monogenic effect – it is more appropriate to suggest that the situation is considerably 
more complicated, and perhaps reflects the complexity of the epileptogenesis process 
itself. 
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2.0. Aims and objectives of this work 
 
The introductory chapter described current knowledge about newly diagnosed 
epilepsy and more extensively elaborated on clinical factors associated with treatment 
outcome, together with methodological and pharmacogenomic aspects. As outlined 
earlier, the majority of patients with newly diagnosed epilepsy will have a favourable 
prognosis while around 30 – 40 % will fail their first anticonvulsant. Early identification 
of patients who are likely fail treatment would potentially pave the way to early 
intervention and improvement of treatment outcomes as well as improvement of 
quality of life. 
 To date, there is only one large scale GWAS study carried out exclusively on patients 
with newly diagnosed epilepsy (Speed et al., 2014a). It did not identify any SNPs with 
genome-wide significance.  Data on associated clinical factors are more widely reported, 
but are often limited by sample size and the results are still controversial. As discussed 
in the introductory chapter, it is advisable to perform GWAS as a univariate analysis and 
also adjusted for clinical covariates. Significant numbers of pharmacogenomic studies 
have investigated specific aspects of epilepsy therapy (mostly drug resistance) but with 
the exception of one or two ADR studies these have been controversial and not 
consistently replicated. This problem could potentially be due to methodological aspects 
of those studies, such as the procedures for cohort assembly and follow up. 
In an effort to improve current knowledge about prognosis of newly diagnosed 
epilepsy, the work described in this thesis had the following aims and objectives: 
1. To assess clinical factors and their relationship with 12 month remission from 
seizures after application of the first well tolerated anticonvulsant. 
a. Data was collected by manual phenotyping of cases, by transcription of existing 
databases into the EpiPGX eCRF, and collected from partners of the EpiPGx research 
consortium. 
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b. Data was then downloaded from the central repository and interrogated by using 
routine descriptive statistical methods. 
c. A logistic regression model assessing association of clinical factors with 12 month 
remission of newly diagnosed epilepsy was applied. 
d. A Cox regression model assessing association of clinical factors with time to onset 
of 12 month remission in newly diagnostic epilepsy was applied. 
2. To investigate the impact of methodological heterogeneity in studies of treatment 
outcome in epilepsy. 
a. Data was collected and processed in the same way as described for aim one above. 
b. Different definitions of remission were applied and the proportions of responders 
compared in each case to assess the impact of terminology on treatment outcome. 
c. The impact of ascertainment methods (prospective vs. retrospective) and duration 
of observation were investigated by routine statistical methods. 
d. The effect of transcription and electronic upload on data quality and reliability 
were assessed by comparing the original SANAD genetic cohort with the newly-
uploaded version of SANAD using routine statistical methods. 
3. To explore genome based biomarkers of treatment response in newly diagnosed 
epilepsy. 
a. A GWAS for treatment response to first well tolerated anticonvulsant was 
performed, with expert input from colleagues and collaborators in Work Package 2 of 
the EpiPGX consortium. 
b. A separate GWAS of 12-month remission on first well tolerated AED in patients 
with newly diagnosed focal epilepsy was also performed using univariate analysis and 
also adjusting for important clinical covariates.  
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3.0. Methods 
 
My thesis is based on the EpiPGX project; hence this chapter will briefly describe the 
overall project, followed by a more detailed description of EpiPGX Work Package 2 
(Genomic Biomarkers of Early Treatment Outcome in Newly Diagnosed Epilepsy). Lastly, 
methods used for analysis of (a) association of clinical covariates, (b) methodological 
aspects of cohort construction, and (c) GWAS will be described. 
 
3.1. General overview of EpiPGX project 
EpiPGX is the acronym for the project whose full title is ‘Epilepsy Pharmacogenomics: 
delivering biomarkers for clinical use’. The project was started on 1st November 2011 
and finished on 31st October 2015. The main project coordinator was Professor Sanjay 
Sisodiya from University College London. It was funded by the European Union Seventh 
Framework Programme (FP7/2007-2013) under the grant agreement n° 279062, as a 
small to medium scale focused research project, involving collaboration between 
academic and public bodies with small to medium sized enterprise.  
The project had the following participants: 
1. University College London (UCL) United Kingdom.  
2. Université Libre de Bruxelles (ULB) Belgium. 
3. Istituto Giannina Gaslini (IGG) Italy. 
4. Eberhard-Karls-Universität Tübingen (EKUT) Germany. 
5. Stichting Epilepsie Instellingen Nederland (SEIN) The Netherlands. 
6. Universitaetsklinikum Bonn (UKB) Germany. 
7. Royal College of Surgeons in Ireland (RCSI) Ireland. 
8. Belfast Health and Social Care Trust (BHSCT) Northern Ireland. 
9. Islensk erfðagreining ehf (deCODE) Iceland. 
  
70 
 
10. Luxembourg Centre for Systems Biomedicine University of Luxembourg (LCSB) 
Luxembourg. 
11. University Medical Center Utrecht (UMCU) The Netherlands. 
12. University of Liverpool (ULIV) United Kingdom. 
13. Imperial College London (IMP) United Kingdom. 
14. University of Glasgow (UGLA) Scotland. 
15. GABO:mi Gesellschaft für Ablauforganisation: Milliarium mbH & Co. KG Germany. 
The project consisted of several work packages, which either provided the practical 
support required for implementation of the project or led a specific research direction. 
The overall main goal of EpiPGX was to investigate and identify genome-based 
predictive biomarkers for clinical application in patients with epilepsy. It covered all 
aspects of epilepsy care, including newly diagnosed and treatment resistant patients as 
well as selective drug response, adverse reactions, and valproate teratogenicity. 
Supportive work packages were involved in the development of unified phenotype 
definitions (in close collaboration with scientific work packages), the support and 
development of a centralised data repository, as well as genotyping and administrative 
support. The work packages, their goals, and leading institutions have been summarised 
in Table 2. The University of Liverpool led Work Package Two (WP2), investigating 
genome-based biomarkers related to treatment outcomes in newly diagnosed epilepsy. 
  
71 
 
Table  2. EpiPGX work package list and their main goals. 
WP 
No 
Title of the work package Lead Main goals 
1 
Characterisation of 
pharmacogenomics phenotypes 
ULB 
Generation of robust phenotype definitions for cross-consortium application 
Implementation, updating and phenotyping quality control 
Interaction with other pharmacogenomics networks and organizations 
2 
Genome-based biomarkers of early treatment 
response in newly diagnosed epilepsy 
ULIV 
Identification of biomarkers for treatment response with first well-tolerated AED 
General and selective drug responsiveness in newly diagnosed epilepsy 
Biomarkers of treatment failure with first AED 
3 
Genome-based biomarker discovery for broad 
AED resistance 
UCL 
Identification of common genetic variants (SNP/CNV) for broad drug resistance 
Genome-based biomarkers of shared rare variants and genes with increased burden of individual 
variants for individuals with extreme phenotypes 
4 
Genome-based biomarker discovery for late 
response to specific AEDs 
EKUT 
Genome-based biomarkers for late response/non-response to specific AEDs in focal and 
generalised epilepsies 
Common genome-based biomarkers for late drug response 
5 
Genome-based biomarker discovery for specific 
ADRs 
RCSI 
Assessment  of common variants as genome-based biomarkers for each AED–associated ADRs 
via genetic mapping across cases and controls 
Rare genetic variants as biomarkers for a specific ADR via high-throughput 
sequencing in selected cases 
6 
Genome-based biomarker discovery for 
valproate teratogenesis 
BHSCT 
To establish genetic and clinical database for babies born with AED-induced major congenital 
malformations and their parents 
Genetic variants associated (including CNV) with major congenital malformations associated with 
in utero exposure to VPA 
Epigenetic changes induced by VPA 
Identification of rare variants associated with AED-induced major congenital malformations 
7 Core analytic and bioinformatic processing LCSB 
To provide bioinformatics support 
To carry out multivariate analysis for genetic variants associated with treatment response 
Assessment of identified variants using computational-based functional and knowledge-driven 
analysis 
8 
Development of diagnostic tests and in silico 
database 
deCODE 
Genotyping 
Development of genomic assays for identified variants and clinical prediction tools 
Generation in-silico virtual test bed for drug development 
9 Project Management GABO:mi Administrative support 
10 Dissemination and training UCL Dissemination and coordination 
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Prior to the start of data collection and cohort assembly, unified phenotype 
definitions were agreed between the centres with subsequent testing and 
implementation (Appendix 2, page 222). As a part of the testing process for how 
phenotypes should be applied, each clinical work package provided a selection of 
anonymised cases. Those cases were then phenotyped and outcomes were compared 
between centres. This effort was coordinated by work-package 1. A similar exercise was 
repeated twice during the project and the results were analysed and reported during 
the annual general assembly of EpiPGX.  
For the data collection, a central repository (electronic case record form; eCRF) was 
used. A paper version of the CRF was produced (Appendix 1, page 201) but the 
electronic version was used exclusively. The eCRF was based on the FileMaker platform 
and hosted on a server at deCODE (Iceland). Each clinical centre accessed the eCRF via 
remote access software. Access was controlled and password protected. Maintenance 
and updating of eCRF was a collaborative effort led by deCODE, LCSB, and assisted by 
the relevant WPs.  
Cases were either manually phenotyped or data were transcribed and uploaded from 
existing clinical databases. Manual phenotyping was done locally utilising clinical notes. 
Policies on data transfer differed from centre to centre. The approach used in Liverpool 
is described in more detail later in this chapter. 
Data relevant to each individual centre were accessible to the respective centre in 
browsing mode using distant access software. Prior to analysis, selected (in case of 
EpiPGX Work package 2, all newly diagnosed) cases were downloaded and transferred 
to Liverpool. Permission to access the data was obtained from individual centres ahead 
of the download. Further work with the data was carried out locally. Genomic data was 
stored on a cluster at the LCSB. The main GWAS analyses were performed on the same 
LCSB cluster, using remote access software.  
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3.2. Ethical aspects 
The EpiPGX project complied with the highest ethical standards, national and local 
regulations. All clinical centres had received prior approval from either their local or 
national ethics committees for pharmacogenomic analysis of contributing samples and 
clinical data. All research activities were undertaken by EU member countries and one 
associated country (Iceland). Strict data confidentiality standards were followed; 
genotypic and phenotypic information was anonymized. In addition, the project had a 
separate ethical advisory board. The project office collected and archived all required 
ethical approvals at the outset of the project. 
3.3. EpiPGX Work Package 2: Detailed description 
3.3.1. Sample size  
One of the main aims of the EpiPGX project was to collect and transfer to a single 
repository all available historical data. There was little active on-going patient 
recruitment during the project, hence no prior sample size calculation was carried out. A 
retrospective power calculation using CaTS software was performed afterwards (Skol et 
al., 2006). This software was designed based on work carried out by Skol et al which 
have shown that a joint analysis is more efficient that two stage replication approach 
(Skol et al., 2006).  
3.3.2. Cohort assembly  
Assembly of a newly diagnosed epilepsy cohort was based on patient status at the 
first visit recorded in their clinical records. Cases with previously existing epilepsy were 
excluded from EpiPGX WP2. Each centre collected data and assembled their cohort 
separately. The eCRF served as a unified and centralised data capture vehicle. Collection 
of data was carried out either manually, utilising contemporary clinical records, or by 
transferring pre-existing clinical trial data or clinical databases. Methods of assembly of 
each separate cohort used in EpiPGX WP2 are summarised in table 3. Once the data 
were collected, they were downloaded from the eCRF and phenotypes were derived. 
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Strict adherence to phenotype definitions was enforced, and only newly diagnosed cases 
were downloaded and utilised. 
Table 3. Methods of assembly and sources of each individual cohort used to form the 
newly diagnosed epilepsy cohort in EpiPGX WP2. 
Cohort Origin Method of data collection 
UCL Institute of Neurology, UCL Manual phenotyping 
EKUT 
Eberhard-Karls-Universität 
Tübingen, Tuebingen, 
Germany 
Manual phenotyping 
ULB Université Libre de Bruxelles 
Data transfer from existing 
clinical database 
RCSI 
Royal College of Surgeons in 
Ireland, Beaumont Hospital 
Manual phenotyping 
ULIV 
University of Liverpool and 
Walton Centre NHS 
Foundation Trust 
Manual phenotyping 
Glasgow 
Epilepsy Unit, Western 
Infirmary, Greater Glasgow & 
Clyde NHS trust 
Manual phenotyping 
Australia 
The Royal Melbourne Hospital 
and the Austin Hospital in 
Victoria 
Data transfer from existing 
clinical trial database 
(coordinated at University of 
Liverpool) 
SANAD University of Liverpool 
Data transfer from existing 
clinical trial database 
 
3.3.3. Data collection and phenotyping 
Phenotyping was carried out separately at each centre. It was done by experienced 
phenotypers (clinical fellows or research nurses) supported as required by clinical 
supervisors. In rare cases when specific questions regarding an individual case arose, it 
was discussed within the relevant work package.  
Identification of cases for inclusion in EpiPGX was in the hands of each centre. There 
was very little ongoing recruitment of patients during the project; cohorts mostly 
  
76 
 
consisted of historical data. Assembly of historical cohorts was influenced by the 
respective purpose and aims of the original studies. 
3.3.3.1. Author’s contribution to phenotyping. 
 
Manual phenotyping of all cases included in the EpiPGx by the WP2 was undertaken 
by the author of this thesis.  
It included both patients with newly diagnosed and established epilepsy. As a part of 
the project, cases with established epilepsy were phenotyped and the data were later 
shared with partners. Cases were phenotyped either in the Walton Centre in Liverpool 
or Epilepsy Research Unit based at the Western Infirmary in Glasgow.  
Manual phenotyping involved all aspects of data capture and extraction. A variety of 
old research and clinical databases were used to trace and cross-link historical cases 
with current clinical records. To provide a maximal capture where required, old scanned 
records were used and notes were retrieved from the off-site storage. All available 
sources including clinical notes, letters and investigation results were reviewed and data 
were extracted. Following extraction, information was entered into an electronic 
database (eCRF). 
In total, 1387 cases with newly diagnosed and established epilepsy were manually 
phenotyped (977 in Glasgow and 410 in Liverpool). 
Due to the patchy information available for several cases from Australia, the 
proportion of cases required a significant manual input by cross checking and adjusting 
the transferred information. All data uploads and phenotype derivation were also 
manually cross-checked. 
3.3.4. Phenotype definitions and their application 
Phenotype definitions were created prior to my involvement in the project; hence I 
claim no authorship of them. Full consortium phenotype definitions (EpiPGX, 2014) are 
available in Appendix 2, page 222.  
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Newly diagnosed epilepsy was defined as: 
“Occurrence of ≥2 clinically definite unprovoked epileptic seizures in the previous 
year or the occurrence of one seizure and the clinician decides to start AEDs. Prospective 
data are preferred, but retrospective data are allowed if based on contemporary 
evidence (i.e. continuous records from initiation of the first AED onwards at a specialist 
epilepsy centre). Patients with known progressive neurological disorders at the time of 
first AED initiation are excluded; patients with prior AED exposure or rescue treatment 
should be noted and the indication recorded.”  
Epilepsy syndromes were defined according to ILAE 1989 Classification (Epilepsy, 
1989).  
For treatment outcome with the first well tolerated AED the following definitions 
were used (EpiPGX, 2014):  
“Remission was defined as any continuous period of ≥12 months complete seizure 
freedom.” It was separated into two subcategories: 
 Immediate – occurring within 14 months of starting the first well-tolerated AED. 
 Deferred – occurring later than 14 months after starting the first well-tolerated AED 
(and prior to initiation of another AED). 
No remission was defined “as continuing seizures after starting the first well-
tolerated, adequately applied and appropriate AED”.  
An AED was considered adequate if subjects were exposed to a minimum therapeutic 
dose of that AED for a sufficiently long time period. A six month period was considered a 
sufficiently long trial period to establish a lack of response. An AED was considered 
appropriate if it had been demonstrated to be effective by past research, preferably by 
randomised controlled trials (e.g. ethosuximide for focal seizures would be considered 
inappropriate). Table 4 summarises the most commonly used AEDs, appropriate seizure 
types, and the minimal therapeutic and World Health Organisation defined daily dose 
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for monotherapy in adult patients according to the EpiPGX phenotyping definitions 
(EpiPGX, 2014). The decision regarding whether or not the AED trial was adequate and 
appropriate was made by a phenotyper and recorded in eCRF. 
Table 4. AEDs, appropriate seizure types, minimum and defined daily doses for AED in 
adults according to EpiPGX phenotyping definitions (EpiPGX, 2014). 
Antiepileptic 
drug 
Focal 
seizures 
Primary 
generalised 
tonic-clonic 
seizures 
Absence 
seizures 
Other 
primary 
generalised / 
unclassified 
seizures 
Minimum 
therapeutic 
dose (mg) 
Defined 
daily 
dose 
(mg) 
Carbamazepine     600 1000 
Clobazam     10 20 
Clonazepam     4 8 
Eslicarbazepine     800 800 
Ethosuximide     1000 1250 
Felbamate     1200 2400 
Gabapentin     1200 1800 
Lacosamide     200 300 
Lamotrigine     150 300 
Levetiracetam     1000 1500 
Oxcarbazepine     900 1050 
Phenobarbital     60 100 
Phenytoin     200 300 
Pregabalin     300 300 
Primidone     750 1250 
Tiagabine     30 30 
Topiramate     100 300 
Valproate     1000 1500 
Vigabatrin     1000 2000 
Zonisamide     150 200 
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EpiPGX WP2 was separated into three tasks:  
 The main aim for task one was to investigate the genome based biomarkers 
associated with 12 month remission of newly diagnosed epilepsy after application of the 
first well-tolerated anticonvulsant. The treatment outcome was split into three 
categories: immediate remission, deferred remission, and no remission. Case control 
and an innovative three-way competing risk survival model was used for analysis. 
 Task two, on the other hand, investigated genome-based biomarkers for general 
versus selective drug responsiveness (i.e. patients who respond to any AED versus 
patients who require a specific AED to achieve seizure control). To achieve this aim, WP2 
collaborated with WP4 which investigated genome-based biomarkers for late response. 
 Task three investigated genome-based biomarkers associated with the first 
treatment failure. Treatment failure is categorised as either being due to lack of efficacy 
or adverse drug reactions. Treatment failure due to lack of efficacy requires appropriate 
and adequate exposure to the first AED. Failure due to adverse drug reactions were 
further split into either ‘on-target’ and ‘off-target’, depending on whether they were 
considered to be directly caused by the drug’s principal pharmacological mechanism of 
action. 
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To standardise clinical data collection, a special data entry manual was created 
(EpiPGX, 2013). It contained a section on general data collection and separate sections 
relevant for each work package. Creation of the manual was led by work-package 1 and 
three, but each subsection was written by the relevant work package. It was made 
available to all members of the consortium. Inclusion of general terms and definitions in 
addition to specific phenotypes ensured unified understanding and application of 
phenotypes and outcome definitions. Flowcharts related to newly diagnosed epilepsy 
and WP2 tasks are shown in Figures 2, 3 and 4. Figure 2 illustrates the general path for 
assessment of inclusion of the subject into WP2, requiring confirmation that the case is 
newly diagnosed and ensuring that data regarding the first anticonvulsant exposure is 
completely captured. Figure 3 is a flowchart illustrating the decision tree specifically for 
task one, evaluating the treatment outcome for the first well-tolerated anticonvulsant. 
This flowchart clearly underlines that the first well-tolerated anticonvulsant is not 
always the first applied drug. Figure 4 is a flowchart illustrating the decision tree for task 
3, which was specifically designed to separate causes of failure of first applied 
anticonvulsant.  
Flow charts were also later utilised in the process of development of code for 
phenotype derivation which was based on raw data. 
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Figure 2. Flowchart to assist eligibility decisions for WP2; according to Data Entry 
Manual (EpiPGX, 2013) 
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Figure  3. Flowchart to assess efficacy outcome with first well-tolerated 
anticonvulsant in newly diagnosed epilepsy used in WP2, Task 1; according to Data Entry 
Manual (EpiPGX, 2013) 
 
Figure 4. Flowchart illustrating decision tree to assess outcome after application of 
first ever anticonvulsant in newly diagnosed epilepsy used in WP2, Task 3; according to 
Data Entry Manual (EpiPGX, 2013) 
 
3.3.4. Data transfer  
Data for the following research cohorts were transferred from their respective 
original databases to the EpiPGX eCRF: 
 SANAD 
 Melbourne 
 ULB 
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The SANAD and Melbourne transfers were carried out in Liverpool, whereas ULB was 
carried out locally in Brussels. Hence, a transfer code for the ULB cohort is not available; 
it was carried out as a collaboration between the local team in Brussels and Roland 
Krause from LCSB. Dr Ben Francis (Department of Biostatistics) was instrumental for all 
data uploads carried out in Liverpool. 
For the SANAD and Melbourne transfers, separate dictionaries linking the original CRF 
with the EpiPGX paper CRF were created. All free text entries were manually reviewed 
and matched accordingly. Afterwards, the data were split into small clusters and batch 
transferred to the eCRF. Initially, the transferred data were uploaded to a test site, 
reviewed, and extensively tested for errors and discrepancies. After review, the data 
were moved to the permanent eCRF, where all cases were manually reviewed and 
treatment outcomes were classified manually according to EpiPGX definitions. During 
this process, treatment outcomes were cross checked against the original database.  
The data transfer dictionary for the SANAD study has been provided in Appendix 3, 
page 227. SANAD patients with previous treatment were highlighted, which allowed 
their exclusion from analyses of newly diagnosed epilepsy. Pre-treatment seizure count 
in the SANAD study was provided in absolute numbers and was transferred accordingly 
to EpiPGX. Tables from 5 to 7 illustrate the approach used to match seizure types, 
epileptic syndromes and EEG results between cohorts. The SANAD study obtained 
additional, more detailed, neuroradiological data as well as follow up data from general 
practitioners after finishing the study. This data was incorporated into the data transfer. 
With regard to treatment outcome, the SANAD study collected data on the number of 
seizures between follow up visits and individual outcomes for each AED, which allowed a 
relatively straightforward calculation of onset of 12 month remission. Remission was 
assumed if there was either at least one 12-month period between recorded seizures 
while on treatment, or only an index seizure and no further seizures recorded. Onset of 
12 month remission was set for the day after the most recent seizure for remissions on 
treatment, or the first day of treatment if there was immediate remission following the 
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onset of treatment. Reasons of treatment failure were recorded in the SANAD study and 
were also transferred to EpiPGX.  
Table  5. Matching of seizure types between SANAD study and EpiPGX. 
SANAD Seizure type EpiPGX seizure type 
Typical Absence Absence 
Atypical Absence Absence 
Febrile convulsions Febrile 
Simple Partial Simple Partial 
Complex Partial Complex Partial 
With Generalised Tonic-Clonic (partial) Secondary GTCs 
Myoclonic Myoclonic 
Tonic-Clonic (generalised)  Primary GTCs 
Atonic Atonic 
Tonic-Clonic Uncertain Unclassified GTCs 
Other (free text entry, single isolated 
case) 
Manual review of free text entry  
 
The Melbourne cohort was based on a prospective observational study. Data 
organisation for it was completely different from the SANAD study, hence it was 
processed separately. In this cohort there were no cases with progressive neurological 
conditions other than brain tumours and these were manually filtered off. Information 
was also available regarding previous exposure to AEDs before recruitment and when 
those AEDs were started. Cases in which an AED was started more than sixty days before 
enrolment were excluded, as they were not considered newly diagnosed. Epilepsy 
syndrome classification was significantly different from that employed in EpiPGX, hence 
all cases were manually matched to EpiPGX definitions using all available covariates. 
Where matching was not possible, cases were recorded as unclassified. Follow up 
information was collected at three months, one year, and two years. The pre-treatment 
seizure count  in the Australian cohort contained the following categories: 1, 2, 3, 4, 5 
and more than 5 seizures before starting the treatment (Speed et al., 2014a). Categories 
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were matched accordingly where possible during data transfer. As there was no relevant 
category for 5 and more, it was matched with the unknown category in EpiPGX. In 
SANAD, the pre-treatment seizure count was collected as an absolute number, hence 
when the data were categorised, there were no cases in the unknown category.  
Subjects were considered in remission if there were no recorded seizures for a period 
covering at least 12 months. 
Table  6. Matching of epilepsy syndromes between SANAD study and EpiPGX. EpiPGX 
had a three level classification of epileptic syndrome, with the first level indicating if the 
syndrome was generalised, localisation related or unclassified; whereas the third level 
described the specific syndrome. Some syndromes are omitted from this table as they 
were not represented in the SANAD study. 
SANAD EpiPGX 
Benign Childhood 
Epilepsy With 
Centrotemporal Spikes 
Localisation 
Related 
Idiopathic 
Benign Childhood 
Epilepsy With 
Centrotemporal 
Spikes 
Childhood Epilepsy 
With Centrotemporal 
Spikes 
Localisation 
Related 
Idiopathic Other 
Childhood Absence Generalised 
Idiopathic Age 
Related 
Childhood Absence 
Epilepsy 
Juvenile Absence Generalised 
Idiopathic Age 
Related 
Juvenile Absence 
Epilepsy 
Juvenile Myoclonic Generalised 
Idiopathic Age 
Related 
Juvenile Myoclonic 
Epilepsy 
Epilepsy With Tonic- 
Clonic Seizures on 
Awakening 
Generalised 
Idiopathic Age 
Related 
Epilepsy with GTCs 
on Awakening 
Generalised Not 
Specified 
Generalised Unclassified  
Unclassified Unclassified   
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Table  7. Matching of EEG between SANAD study and EpiPGX 
SANAD EEG EpiPGX EEG 
Abnormal   NO Normal 
Abnormal  YES Non Specific   Abnormal non specific 
Abnormal YES 
Generalised 
Activity Slow Wave 
Spiking    
Abnormal Epileptiform 
Abnormal YES 
Generalised 
Activity Slow 
without spiking    
Abnormal Non-specific 
Abnormal  YES 
Focal Activity 
Paroxysmal with 
Spiking  
Abnormal Epileptiform 
Abnormal  YES 
Focal Activity 
Paroxysmal 
without Spiking  
Abnormal Non Specific 
 
The data for both cohorts were initially uploaded into a trial mode and were 
extensively checked for any inconsistencies and systematic errors, and afterwards were 
moved to a permanent database. Those checks were carried out by myself.  
3.4. Statistical and genetic analysis 
3.4.1. Phenotype derivation 
Prior to analysis, all newly diagnosed cases were filtered and then downloaded from 
the EpiPGX eCRF. Raw data were processed and a phenotype derivation produced. This 
was carried out by Dr Sarah Langley (Imperial College London), with clinical input and 
quality control undertaken by myself.  
Seizure types in EpiPGX were classified according to the ILAE 1981 classification 
(Bancaud et al., 1981).  
During the phenotype derivation to ensure consistency with previous prognostic work 
carried out on the SANAD study (Bonnett et al., 2014b, Bonnett et al., 2012), seizure 
types were transformed accordingly. Matching of the seizure types is summarised in 
table 8. In the EpiPGx eCRF, the pre-treatment seizure count was collected separately 
for GTC, non-GTC and combined (unknown) seizure types. It was entered separately in 
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each of these categories either as an absolute or categorical value (including unknown), 
but not as both. This created a mixture of categorical and absolute values and rendered 
the creation of continuous values impossible. Hence, in order to avoid losing cases with 
categorical values, the data were categorised.   
Table  8. Transformation of seizure type to match earlier prognostic work on the SANAD 
study. 
Seizure type according earlier 
SANAD prognostic work (Bonnett 
et al., 2014b, Bonnett et al., 2012) 
Matched seizure types according to 
EpiPGX 
Simple or complex partial only 
Simple partial or complex partial seizures 
without any others 
Secondary generalised tonic-clonic 
Secondarily generalised tonic-clonic 
seizures 
Generalised tonic-clonic seizures 
only 
Secondarily generalised tonic-clonic, 
primary generalised tonic-clonic or 
unclassified generalised tonic-clonic 
seizures without any other 
Absence seizures Absence seizures 
Myoclonic or absence seizures 
with tonic-clonic seizures 
Absence or myoclonic with primary 
generalised tonic-clonic or unclassified 
generalised tonic-clonic seizures 
Unclassified tonic-clonic seizures 
Unclassified generalised tonic-clonic 
seizures 
Other/Uncertain Other/Uncertain. 
 
Epilepsy types were divided into three categories, either focal, generalized or 
unclassified.  
The results of the imaging studies were coded either as normal, abnormal focal, 
abnormal nonspecific or not done/not known. Similar coding was used for EEG results 
where abnormal was replaced with either epileptiform or non-specific abnormalities. 
Results of the first investigation were used. 
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A positive family history was defined as the documented presence of any relative 
with epilepsy. The EpiPGX eCRF coded family history as a variable with three potential 
values – present, absent or unknown. In the phenotype derivation variables were 
dichotomised by collapsing together unknown or absent categories. 
The outcome of the neurological examination in eCRF was coded as either normal, 
abnormal, not applicable or unknown. Similar to the other co-variates in the phenotype 
derivation, it was dichotomised. Two categories were created: abnormal and 
normal/unknown/not applicable. 
Data collection on the presence of learning disabilities (LDs) began mid-way through 
the project; hence some of the cases phenotyped during the first half of the project 
lacked this information. To create a binary variable category for phenotype derivation, 
“yes” and “not known” were collapsed together.  
The value of the variable time from first seizure to first AED was calculated in months 
by subtracting the date of the first seizure from the date of the first AED. Hence when 
the date of the first seizure was unknown, the value of the variable was coded as 
missing. 
Follow up length was calculated in years by subtracting the date of the first visit from 
the date of the last visit.   
3.4.2. Statistical analysis of clinical factors associated with treatment 
outcome 
To ensure consistency between all analyses conducted during the EpiPGX project, a 
single phenotype derivation was used for statistical analysis of associations with 
treatment outcomes. Descriptive statistical methods were initially applied to explore the 
data. For analysis of association, logistic regression and Cox regression were used. A 
prior univariate analysis was performed with each factor included in the initial logistic 
and Cox regression models. The Bonferroni method was applied for corrections of 
multiple testing where there were multiple tests for the same hypothesis. 
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The logistic regression used backward selection using Wald statistics. The probability 
for stepwise entry was set at 0.05 and for removal 0.10. Results were plotted using 
forest plot as log transformation of Exp (B) value.  
For the Cox regression, time to 12 month remission was calculated by subtracting the 
start date of the first well-tolerated AED from the first day of onset of the corresponding 
12 month remission. This approach was different from the SANAD study where time to 
remission was calculated by subtracting the date of randomisation from the first date 
after continuous seizure freedom. Time to 12 month remission calculation is illustrated 
in figure 5.  
 
Figure 5. Flowchart illustrating the calculation of time to 12 month remission in 
EpiPGX and for comparison in the SANAD study. 
Patients who did not experience remission with the first well-tolerated 
anticonvulsant, or had it withdrawn due to ADRs, were right-censored. For the survival 
analysis stepwise variable selection, Wald statistics were used; probability for stepwise 
entry was set at 0.05 and for removal at 0.10. 
EpiPGX GWAS analyses were later adjusted for factors significantly associated with 12 
months’ remission. 
3.4.3. Assessment of impact of study methodology  
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The impact of study methodology and methods of cohort assembly were assessed 
separately. The EpiPGX project is a multinational research consortium, hence effect of 
origin of cohort was explored in some detail. Additionally, as the EpiPGX research cohort 
was assembled from a mixture of old historical datasets, the effect of original mode of 
case ascertainment was explored. Impacts of various study parameters (duration of 
observation, definition of remission) were also separately assessed.  
The definition of remission for our study required at least a continuous 12-month 
period of freedom from seizures. To assess how changing the length of the defined 
seizure freedom period affects the proportion of patients labelled as being in remission, 
the proportions of patients counted as being in remission after applying different length 
criteria of seizure freedom were compared.  The one, two, five or 10-year periods of 
seizure freedom were separately applied to the patient cohort created from patients 
with at least equal follow up length to applied remission period. A separate group of 
remission lasting for a whole period of observation was also created. It was defined as 
seizure freedom up to the last visit, irrespective of how long the follow-up period was. 
 Association of the follow up length, origin of cohort, and mode of case ascertainment 
with the binary treatment outcome was assessed with a logistic regression. The same 
parameters were used as for the analysis of clinical factors. The digital data transfer 
process from existing clinical databases has the potential to introduce systematic error 
and distortion of data at various levels, hence it was also separately assessed. The 
genetic and statistical analysis performed by the SANAD study and EpiPGX utilized data 
derivations rather than the original raw data. Hence, to assess how the transformation 
and uploading of data affected their quality, SANAD cases from the EpiPGX phenotype 
derivation were compared with SANAD cases from the phenotype derivation created for 
an earlier genetic study (Speed et al., 2014a). As the SANAD study used different 
variables and definitions, the co-variates underwent some degree of transformation and 
were then uploaded to the central EpiPGx repository. To assess how this process 
affected them, the concordance of the basic demographic and most important co-
variates was investigated. 
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Phenotype derivation for the EpiPGx study was created by selecting newly diagnosed 
cases from the eCRF and then extracting information in accordance with the task 1 
definition. Similarly, the SANAD genetic dataset was based on the SANAD study and was 
created for an earlier GWAS on newly diagnosed epilepsy (Speed et al., 2014a). The 
inclusion criteria in SANAD differed slightly from the EpiPGx inclusion criteria. The 
SANAD study permitted some cases with previous inadequate and inappropriate 
exposure to AED or relapses after long-term remission. On the other hand, EpiPGX WP2 
recruited only cases of newly diagnosed epilepsy. Cases with previous AED exposure in 
the SANAD genetic data set were filtered off based on whether there existed any history 
of previous monotherapy. 
For exploration of the impact of study methodology and data transfer, a variety of 
descriptive statistics were used including contingency tables, Cohen’s kappa coefficients 
for categorical variables, and Lin’s concordance correlation coefficients for continuous 
variables.  
 
For statistical data processing, MS Excel 2010 and IBM SPSS version 22 were used. 
Lin’s concordance correlation coefficient was calculated using an internet calculator 
(http://services.niwa.co.nz/services/statistical/concordance). 
 
3.4.4. Genotyping 
There were two types of genetic data; either historical GWAS data which were 
genotyped as a part of previous studies, or de novo GWAS data genotyped at deCODE as 
part of EpiPGX. 
In the majority of cases, DNA samples had been collected previously and extracted 
from either from blood or saliva. 
Genotyping of samples sent to deCODE was performed on Illumina OmniExpress-12 
v1.1 and -24 v1.1 single nucleotide polymorphism (SNP) arrays. BeadStudio (Illumina; 
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version 2.0) was used to call genotypes, normalise signal intensity data and establish the 
log R ratio and B allele frequency at every SNP.   
The historical UK samples (SANAD and ULIV cohorts) were genotyped at the 
Wellcome Trust Sanger Institute on the Illumina 660 chip. The Melbourne samples were 
also genotyped using the same platform at the same institution, but at a different time. 
Sample QC criteria were the same for both the SANAD, ULIV and Melbourne cohorts and 
have been described previously (Speed et al., 2014a). 
3.4.5. GWAS QC and imputation  
All GWAS QC and imputation for EpiPGX was performed by deCODE (courtesy of Dr 
Andrés Ingason). QC involved several steps. Initially all markers with a very high (> 0.9) 
rate of missing genotypes were removed. As there were samples from multiple 
European countries, the cohorts were then split according to origin. A Hardy-Weinberg 
equilibrium (HWE) was calculated for each group separately. All samples with < 0.98 
genotype rate and all markers with < 0.95 genotype rate, < 0.01 minor allele frequency 
(MAF), or P < 1 x 10-6 for HWE in any of the sample subgroups were removed. In the next 
QC step using a window size of 100 markers shifting by 25 markers at a time and 
removing one half of every SNP pair with genotypic r
2 
> 0.1 a subset of markers 
independent of each other with respect to the linkage disequilibrium (LD) was created. 
Then by using this subset of markers heterozygosity (HET), identity by state (IBS) and 
sex was calculated. Samples with outlying HET values (> 5 standard deviations (SD) 
from the median of the whole sample); one half of all sample pairs with pihat > 0.9 IBS, 
and c) and all samples where sex determined from genotype did not match reported 
gender were removed. At the next step array-specific maps were retrieved from the 
website of Will Rayner at the Wellcome Trust 
(http://www.well.ox.ac.uk/~wrayner/strand/) and were used to update all marker 
positions and chromosome numbers to the Genome Reference Consortium Human Build 
37 (GRCh37). Then to avoid strand issues all A/T and C/G markers were removed.In the 
next step extraction of genotypes for 2,766 ethnicity-sensitive SNPs common to all 
Illumina SNP arrays (Supplement 1) were done and STRUCTURE 2.2 (Pritchard et al., 
2000) were used to derive European, Asian and African ancestry probabilities,respective 
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samples of Hapmap Yoruba in Ibadan, Nigeria Japanese in Tokyo, Japan and Han Chinese 
in Beijing, China and Utah residents with ancestry from northern and western Europe 
were used as reference populations, and samples with less than 90% European ancestry 
were removed. Quality control of genotypes was done using PLINK 1.9 (Purcell et al., 
2007). 
Genotypes were split up according to chromosome arms (the X chromosome was 
additionally split into pseudo-autosomal regions (PAR) and non-PAR) further step 
involved creation of phased haplotypes using SHAPEIT v2 (O'Connell et al., 2014, 
Delaneau et al., 2014, Delaneau et al., 2013b, Delaneau et al., 2013a, Delaneau et al., 
2012) The imputation of genotypes in our dataset were done by using IMPUTE version 
2.3.0 (Howie et al., 2009, Howie et al., 2012).  
Further processing was conducted by Dr Ben Francis; this involved the merging of all 
genetic datasets and retaining only common SNPs. The merged dataset was pruned 
down to low linkage disequilibrium SNPs and principal component analysis was carried 
out. 
All GWAS were performed by EpiPGX statisticians according to a defined analysis 
plan. Analysis was carried out on a server based at LCSB. GWAS was performed both as 
univariate and after adjusting for clinically significant factors as determined by logistic 
regression. 
As a part of my PhD project, I undertook a separate GWAS using all newly diagnosed 
cases with focal epilepsy for which genetic data was available locally. It was done locally 
on the University of Liverpool High Performance Computing Cluster with SNPtest version 
2.4.1 (Marchini et al., 2007).  
In a similar way to the original EpiPGX GWAS, it was performed both as a univariate 
analysis and after adjusting for clinically important factors. To determine the significant 
clinical factors associated with 12 month remission for the further adjustment of GWAS, 
a binary logistic regression using the same parameters as described earlier but only 
including those with focal epilepsy and locally stored DNA (patients from SANAD, 
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Glasgow, ULIV and the Australian cohort) were carried out. The following clinical 
covariates were included in the logistic regression model: 
 Age at onset in years 
 Neurological examination previously undertaken 
 Febrile seizures previously experienced 
 Positive family history of epilepsy 
 EEG 
 CT 
 MRI 
 Pre-treatment seizure count 
 Seizure type classified using the same approach as for a full logistic regression 
model 
 Origin of cohort (separate co-variate included to represent each different cohort: 
ULIV, GLA, SANAD, and AUS) 
 Whether study was prospective or retrospective 
For the purposes of the logistic regression, the following variables were set as a 
baseline: 1 – 2 seizures before treatment, and normal for EEG, MRI and CT. Pre-
treatment seizure frequency in the Australian research cohort was coded as a 
categorical variable with values from one to five and more than five. As described 
earlier, during the transfer and uploading of the Australian data, the values were 
categorised according to the EpiPGX eCRF, hence there were no subjects in the 
categories with 6 – 10, 11 – 20 or 21 or more seizures before starting the treatment. This 
lead to p-values of -1 when GWAS was adjusted simultaneous for both pre-treatment 
seizure count and origin of cohort, rendering adjustment for both fators impossible. As 
the logistic regression model based on the full cohort had shown that the mode of case 
ascertainment (prospective vs. retrospective) was statistically significantly associated 
with the treatment outcome, it was decided to replace the origin of the cohort with the 
variable representing whether the follow-up was prospective or retrospective. Cases 
from the SANAD study and Australia were considered to be prospective, whereas the 
rest of the cohorts were assembled retrospectively. 
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The GWAS analysis was adjusted for the first five principal components (population 
stratification) and co-variates statistically significantly associated with treatment 
outcome from the multivariable logistic regression model.  
 Initial GWAS was carried out using an additive model, and significant SNPs were later 
retested using the dominant model of inheritance. The genomic inflation factor was 
calculated for GWAS with additive mode of inheritance for both the univariate model 
and after adjustment for significant clinical factors. Results were plotted as Manhattan 
and QQ plots. For plotting results of individual SNPs, LocusZoom software were used 
(Pruim et al., 2010). 
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4.0. Results 
4.1. Descriptive statistics 
For the purpose of describing the research cohort, data on all of the patients included 
in work package 2 task 1 were used (n= 1906). Due to missing data, fewer cases 
(n=1723) were included in the logistic and Cox regression models. A full flowchart 
detailing the missing information is presented in Figure 6.  
 
 
Figure 6. Flowchart detailing case attrition due to missing data. 1906 patients were 
included in the study and 1723 (90.4%) were analysed for a logistic and Cox regression, 
whereas 1744 were used for the descriptive statistical analysis. 
 
For consistency with the GWAS and the rest of the analysis carried out as a part of 
the EpiPGX project, the phenotype derivation carried out by Dr Sarah R Langley were 
1723 (90.4%) 
1 (0.05%) no information on follow up 
length 
20 (1.05%) no data on time from first 
seizure to first AED 
162 (8.5%) no data on treatment outcome 
1906 patients 
Logistic and Cox regression 
1744 Cases with treatment 
outcomes available were used 
for descriptive statistical 
analysis 
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used for all analysis unless stated otherwise. The phenotype derivation was created 
using a full data set; it captured phenotypes which were constructed before the onset of 
data collection using agreed definitions.  
4.1.1. Remission 
 
Remission was defined as any continuous period completely free of seizures, equal to 
12 months or longer. No remission was defined as on-going seizures after starting the 
first well-tolerated, adequately applied and appropriate AED. Binary outcomes 
(remission vs. no remission) in newly diagnosed epilepsy cases were available on 1744 
subjects (91.5%).The 12 month remission was observed in 982 of these (56.3%).  
The proportion of subjects experiencing 12 month remission was different between 
cohorts. The Australian cohort had the highest proportion of remissions (n = 124; 
72.5%), followed by SANAD (n = 439; 58.7%), Glasgow (n = 238; 57.3%) and EKUT (n = 
133; 56.6%). The no remission rate was higher in the ULIV (n = 45; 84.9%), UCL (n = 27; 
81.8%) and ULB (n = 13; 76.5%) cohorts. A Pearson’s chi-square test showed statistically 
significant differences (p < 0.001) between cohorts in terms of the proportion of 
patients achieving 12 months’ remission with the first well-tolerated AED. Details of 
patient outcome, stratified in detail by cohort, are summarised in Table 9. 
In addition to the occurrence of remission, the time taken to achieve remission (time 
to start of 12 month remission) was separately assessed. From the 982 patients 
experiencing remission after the application of the first anticonvulsant, 699 (71.2%) had 
immediate remission, while the rest (n = 283, 28.8%) experienced deferred remission 
(onset of remission more than two months after the application of the first well-
tolerated anticonvulsant). The data did not follow a normal distribution, but was skewed 
towards the left. A zero value for time to remission indicates an immediate onset of 
remission. The median time to a 12 months’ period of remission was 0.0 days, the mean 
= 126, SD = 389 and IQR = 0 – 90. The relatively large difference (126 days) between the 
observed mean and median indicates the presence of outliers with a late onset of 
remission. On comparing time to 12 month remission between cohorts using a Kaplan-
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Meier approach there was a statistically significant difference (p<0.001). In the majority 
of cohorts (ULB, Glasgow, Australia, SANAD) median time for the onset of 12 month 
remission was zero, whereas RCSI had the longest median time of 152 days. Further 
details of time to onset of 12 month remission stratified by cohort are presented in 
Table 10 and in Figures 7 and 8. 
Table  9. Distribution of binary treatment outcomes (remission vs. no remission) in 
newly diagnosed epilepsy cases stratified by the cohort (n = 1744) 
Cohort 
12 month remission with the first AED 
No remission Remission Total 
n % n % n % 
 
UCL 27 81.8% 6 18.2% 33 1.9% 
ULB 13 76.5% 4 23.5% 17 1.0% 
EKUT 102 43.4% 133 56.6% 235 13.5% 
RCSI 42 58.3% 30 41.7% 72 4.1% 
Glasgow 177 42.7% 238 57.3% 415 23.8% 
ULIV 45 84.9% 8 15.1% 53 3.0% 
Australia 47 27.5% 124 72.5% 171 9.8% 
SANAD 309 41.3% 439 58.7% 748 42.9% 
Entire Cohort 762 43.7% 982 56.3% 1744 100.0% 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
Table 10. Time to onset of 12 month remission in days (mean, median, SD and IQR) after 
application of first well tolerated anticonvulsant stratified by cohort (n = 982) 
Cohort 
Time to onset of 12 month remission (days) 
Mean Standard deviation Median IQR 
 
UCL 24 42 8 0 – 19 
ULB 5 10 0 0 – 10 
EKUT 64 142 3 0 – 35 
RCSI 1074 1599 152 0 – 1564 
Glasgow 111 268 0 0 – 107 
ULIV 68 128 1 0 – 100 
Australia 29 79 0 0 – 29 
SANAD 120 239 0 0 – 139 
Entire Cohort 126 389 0 0 – 90 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
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Figure 7. Box plot for time to onset of 12 month remission after application of first 
well tolerated anticonvulsant (n = 982). Distribution of time is shown in days separately 
for each cohort. The middle  line indicates median, whereas boundaries indicates 75th 
and 25th percentile. The whiskers represent the lowest and highest non-outlier value.  
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; 
EKUT -  Eberhard-Karls-Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; 
University of Liverpool; SANAD - Standard and New Antiepileptic Drugs Study. 
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Figure 8. Kaplan-Meier plot for time to 12 month remission (days) in newly diagnosed 
epilepsy cases after application of the first well-tolerated anticonvulsant stratified by 
cohort (n = 1744). UCL – University College London; ULB - Hôpital Erasme, Université 
Libre de Bruxelles; EKUT -  Eberhard-Karls-Universität Tübingen; RCSI - Royal College of 
Surgeons in Ireland; University of Liverpool; SANAD - Standard and New Antiepileptic 
Drugs Study. 
4.1.2. Age at diagnosis 
Age at diagnosis was available for all patients (n = 1906). The median age at diagnosis 
was 33.57 (IQR 19.92 - 50.27), and the data was positively skewed, with a single peak 
around adolescence (Figure 3). The cohort from Australia had the highest median age at 
diagnosis (38.5 years), whereas the EKUT cohort had the lowest (31.6 years). The data 
are further summarised in Table 11 and Figure 9. Only 13.3% (n = 252) of the subjects 
included in the study were aged 16 or younger, hence our study is more representative 
of the adult population. The majority (72.5%) of the patients included were diagnosed 
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between 2000 and 2010, with only 23.4% being diagnosed earlier than 2000. The 
proportion of the cases diagnosed with epilepsy per decade, is presented in Table 12. 
 
Figure 9. Histogram of distribution of age at diagnosis for patients with newly 
diagnosed epilepsy (n = 1906) 
Table 11. Age at diagnosis of patients with newly diagnosed epilepsy (n = 1906) 
stratified by cohort 
Cohort 
Age at diagnosis (years) 
Number Mean 
Standard 
deviation 
Median IQR 
 
UCL 36 30.3 15.5 24.0 19.1 – 36.2 
ULB 29 40.2 22.0 39.1 23.2 – 53.1 
EKUT 247 23.4 17.0 16.8 11.9 – 31.1 
RCSI 73 31.2 15.6 25.2 19.4 – 39.6 
Glasgow 462 38.0 17.4 36.0 22.3 – 51.6 
ULIV 53 32.8 13.6 31.6 20.2 – 45.1 
Australia 228 40.6 18.9 38.5 23.6 – 53.9 
SANAD 778 38.3 19.0 36.6 21.7 – 52.9 
Entire 
Cohort 
1906 36.0 18.8 33.6 19.9 – 50.3 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
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Table  12. Period of diagnosis stratified in steps of 10 years (n = 1906) 
Period of diagnosis (10 years) 
Period Frequency % 
1960 – 1969  1 0.1 
1970 – 1979  3 0.2 
1980 – 1989  24 1.3 
1990 – 1999 416 21.8 
2000 – 2009 1382 72.5 
2010 – current 80 4.2 
Total 1906 100.0 
 
4.1.3. Gender 
Data on gender were available for all subjects (n=1906, 100%). There were marginally 
more males than females, with 989 males (51.9%) and 917 females (48.1%). The data 
are further summarised by cohort in Table 13 and Figure 10. 
Cohorts from UCL (n = 14; 38.9%) and ULIV (n = 22; 41.5%) had the lowest proportion 
of males whereas Glasgow (n = 264; 57.1%) and ULB (n = 16; 55.2%) had the highest 
proportion of males. Gender distribution between the cohorts was uneven and a further 
Chi Square test confirmed a statistically significant difference in the distribution of 
gender between cohorts (p = 0. 008). 
Additionally, stratification according to epilepsy type showed that focal epilepsy 
(males = 52.1%; females = 47.9%) and unclassified epilepsy (males = 60.7%; females = 
39.3%) had a higher proportion of males than females, whilst the opposite was observed 
for generalised epilepsy (males = 45.5%; females = 54.5%). 
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Figure 10. Gender of patients with newly diagnosed epilepsy stratified by cohort (n = 
1906). UCL – University College London; ULB - Hôpital Erasme, Université Libre de 
Bruxelles; EKUT -  Eberhard-Karls-Universität Tübingen; RCSI - Royal College of Surgeons 
in Ireland; University of Liverpool; SANAD - Standard and New Antiepileptic Drugs Study. 
 
Table  13. Gender of patients with newly diagnosed epilepsy stratified by cohort 
Cohort 
Gender 
Male Female 
n % n % 
 
UCL 14 38.9% 22 61.1% 
ULB 16 55.2% 13 44.8% 
EKUT 107 43.3% 140 56.7% 
RCSI 35 47.9% 38 52.1% 
Glasgow 264 57.1% 198 42.9% 
ULIV 22 41.5% 31 58.5% 
Australia 113 49.6% 115 50.4% 
SANAD 418 53.7% 360 46.3% 
Entire Cohort 989 51.9% 917 48.1% 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
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4.1.4. Epilepsy type 
Epilepsy type was categorised into three groups: focal (n = 1346; 70.6%), generalised 
(n = 341; 17.9%) or unclassified (n = 219; 11.5%). Due to the small numbers, 
undetermined syndromes with focal and generalised features (n = 3) were collapsed 
together with unclassified epilepsy. Table 14 summarises the distribution of epilepsy 
type according to the cohort. For the purpose of analysis,  the SANAD arms A and B were 
collapsed together, however in order to better illustrate the distribution of epilepsy 
types between cohorts they are separated in Table 14. The SANAD arm A recruited only 
focal epilepsy, whereas arm B recruited generalised and unclassified cases. In the SANAD 
study, the initial assignment to arm A or B was based on initial syndromic diagnosis, but 
the epilepsy classifications were reviewed during the study as required. Hence there are 
10 cases of focal epilepsy in arm B and 53 unclassified and 5 generalised epilepsy cases 
in arm A. 
Table  14. Distribution of epilepsy type (focal, generalised and unclassified) stratified by 
cohort (n= 1906). 
Cohort 
Epilepsy classification 
Focal Generalised Unclassified Total 
n % n % n % n 
 
UCL 25 69.4% 6 16.7% 5 13.9% 36 
ULB 20 69.0% 3 10.3% 6 20.7% 29 
EKUT 128 51.8% 116 47.0% 3 1.2% 247 
RCSI 59 80.8% 13 17.8% 1 1.4% 73 
Glasgow 362 78.4% 54 11.7% 46 10.0% 462 
ULIV 43 81.1% 6 11.3% 4 7.5% 53 
Australia 160 70.2% 26 11.4% 42 18.4% 228 
SANAD B 10 5.5% 112 61.9% 59 32.6% 181 
SANAD A 539 90.3% 5 0.8% 53 8.9% 597 
Entire Cohort 1346 70.6% 341 17.9% 219 11.5% 1906 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
The distribution of epilepsy syndromes was different between cohorts; as expected, 
SANAD arm B and EKUT had the highest proportion of patients with generalised 
epilepsy. The EKUT cohort, similarly to the SANAD arm B, was originally assembled for 
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studies of generalised epilepsy plus unclassified epilepsy in case of SANAD arm B. The 
highest proportion of focal epilepsy was observed in ULIV (81.8%), RCSI (80.8%) and 
Glasgow (78.4%). The cohorts which were electronically transferred contained a higher 
number of unclassified cases (ULB had 20.7% whereas Australia had 18.4%). 
In the phenotype derivation created for the purpose of data analysis, epilepsy types 
were divided into three broad categories (generalised, focal, unclassified) whereas the 
original eCRF contained the more elaborate ILAE 1989 classification (Epilepsy, 1989), 
hence for a more detailed description of epilepsy type the original data files were used. 
Figures 11 and 12 summarise the distribution of aetiological classifications for both focal 
and generalised epilepsy. The majority of patients with focal epilepsy had a cryptogenic 
epilepsy (n = 879; 65%), followed by symptomatic (n = 449; 33%). 
Figure 11. A pie chart based on raw data illustrating aetiological classification 
(symptomatic, cryptogenic, idiopathic or unclassified) for newly diagnosed focal epilepsy 
(n = 1348). 
In most cases, the localisation of the onset lobe was unknown (n = 911; 67.58%). The 
most common lobe of onset documented was temporal (n = 332; 24.63%), followed by 
Cryptogenic, n = 
879; 65% 
Idiopathic, n = 8; 
1% 
Symptomatic, n = 
449; 33% 
Unclassified, n 
= 12, 1% 
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frontal (n = 69; 5.12%), parietal (n = 22; 1.63%), and occipital (n = 14; 1.04%). There were 
12 cases of mesial temporal lobe epilepsy in the cohort. 
In cases of generalised epilepsy, the two most common syndromes were unclassified 
epileptic syndrome in 34% of cases, and JME (also 34%); childhood absence accounted 
for 12% and juvenile absence epilepsy for 9%. Rare epileptic syndromes were collapsed 
into the category “other”, and were observed in 11% of cases with generalised epilepsy. 
 
Figure 12. A pie chart based on a raw data illustrating aetiological classification 
(Juvenile myoclonic epilepsy, Juvenile absence epilepsy, Childhood absence epilepsy and 
unclassified or other) of generalised epilepsy (n = 308). 
  
Childhood absence 
epilepsy, n = 41; 
12% 
Juvenile absence 
epilepsy, n = 31; 
9% 
Juvenile myoclonic 
epilepsy, n = 116; 
34% 
Other; n = 36, 11% 
Unclassified, n = 
117; 34% 
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4.1.5. Pre-treatment seizure count 
 The reasons behind using categorical values have been described in detail in the 
methods section. The majority of cases (n = 1033; 59.23%) had categorical values for 
pre-treatment seizure count. 
As can been seen from Figure 13, the seizure frequency distribution was uneven with 
two peaks. The majority of patients had either 1 or 2 seizures (n = 394; 20.7%), 3 – 5 
seizures (n = 441 23.1%) or 21 or more (n = 458; 24.0%) before starting treatment. 
Furthermore, a significant proportion (n =301; 15.8%) of patients had an unknown pre-
treatment seizure count. 
Figure 13. Pre-treatment seizure count (%) stratified in categories (1-2; 3-5; 6-10; 11-
20; 21+ and unknown). 
The number of pre-treatment seizures differed between cohorts. Noticeably, the 
Australian cohort had a very small number (or no cases at all) in the 11 – 20 and 21+ 
categories. This observation is due to differences between the categories used for the 
data collection which did not exactly match the categories used in EpiPGX (Speed et al., 
2014a). In SANAD, the pre-treatment seizure count was collected as an absolute 
number, hence when the data was categorised there were no cases in the unknown 
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category. More detailed data on pre-treatment seizure frequency, stratified by cohort, is 
presented in Table 15. 
The effect of seizure type on the number of seizures reported was also assessed. Of 
all seizure types, as expected, myoclonic and absence seizures had the highest 
proportion of unknown pre-treatment seizure counts (26.8% and 28.5%) or 21 or more 
seizures (54.9% and 47.6%) before starting the treatment. This observation probably 
reflects the underlying high frequency and minimal intrusiveness of those seizure types. 
Interestingly, most (42.6%) patients with simple and complex partial seizures also 
reported more than 21 seizures before starting treatment.  Epilepsies expressing 
generalised tonic-clonic seizures (either secondarily, primarily or unknown) had a lower 
number of unknown seizure counts before treatment, as well as a lower total number of 
seizures before the initiation of the treatment. Further data describing the pre-
treatment seizure count, stratified by seizure type, are presented in Table 16. 
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Table  15. Categorised pre-treatment seizure count stratified by cohort (n = 1906) 
Cohort 
Pre-treatment seizure frequency 
1 – 2 3 - 5 6 - 10 11 – 20 21+ not known 
n 
% of 
cohort 
n 
% of 
cohort 
n 
% of 
cohort 
n 
% of 
cohort 
n 
% of 
cohort 
n 
% of 
cohort 
 
UCL 1 2.8% 6 16.7% 0 0.0% 3 8.3% 3 8.3% 23 63.9% 
ULB 7 24.1% 0 0.0% 0 0.0% 3 10.3% 1 3.4% 18 62.1% 
EKUT 57 23.1% 36 14.6% 11 4.5% 9 3.6% 79 32.0% 55 22.3% 
RCSI 21 28.8% 7 9.6% 2 2.7% 1 1.4% 6 8.2% 36 49.3% 
Glasgow 115 24.9% 137 29.7% 57 12.3% 25 5.4% 57 12.3% 71 15.4% 
ULIV 8 15.1% 15 28.3% 4 7.5% 2 3.8% 3 5.7% 21 39.6% 
Australi
a 
78 34.2% 61 26.8% 8 3.5% 0 0.0% 4 1.8% 77 33.8% 
SANAD 107 13.8% 179 23.0% 97 12.5% 90 11.6% 305 39.2% 0 0.0% 
Entire 
cohort 
394 20.7% 441 23.1% 179 9.4% 133 7.0% 458 24.0% 301 15.8% 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University 
of Liverpool; SANAD - Standard and New Antiepileptic Drugs Study. 
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Table 16. Distribution of pre-treatment seizure count stratified by seizure type (n = 1906) 
 
Simple 
or 
complex 
partial 
only 
Secondary 
generalised 
tonic- clonic 
Absence 
seizures 
Generalised 
tonic-clonic 
seizures 
only 
Myoclonic 
or absence 
seizures 
with tonic- 
clonic 
seizures 
Unclassified 
tonic-clonic 
seizures 
Other 
seizures 
Pre- 
treatment 
seizure 
count 
1 - 2 
n 27 183 8 253 21 103 14 
% 6.9% 23.0% 5.6% 40.3% 8.5% 33.0% 20.6% 
3 - 5 
n 42 214 13 239 22 110 28 
% 10.8% 26.9% 9.2% 38.1% 8.9% 35.3% 41.2% 
6 - 10 
n 43 92 4 47 11 22 6 
% 11.0% 11.6% 2.8% 7.5% 4.5% 7.1% 8.8% 
11 - 20 
n 55 54 1 22 5 13 3 
% 14.1% 6.8% 0.7% 3.5% 2.0% 4.2% 4.4% 
21+ 
n 166 146 78 19 117 18 12 
% 42.6% 18.4% 54.9% 3.0% 47.6% 5.8% 17.6% 
Not 
known 
n 57 106 38 48 70 46 5 
% 14.6% 13.3% 26.8% 7.6% 28.5% 14.7% 7.4% 
Entire 
Cohort 
n 390 795 142 628 246 312 68 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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4.1.6. Seizure type 
The most commonly observed seizure type was secondarily generalised tonic-clonic 
(n= 795; 41.7%), followed by complex partial (n = 707; 37.1%) and simple partial (n = 
426; 22.4%). On the other hand, tonic (n = 2; 0.1%), atonic (n = 3; 0.2%) or clonic (n = 72; 
3.8%) seizure types were observed relatively rarely. It was impossible to classify partial 
seizures type in 2.7% (n = 52), and much more often it was impossible to classify 
generalised tonic-clonic seizures (n = 312; 16.4). Further detailed data on seizure types 
according to the original categories are presented in Table 17. 
To ensure consistency with previous work based on the SANAD analysis of association 
seizure types were transformed according to the previous statistical modelling (Bonnett 
et al., 2014b, Bonnett et al., 2012), and those categories are described in more detail in 
the methods section..  
The most frequently observed seizure types were those that included generalised 
tonic-clonic seizures. Secondarily generalised tonic-clonic seizures were observed in 
41.7% of patients, and 32.9% of all patients experienced only generalised tonic-clonic 
seizures. Isolated simple or complex partial seizures were observed in 20.5% of the 
patients, and absence seizures in 7.5%. The frequency of the transformed seizure 
categories separated by cohort is further summarised in Table 18. 
Seizure type data contained information on all of the seizure types ever experienced 
by the subject. It also includes seizure types appearing later during the course of the 
illness. EpiPGx did not collect data on the type of index seizure leading to diagnosis of 
epilepsy; hence it is impossible to derive the type of the index seizure. To assess the 
number of seizure types per subject, the original seizure categories were used. More 
than half of the subjects (n = 1050; 55.1%) had only one seizure type; 36.9% (n = 703) 
had two; 7.5% (n = 142) had three; 0.2% (n = 3) had four and a single patient (0.1%) had 
five seizure types. There were 7 (0.4%) cases without any seizure type entered. 
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Table 17. Distribution of seizure types according to ILAE 1981 seizure classification 
(Bancaud et al., 1981) 
Seizure type n % 
Primary generalised tonic-clonic 236 12.4 
Absence 142 7.5 
Clonic 72 3.8 
Tonic 2 0.1 
Atonic 3 0.2 
Myoclonic 139 7.3 
Simple partial 426 22.4 
Complex partial 707 37.1 
Secondarily GTC 795 41.7 
Unclassified partial 52 2.7 
Unclassified GTC 312 16.4 
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Table  18. Distribution (%) of seizure types categorised according to SANAD seizure classification and stratified by cohort 
Cohort 
Simple or 
complex 
partial 
only 
Secondary 
generalise
d tonic-
clonic 
Generalised 
tonic-clonic 
seizures 
only 
Absence 
seizures 
Myoclonic or 
absence seizures 
with tonic-clonic 
seizures 
Unclassi
fied 
tonic-
clonic 
seizures 
Other 
seizur
es 
 
UCL 22.2% 47.2% 25.0% 11.1% 13.9% 8.3% 5.6% 
ULB 20.7% 41.4% 34.5% 0.0% 3.4% 13.8% 6.9% 
EKUT 14.2% 38.1% 23.9% 22.7% 33.2% 0.4% 0.0% 
RCSI 15.1% 56.2% 21.9% 6.8% 9.6% 15.1% 2.7% 
Glasgow 12.3% 44.4% 37.2% 3.2% 9.7% 30.5% 1.7% 
ULIV 7.5% 45.3% 11.3% 7.5% 11.3% 34.0% 1.9% 
Australia 20.6% 35.1% 48.2% 5.7% 10.5% 20.6% 2.2% 
SANAD 28.5% 41.4% 31.6% 5.8% 9.8% 11.2% 7.5% 
Entire 
cohort 
20.5% 41.7% 32.9% 7.5% 12.9% 16.4% 4.1% 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; 
University of Liverpool; SANAD - Standard and New Antiepileptic Drugs Study 
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4.1.7. Investigations 
Where the available results of the EEG, MRI and CT were collected, they were 
categorised as either normal, abnormal-specific (epileptiform for the EEG and focal and 
attributable to epilepsy for imaging studies), abnormal non-specific, or not done. EEG 
results were available in 1575 (82.6%) cases. The majority of patients had normal EEG 
results (n = 650; 34.1%) followed by abnormal epileptiform EEG (n = 568; 29.8%), 
abnormal non-specific (n = 357; 18.7%) and not done (n = 331; 17.4%). 
Data on CT head scans were available for 860 (45.4%) subjects. One half (n = 1046; 
54.9%) of patients did not have a CT head scan performed, probably due to the general 
trend in neurology to utilise more MRI. It has already been pointed out that the majority 
of patients were diagnosed after the year 2000, when MRI was the method of choice for 
imaging in epilepsy. Diagnostic yield for the CT head scan was relatively low. From all the 
cases that included it, only 18.37% (n = 158) had relevant focal abnormalities. 
MRI imaging was performed in 1412 (74.5%) cases. The majority of patients had 
normal imaging results (958 out of 1412; 67%); relevant focal abnormalities were 
detected in 311 out of 1412 (22.02%) patients. To replicate the imaging co-variate used 
in the SANAD study, all of the neuroimaging categories were collapsed together and a 
new mixed CT/MRI variable was created. It had three categories: normal, abnormal or 
not done, and MRI result would have precedence over CT. Some form of neuroimaging 
was performed on 1656 (86.9%) subjects and no imaging was done, or the results were 
unknown, in 250 (13.1%) cases. The majority of patients, 1140 out of 1656 (68.84%), had 
normal neuroimaging, whereas 516 (31.16%) had some abnormalities. More detailed 
information on the investigation results is presented in Table 19. 
There were 616 individuals who had both a CT and an MRI examination. From these, 
138 had a focal lesion demonstrated on an MRI, 120 (87.0%) had reported focal 
abnormalities on a CT scan, 12.3% (n = 17) were reported as normal and one (0.7%) had 
non-specific abnormalities on a CT scan. The highest concordance was observed 
between normal results of both modalities – 99.3% had concordant scans. Non-specific 
abnormalities on the other hand had the worst concordance; out of 43 patients who had 
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them reported on an MRI, only 37.2% had the same category based on the results of a 
CT scan, with 55.8% being reported as normal using the CT scan. 
 4.1.8. Family history 
In total, 365 subjects (19.2%) had a positive family history, while the rest had an 
absent or unknown family history. A positive family history was unevenly distributed 
between cohorts. There were no cases with family history recorded as positive in the 
UCL cohort, whereas ULB (n = 11; 37.9%) and Glasgow (n = 136; 29.4%) had the highest 
proportion of patients with a positive family history. Further data on family history 
stratified by cohort has been summarised in Table 20. 
Table  19. Positive family history stratified by cohort 
 
Positive family history 
None /Unknown Yes 
n % n % 
Cohort 
UCL 36 100.0% 0 0.0% 
ULB 18 62.1% 11 37.9% 
EKUT 193 78.1% 54 21.9% 
RCSI 55 75.3% 18 24.7% 
Glasgow 326 70.6% 136 29.4% 
ULIV 40 75.5% 13 24.5% 
Australia 167 73.2% 61 26.8% 
SANAD 706 90.7% 72 9.3% 
Entire cohort 1541 80.8% 365 19.2% 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
As described earlier this variable was dichotomized hence to assess the number of 
cases with unknown family history, the original dataset were used. There were 201 
(10.55%) cases with unknown status and 1340 (70.30%) with a negative family history 
out of 1906. 
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Table  20. Investigation results (EEG, CT, MRI) stratified by cohort 
 
Cohort 
UCL ULB EKUT RCSI Glasgow ULIV Australia SANAD Entire Cohort 
n % n % n % n % n % n % n % n % n % 
EEG 
Normal 3 8.3% 5 17.2% 30 12.1% 15 20.5% 139 30.1% 11 20.8% 150 65.8% 297 38.2% 650 34.1% 
Epileptiform 16 44.4% 12 41.4% 126 51.0% 15 20.5% 112 24.2% 11 20.8% 76 33.3% 200 25.7% 568 29.8% 
Non-specific 8 22.2% 0 0.0% 28 11.3% 10 13.7% 127 27.5% 13 24.5% 0 0.0% 171 22.0% 357 18.7% 
Not done / 
NK* 
9 25.0% 12 41.4% 63 25.5% 33 45.2% 84 18.2% 18 34.0% 2 0.9% 110 14.1% 331 17.4% 
 
CT 
Normal 3 8.3% 0 0.0% 24 9.7% 24 32.9% 149 32.3% 18 34.0% 0 0.0% 437 56.2% 655 34.4% 
Focal 2 5.6% 0 0.0% 4 1.6% 17 23.3% 22 4.8% 10 18.9% 0 0.0% 103 13.2% 158 8.3% 
Non-specific 0 0.0% 0 0.0% 7 2.8% 2 2.7% 22 4.8% 4 7.5% 0 0.0% 12 1.5% 47 2.5% 
Not done / 
NK* 
31 86.1% 29 100.0% 212 85.8% 30 41.1% 269 58.2% 21 39.6% 228 100.0% 226 29.0% 1046 54.9% 
 
MRI 
Normal 18 50.0% 5 17.2% 109 44.1% 34 46.6% 229 49.6% 19 35.8% 195 85.5% 349 44.9% 958 50.3% 
Focal 9 25.0% 20 69.0% 42 17.0% 19 26.0% 57 12.3% 10 18.9% 33 14.5% 121 15.6% 311 16.3% 
Non-specific 6 16.7% 0 0.0% 25 10.1% 6 8.2% 88 19.0% 9 17.0% 0 0.0% 9 1.2% 143 7.5% 
Not done / 
NK* 
3 8.3% 4 13.8% 71 28.7% 14 19.2% 88 19.0% 15 28.3% 0 0.0% 299 38.4% 494 25.9% 
*NK = not known 
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4.1.9. Neurological examination / sequelae 
The majority of patients (n=1754; 92.0%) had a normal/unknown/not applicable 
neurological examination and 152 (8.0%) had a documented abnormal examination. The 
ULB cohort (n = 7; 24.1%), ULIV (n = 12; 22.6%) and RCSI (n = 15; 20.5%) had the highest 
proportion of subjects with an abnormal neurological examination, whereas the 
Australian cohort (n = 10; 4.4%), Glasgow (n = 20; 4.3%) and SANAD (n = 46; 5.9%) had the 
least number of documented cases with an abnormal examination. More detailed results 
stratified by cohort are presented in Table 21. 
Table  21. Results of neurological examination stratified by cohort 
Cohort 
Neurological examination 
Normal / Not available Abnormal 
n % n % 
 
UCL 30 83.3% 6 16.7% 
ULB 22 75.9% 7 24.1% 
EKUT 211 85.4% 36 14.6% 
RCSI 58 79.5% 15 20.5% 
Glasgow 442 95.7% 20 4.3% 
ULIV 41 77.4% 12 22.6% 
Australia 218 95.6% 10 4.4% 
SANAD 732 94.1% 46 5.9% 
Entire Cohort 1754 92.0% 152 8.0% 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
 
To assess the number of cases with unknown or not applicable outcomes, the original 
dataset was explored (n = 1906). There were 1658 (86.99%) cases with normal 
neurological examination, 151 with abnormal (7.92%) and 97 (5.09%) with either 
unknown or not applicable status. 
4.1.10. Febrile convulsions 
A history of febrile convulsions was documented in 75 (3.9%) cases. There were 
differences observed between cohorts, with ULB having no history and 6.5% of the EKUT 
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subjects and 5% of SANAD subjects having a history of febrile convulsions. The data on 
febrile convulsions is summarised by cohort in Table 22. 
Table  22. Presence or absence of past medical history of febrile convulsion stratified by 
cohort (n = 1906) 
Cohort 
Febrile convulsions 
No Yes 
n % n % 
 
UCL 35 97.2% 1 2.8% 
ULB 29 100.0% 0 0.0% 
EKUT 231 93.5% 16 6.5% 
RCSI 71 97.3% 2 2.7% 
Glasgow 448 97.0% 14 3.0% 
ULIV 52 98.1% 1 1.9% 
Australia 226 99.1% 2 0.9% 
SANAD 739 95.0% 39 5.0% 
Entire Cohort 1831 96.1% 75 3.9% 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
4.1.11. Learning disabilities 
There were 1369 (71.8%) cases with unknown status or present known learning 
disabilities and 537 (28.2%) with no history of LDs. Because data was recoded in the 
phenotype derivation, the original data file was used to describe in detail the distribution 
of learning disabilities. Wide differences in the presence of LDs between cohorts were 
observed. The UCL and ULB cohorts had no cases with documented learning disabilities, 
and the ULB cohort had no collected data on LDs. UCL is a relatively small cohort with a 
high proportion of unknown (66.67%) LD status. The highest proportion of unknown data 
was in the ULB (100%), Australia (99.13%) and SANAD (93.44%) cohorts. More detailed 
results are summarised in Table 23.  
In summary, due to the fact that the collection of the data on LDs was started in the 
middle of the project, the results of this co-variate are very unreliable.  
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Table  23. Distribution of learning disabilities stratified by cohort based on a raw data file. 
Cohort 
Learning disabilities 
Yes % No % Not known % Total 
Australia 1 0.44% 1 0.44% 227 99.13% 229 
EKUT 4 1.63% 13 5.28% 229 93.09% 246 
Glasgow 5 1.08% 434 93.94% 23 4.98% 462 
RCSI 3 4.11% 38 52.05% 32 43.84% 73 
SANAD 29 3.73% 22 2.83% 727 93.44% 778 
UCL 0 0.00% 12 33.33% 24 66.67% 36 
ULB 0 0.00% 0 0.00% 29 100.00% 29 
ULIV 4 7.55% 17 32.08% 32 60.38% 53 
Entire cohort 46 2.41% 537 28.17% 1323 69.41% 1906 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
 
4.1.12. Time from first seizure to first AED 
Data for this co-variate were available for 1873 subjects; in 25 cases it was missing and 
in 8 cases values were negative. Negative values probably were due to errors in 
phenotyping. The distribution of this co-variate was skewed towards the left (see Figure 
14.) The distribution of the data showed a single early peak with a relatively steep fall off. 
The median time from the first seizure to the first AED was 11.53 months, the mean time 
was 42.62 months and IQR was 4.01 - 37.42. 
There were differences observed between cohorts, with RCSI (median = 4.57 months), 
EKUT (median = 4.99 months) and ULB (median = 6.14 months) having the shortest 
median time, whereas SANAD (median = 14.64 months) and UCL (median = 14.92 months) 
had the longest time from first seizure to first AED. The rest of the data, separated by 
cohort, are presented in Table 24. For the analysis of association, a logarithmic 
transformation of the data was used. 
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Table  24. Time (in months) from first seizure to first AED stratified by cohort. IQR – 
interquartile range. 
Cohort 
Time from first seizure to first AED 
Mean 
Standard 
deviation 
Median IQR 
 
UCL 33.57 48.00 14.92 2.92 - 34.63 
ULB 17.60 25.59 6.14 1.02 - 18.56 
EKUT 18.26 40.74 4.99 1.12 - 15.97 
RCSI 17.22 30.13 4.57 0.26 - 17.51 
Glasgow 39.10 72.69 11.47 4.25 - 37.40 
ULIV 34.41 62.75 10.78 3.06 - 32.95 
Australia 44.34 83.90 13.04 3.84 - 36.93 
SANAD 55.82 100.78 14.64 5.98 - 50.00 
Entire Cohort 42.62 83.06 11.53 4.01 - 37.42 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
 
Figure 14. Histogram of frequency distribution for time from first seizure to first AED in 
months (n = 1873). 
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4.1.13. First well-tolerated anti-epileptic drug 
Data on the application of the first applied anticonvulsant was available in 1874 cases 
(98.3%) and was missing in 32 cases (1.7%). This information is required for assessment of 
treatment outcome; as such, these 32 cases were excluded from further analysis.  
The data on the first applied anticonvulsant stratified by cohort is presented in Table 
25 and Figure 15 summarises the frequency of individual AEDs. Three subjects in Glasgow 
had participated in a randomised clinical trial for newly diagnosed epilepsy. They were 
exposed to one of the currently approved AEDs. The results of un-blinding after the end of 
the trial were not stored in clinical notes for those cases. As tasks one and three of work 
package two do not investigate selective drug response, they were included in the study. 
Several cohorts were initially assembled as clinical trials, for example, lamotrigine and 
levetricetam were extensively researched in the Glasgow and SANAD studies. Hence, our 
data are not representative of a baseline population of newly diagnosed epilepsy cases, 
nor do they characterise the routine non-clinical trial prescribing patterns of the recruiting 
centre. Overall, the most commonly prescribed anticonvulsant was lamotrigine (n= 478; 
25.1%) followed by valproate (n = 415; 21.8%) and carbamazepine (n = 338; 17.7%). 
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Table  25. First applied anticonvulsant in newly diagnosed epilepsy according to the research cohort (n = 1874) 
Generic name of 
AED 
Cohort 
UCL ULB EKUT RCSI Glasgow ULIV Australia SANAD Entire Cohort 
n % n % n % n % n % n % n % n % n % 
Missing 0 0.0 1 3.4 0 0.0 0 0.0 10 2.2 0 0.0  8  3.5 13 1.7 32 1.7 
Carbamazepine 6 16.7 3 10.3 20 8.1 17 23.3 34 7.4 20 37.7 87 38.2  151 19.4  338  17.7 
Clobazam 1 2.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0  0  0.0  0 0.0  1 0.1 
Ethosuximide 0 0.0 0 0.0 8 3.2 0 0.0 0 0.0 0 0.0  0  0.0  1 0.1  9 0.5 
Felbamate 0 0.0 0 0.0 0 0.0 0 0.0 3 0.6 0 0.0  0  0.0  0 0.0  3 0.2 
Gabapentin 0 0.0 0 0.0 0 0.0 2 2.7 6 1.3 1 1.9  1  0.4  103 13.2  113 5.9 
Lacosamide 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0  0  0.0 0 0.0  1 0.1 
Levetiracetam 3 8.3 7  24.1 36 14.6 12 16.4 76 16.5 0 0.0   18  7.9 7 0.9  159 8.3 
Levetiracetam x 
Carbamazepine 
0 0.0 0 0.0 0 0.0 0 0.0 2 0.4 0 0.0  0  0.0 0 0.0  2 0.1 
Lamotrigine 14 38.9 3  10.3 61 24.7 11 15.1 151 32.7 9 17.0   25  11.0  204 26.2  478  25.1 
Oxcarbazepine 0 0.0 0 0.0 15 6.1 6 8.2 17 3.7 0 0.0 0 0.0 59 7.6   97  5.1 
Phenobarbital 0 0.0 0 0.0 2 0.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2  0.1 
Pregabalin 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1  0.1 
Phenytoin 3 8.3 2 6.9 4 1.6 14 19.2 2 0.4 6 11.3 12 5.3 1 0.1 44  2.3 
Sulthiame 0 0.0 0 0.0 3 1.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3  0.2 
Tiagabine 0 0.0 0 0.0 0 0.0 0 0.0 2 0.4 0 0.0 0 0.0  0 0.0 2  0.1 
Topiramate 2 5.6 1 3.4 8 3.2 0 0.0 30 6.5 1 1.9 3 1.3  158 20.3  203  10.7 
Topiramate x 
Valproate 
0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0  0 0.0 1  0.1 
Vigabatrin 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0  1 0.1 1  0.1 
Valproate 7 19.4 12 41.4 88 35.6 11 15.1 127 27.5 16 30.2 74 32.5    80 10.3  415 21.8 
Zonisamide 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 
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Figure 15. The distribution of the first well-tolerated anticonvulsant in cases of newly 
diagnosed epilepsy (n = 1874) 
4.2. Logistic regression 
A logistic regression analysis was used to assess the predictive role of clinical co-
variates on the occurrence of seizure remission for at least 12 months in patients with 
newly diagnosed epilepsy after application of the first anticonvulsant. A full list of clinical 
covariates tested for association is presented in Table 26 a and b. In total, 1906 cases 
were selected for the analysis; 1723 (90.4%) were included and 183 (9.6%) were 
excluded due to missing information. Reasons for exclusion are the same as presented 
at the beginning of this chapter. 
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Univariate analysis showed that age at diagnosis, follow-up length, gender, epilepsy 
type, neurological examination results, generalised tonic-clonic seizures only, pre-
treatment seizure count, cohort, and EEG and MRI results are statistically significantly 
associated at level of p < 0.05 with the presence of 12-month remission in newly 
diagnosed epilepsy after application of the first well-tolerated anticonvulsant. Full 
results of the univariate analysis are presented in Table 26 a and b. 
Table  26a. Univariate analysis of all continuous clinical factors included in logistic 
regression model (IQR – inter quartile range) 
Continuous co – 
variates 
Total Median; IQR p-value 
p-value (Bonferonni 
correction) 
Age at diagnosis 
(years) 
1744 
Median = 33.21; IQR 
19.85 - 49.63 
0.001 0.021 
Time from first 
seizure to AED in 
years (log) 
1724 
Median = 2.54;   IQR 
2.08 - 3.04 
0.465 1.0 
Follow-up length 
(years) 
1743 
Median = 3.62;   IQR 
2.22 - 5.70 
0.008 0.155 
Table 26b. Univariate analysis of all categorical clinical factors included in logistic 
regression model. 
Categorical co-
variates (n=1744) 
 Total % p-value 
p-value (Bonferonni 
correction) 
Gender 
Males 898 51.5% 
0.008 0.155 
Females 846 48.5% 
Positive family history 
Yes 331 19.0% 
0.963 1.0 
No / NK 1413 81.0% 
Neurological 
examination 
Abnormal / NA 139 8.0% 
0.000 0.000 
Normal 1605 92.0% 
Febrile seizures 
Yes 73 4.2% 
0.322 0.999 
No / NA 1671 95.8% 
Learning disabilities 
Present / NK 489 28.0% 
0.430 1.0 
Absent 1255 72.0% 
Seizure type  
Simple or complex 
partial only 
Yes 357 20.5% 
0.072 0.792 
No 1387 79.5% 
Secondary generalised 
tonic-clonic 
Yes 722 41.4% 
0.128 0.944 
No 1022 58.6% 
Generalised tonic-
clonic seizures only 
Yes 564 32.3% 
0.000 0.000 
No 1180 67.7% 
Absence seizures 
Yes 131 7.5% 
0.613 1.0 
No 1613 92.5% 
Myoclonic or absence 
seizures with tonic-
clonic seizures 
Yes 226 13.0% 
0.915 1.0 
No 1518 87.0% 
Unclassified tonic-
clonic seizures 
Yes 289 16.6% 
0.064 0.751 
No 1455 83.4% 
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Other seizures 
Yes 75 4.3% 
0.956 1.0 
No 1669 95.7% 
Epilepsy type   
Focal epilepsy - 
baseline 
 
1235 70.8% 
0.004 0.081 
Generalised epilepsy 316 18.1% 
Unclassified epilepsy 193 11.1% 
Pre-treatment seizure count   
1 – 2 (baseline) 
 
364 20.9% 
0.000 0.000 
3 - 5 395 22.6% 
6 – 10 165 9.5% 
11 - 20 127 7.3% 
21 + 435 24.9% 
Pre-treatment seizure 
count unknown 
258 14.8% 
Cohort   
SANAD (baseline) 
 
748 42.9% 
0.000 0.000 
UCL 33 1.9% 
ULB 17 1.0% 
EKUT 235 13.5% 
RCSI 72 4.1% 
Glasgow 415 23.8% 
ULIV 53 3.0% 
Australia 171 9.8% 
EEG   
EEG Normal (baseline) 
 
586 33.6% 
0.000 0.002 
EEG Epileptiform 511 29.3% 
EEG Abnormal non-
specific 
342 19.6% 
EEG Not done/not 
known 
305 17.5% 
MRI   
MRI Normal (baseline) 
 
866 49.7% 
0.000 0.007 
MRI Focal 281 16.1% 
MRI Abnormal non-
specific 
130 7.5% 
MRI Not done/not 
known 
467 26.8% 
CT   
CT Normal (baseline) 
 
623 35.7% 
0.239 0.996 
CT Focal 155 8.9% 
CT Abnormal non-
specific 
42 2.4% 
CT Not done/not 
known 
924 53.0% 
NK – Not known; NA – Not available 
Fitting a multivariable binary logistic regression model showed that epilepsy type, 
pre-treatment seizure count, age at diagnosis, origin of cohort, EEG results, generalised 
tonic-clonic seizures only, CT and MRI results, and follow-up length were all significantly 
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associated with outcome. Older age at diagnosis and the presence of generalised tonic-
clonic seizures increased the probability of attaining a 12-month remission. On the other 
hand, an abnormal neurological examination was associated with a reduced probability 
of experiencing a 12-month freedom from seizures. The direction of effect for epilepsy 
type pointed towards a higher probability of experiencing remission in the case of 
generalised epilepsy. A negative direction of effect was observed in cases of focal 
abnormalities on MRI image, and not done or unknown EEG. Direction of effect in the 
case of focal abnormal CT pointed towards a higher probability of experiencing 
remission. A more complex picture was observed in the case of pre-treatment seizure 
frequency, with 6 – 10, more than 21, or an unknown number of seizures before starting 
treatment having a negative direction of effect on the probability of a 12-month 
remission. The full results of the logistic regression are summarised in Figure 16 and 
Table 27. The Cox and Snell R Square for the final model was 0.135 and the Nagelkerke R 
Square was 0.181. 
Table  27. Multivariable logistic regression model for 12-month seizure remission in 
newly diagnosed epilepsy (n = 1723) 
Co-variate  p-value Odds Ratio 95% C.I. for Odds Ratio 
Male 0.066 1.218 0.987 1.502 
Age at diagnosis 0.000 1.019 1.012 1.026 
Abnormal neurological examination 0.000 0.438 0.289 0.666 
Generalised tonic-clonic seizures only 0.000 1.734 1.320 2.278 
Follow-up length 0.000 1.054 1.023 1.085 
Epilepsy type 
Focal (baseline)     
Generalised 
0.000 
1.944 1.385 2.728 
Unclassified 0.954 0.658 1.381 
Pre-treatment seizure count 
1 – 2 (baseline)     
3 - 5 
0.001 
1.033 0.743 1.437 
6 - 10 0.600 0.393 0.914 
11 - 20 0.742 0462 1.191 
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21 + 0.564 0.379 0.838 
Not known pre-treatment seizure 
count 
0.564 0.379 0.838 
Cohort 
SANAD (baseline)     
UCL 
0.000 
0.135 0.047 0.388 
ULB 0.320 0.092 1.119 
EKUT 0.953 0.646 1.408 
RCSI 0.430 0.225 0.823 
Glasgow 0.740 0.541 1.011 
ULIV 0.091 0.037 0.220 
Australia 1.392 0.847 2.288 
EEG 
EEG Normal (baseline)     
EEG Epileptiform 
0.028 
0.956 0.713 1.282 
EEG Abnormal non-specific 0.915 0.676 1.239 
EEG Not done/not known 0.624 0.451 0.864 
CT 
CT Normal (baseline)     
CT Abnormal focal 
0.030 
1.633 1.009 2.645 
CT Abnormal non-specific 0.576 0.275 1.207 
CT Not done/not known 1.265 0.962 1.662 
MRI 
MRI Normal (baseline)     
MRI Abnormal focal 
0.009 
0.560 0.385 0.814 
MRI Abnormal non-specific 1.093 0.701 1.705 
MRI Not done/not known 1.036 0.790 1.359 
SANAD is the only included cohort that was a randomised clinical trial and it provides 
43% of all cases. To assess the impact of this cohort on the results, a sensitivity analysis 
was carried out by repeating the above analyses but this time excluding all of the SANAD 
cases. Gender, epilepsy type, age at onset, generalised tonic-clonic seizures only, EEG, 
MRI, follow-up length and origin of cohort remained significant in this sensitivity 
analysis, whilst the variables pre-treatment seizure number and CT imaging results lost 
their significance. 
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Figure 16. Forest plot (log scale) of results of logistic regression for treatment 
outcome (12 month remission vs. no remission) in newly diagnosed epilepsy after 
application of first anticonvulsant. The following categories are assumed baseline for the 
categorical covariates: female sex, focal epilepsy, 1-2 seizures before starting treatment, 
normal EEG, normal CT, normal MRI and SANAD. Right lateral column demonstrates 95% 
C.I. for Odds Ratio. OR > 1 indicates a higher probability of 12 months remission. 
0.01 0.1 0.2 0.5 1 2 5
Australia 1.39 (0.85, 2.29)
University of Liverpool 0.09 (0.04, 0.22)
Epilepsy Unit, Western Infirmary, Glasgow 0.74 (0.54, 1.01)
Royal College of Surgeons in Ireland 0.43 (0.22, 0.82)
Eberhard-Karl s-Universität Tübingen 0.95 (0.65, 1.41)
Hôpital Erasme, Université Libre de Bruxel les 0.32 (0.09, 1.12)
Insti tute of Neurology, Universi ty College London 0.13 (0.05, 0.39)
MRI Not done / NK 1.04 (0.79, 1.36)
MRI Abnormal  non - speci fic 1.09 (0.70, 1.71)
MRI Abnormal  focal 0.56 (0.39, 0.81)
CT Not done / NK 1.26 (0.96, 1.66)
CT Abnormal non – specific 0.58 (0.28, 1.21)
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EEG Abnormal non - specifi c 0.91 (0.68, 1.24)
EEG Epi leptiform 0.96 (0.71, 1.28)
Follow up length 1.05 (1.02, 1.08)
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Pre-treatment seizure count unknown 0.56 (0.38, 0.84)
21 or more seizures before starting treatment 0.56 (0.39, 0.81)
11 - 20 seizures before starting treatment 0.74 (0.46, 1.19)
6 - 10 seizures before starting treatment 0.60 (0.39, 0.91)
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4.3. Cox regression 
After the logistic regression analysis, a Cox regression proportional hazard analysis 
was carried out. This was used to assess the association between the predictive role of 
the same clinical covariates and the time to a 12-month seizure remission in patients 
with newly diagnosed epilepsy after application of the first anticonvulsant. 
In total, 1906 cases were selected for the analysis, and 1723 (90.4%) were included; 
an event occurred in 50.8% (n = 968) cases and 39.6% (n = 755) were censored. The 
reasons for the missing data were identical to those described in the logistic regression 
paragraph. Before Cox regression univariate analysis was performed, for categorical 
variables log-rank test was used but for continuous variables Cox regression with single 
co-variate were used. Results of the univariate analysis are presented in table 28 a and 
b.  
Table  28a. Univariate analysis of all continuous clinical factors included in Cox 
regression model. As distribution of data was identical with logistic regression summary 
statistics have been omitted. 
Continuous co – variates Total 
p-
value 
p-value 
(Bonferonni 
correction) 
Age at diagnosis (years) 1744 0.000 0.002 
Time from first seizure to 
AED in years (log) 
1724 0.185 0.986 
Follow-up length (years) 1743 0.000 0.000 
Table 28b. Univariate analysis of all categorical clinical factors included in Cox 
regression model. As distribution of data was identical with logistic regression summary 
statistics have been omitted.  
Categorical co-variates (n=1744)  p-value 
p-value (Bonferonni 
correction) 
Gender 
Males 
0.004 0.074 
Females 
Positive family history 
Yes 
0.934 1.0 
No / NK 
Neurological examination 
Abnormal / NA 
0.000 0.000 
Normal 
Febrile seizures 
Yes 
0.256 0.998 
No / NA 
Learning disabilities 
Present / NK 
0.133 0.950 
Absent 
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Seizure type 
Simple or complex partial only 
Yes 
0.072 0.790 
No 
Secondary generalised tonic-clonic 
Yes 
0.0622 0.740 
No 
Generalised tonic-clonic seizures only 
Yes 
0.000 0.000 
No 
Absence seizures 
Yes 
0.562 1.0 
No 
Myoclonic or absence seizures with 
tonic-clonic seizures 
Yes 
0.869 1.0 
No 
Unclassified tonic-clonic seizures 
Yes 
0.065 0.756 
No 
Other seizures 
Yes 
0.888381 1.0 
No 
Epilepsy type 
Focal epilepsy - baseline 
 0.000 0.007 Generalised epilepsy 
Unclassified epilepsy 
Pre-treatment seizure count 
1 – 2 (baseline) 
 0.000 0.000 
3 - 5 
6 – 10 
11 - 20 
21 + 
Pre-treatment seizure count unknown 
Cohort 
SANAD (baseline) 
 0.000 0.000 
UCL 
ULB 
EKUT 
RCSI 
Glasgow 
ULIV 
Australia 
EEG 
EEG Normal (baseline) 
 0.000 0.001 
EEG Epileptiform 
EEG Abnormal non-specific 
EEG Not done/not known 
MRI 
MRI Normal (baseline) 
 0.000 0.003 
MRI Focal 
MRI Abnormal non-specific 
MRI Not done/not known 
CT 
CT Normal (baseline) 
 0.0938 0.874 
CT Focal 
CT Abnormal non-specific 
CT Not done/not known 
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The Cox regression model showed that gender, epilepsy type, pre-treatment seizure 
count, age at diagnosis, origin of cohort, EEG results, generalised tonic-clonic seizures 
only and MRI results were all significantly associated with time to onset of 12 months 
remission after application of the first well tolerated AED. An increase in age at diagnosis 
and the presence of generalised tonic-clonic seizures were associated with shorter time 
to onset of 12 months remission. On the other hand, an abnormal neurological 
examination was associated with a longer time to experience a 12-month freedom from 
seizures. The direction of effect for epilepsy type pointed towards a shorter time to 
onset for remission in the case of generalised epilepsy. A negative direction of effect 
was observed in the case of focal abnormalities on the MRI image, and not done or 
unknown EEG. In the case of the pre-treatment seizure count, a more complex picture 
was observed, with 6 – 10, more than 21, or an unknown number of seizures before 
starting treatment having a negative direction on time to onset of 12 month-remission. 
The full results of the Cox regression are presented in Table 29 and in figure 17.  
The assumption of proportionality of hazards over time was checked with Schoenfield 
residuals (data not shown) and this was not upheld for all covariates The internal validity 
of the model was assessed by Harrell’s C and Somers’ D index. The value for Harrell's C 
was 0.6853360185 and for Somers' D it was 0.3706720371 (Harrell et al., 1996). 
 
Table  29. Cox regression model for 12 month seizure remission in newly diagnosed 
epilepsy (n = 1723) 
Covariate p-value Hazard Ratio 
95.0% CI for Hazard Ratio 
Lower Upper 
Male 0.058 1.135 0.996 1.294 
Age at diagnosis 0.000 1.011 1.007 1.015 
Generalised tonic-clonic 
seizures only 
0.000 1.405 1.201 1.644 
Abnormal neurological 
examination 
0.001 0.595 0.438 0.807 
Epilepsy type 
Focal (background) 
0.002 
 
Generalised 1.436 1.169 1.763 
Unclassified 0.998 0.806 1.237 
Pre-treatment seizure count 
1 – 2 (background) 0.001  
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3 – 5 1.022 0.853 1.225 
6 – 10 0.754 0.578 0.983 
11 – 20 0.785 0.588 1.047 
21 or more 0.678 0.541 0.850 
Pre-treatment seizure 
count unknown 
0.765 0.598 0.978 
EEG 
EEG Normal 
0.036 
 
EEG Epileptiform 0.994 0.833 1.188 
EEG Abnormal non-
specific 
0.966 0.801 1.164 
EEG Not done/not known 0.746 0.604 0.922 
CT 
CT Normal (background) 
0.088 
 
CT Abnormal focal 1.324 0.977 1.795 
CT Abnormal non – 
specific 
0.716 0.432 1.188 
CT Not done/not known 1.116 0.942 1.321 
MRI 
MRI Normal 
(background) 
0.017 
 
MRI Abnormal focal 0.709 0.551 0.912 
MRI Abnormal non-
specific 
1.082 0.824 1.423 
MRI Not done/not known 1.057 0.893 1.250 
Cohort 
SANAD (background) 
0.000 
 
UCL 0.269 0.109 0.666 
ULB 0.570 0.208 1.560 
EKUT 1.169 0.917 1.490 
RCSI 0.647 0.430 0.974 
Glasgow 0.871 0.722 1.052 
ULIV 0.192 0.094 0.394 
Australia 1.185 0.901 1.557 
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Figure 17. Forest plot (log scale) of results of Cox regression for time to onset of 12 
months remission in newly diagnosed epilepsy after application of the first 
anticonvulsant. The following categories are assumed baseline for the categorical 
covariates: female sex, focal epilepsy, 1-2 seizures before starting treatment, normal 
EEG, normal CT, normal MRI and SANAD. Right lateral column demonstrates 95.0% CI for 
Hazard Ratio. HR > 1 indicates a shorter time to 12 months remission. 
  
HR > 1   HR < 1 
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Due to the heterogeneity of the remission rates observed across the cohorts, a 
further Cox regression was performed and stratified by cohort. The parameters of the 
model were identical to the previously described model. The results of this model are 
presented in the table 30. 
Table 30. Cox regression model for time to 12 month seizure remission in newly 
diagnosed epilepsy after the application of first well tolerated AED, stratified by cohort 
(n=1723) 
Covariate p-value 
Hazard 
Ratio 
95.0% CI for Hazard 
ratio 
Lower Upper 
Male 0.049 1.140 1.000 1.299 
Age at diagnosis 0.000 1.010 1.006 1.014 
Abnormal neurological 
examination 
0.001 0.598 0.441 0.812 
Generalised tonic-clonic 
seizures only 
0.000 1.402 1.198 1.640 
Epilepsy type 
Focal (baseline) 
0.000 
   
Generalised 1.487 1.213 1.822 
Unclassified 0.996 0.804 1.235 
Pre - treatment seizure count 
1 – 2 (baseline) 
0.002 
   
3 – 5  1.013 0.845 1.214 
6 – 10 0.750 0.575 0.978 
11 – 20  0.787 0.590 1.050 
21 or more 0.675 0.539 0.846 
Pre - treatment seizure 
count unknown 
0.768 0.600 0.983 
EEG 
EEG Normal(baseline) 
0.051 
   
EEG Epileptiform 1.001 0.838 1.196 
EEG Abnormal non-specific 0.975 0.808 1.176 
EEG Not done/not known 0.762 0.618 0.939 
MRI 
MRI Normal (baseline) 
0.070 
   
MRI Abnormal focal 0.808 0.657 0.994 
MRI Abnormal non-specific 1.119 0.854 1.467 
MRI Not done/not known 1.069 0.908 1.257 
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The stratified Cox regression model showed that age at onset, male sex, and 
generalised tonic-clonic seizures only are statistically significantly associated with a 
shorter time to 12 remission, whereas abnormal neurological examination was 
associated with a longer time to 12 month remission. Epilepsy type was also significantly 
associated with the outcome; generalised epilepsy had a positive direction of effect. 
Both MRI and EEG were not significantly associated with the outcome but remained in a 
final model.   
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4.4. Impact of methodology 
4.4.1. Cohort 
Both the logistic and Cox regression analyses described earlier in this chapter 
demonstrated that non-clinical factors are associated with 12 month remission in newly 
diagnosed epilepsy. The role of non-clinical variables such as the origin of the cohort, 
the length of the observation period, and the mode of case ascertainment will be 
assessed in this section. 
The origin of the cohort does not have a clinical meaning, but it encompasses the way 
that the study was set up and conducted. The biggest contributor to our study was the 
SANAD study with 778 cases – 96.14% (n = 748) were included in the analysis. The next 
largest cohort was from Glasgow (n = 462), of which 43 cases (10.61%) were excluded. 
This indicates that cases can be lost both in the case of manual phenotyping and data 
transfer. Interestingly, a manually phenotyped cohort like ULIV had no losses at all, 
indicating a potential underlying selection bias, by selecting for initial genotyping cases 
with full clinical information available. The most significant proportional reduction of 
cases occurred in the ULB (34.48%), Australia (29.39%) and UCL (13.89%) cohorts. Due to 
the complicated and protracted data transfer from the clinical database, the ULB cohort 
lost proportionally the highest amount of cases. Data transfer was complicated by the 
complexity of linking values between the database used for clinical purposes and the 
EpiPGX eCRF. In the case of the cohort from Glasgow, losses were mostly due to 
incomplete (less than 12 months) follow-up due to a strain on services at certain periods 
of time. The Australian cohort, similarly to ULB and SANAD, was transferred 
electronically from the original research database. Cases from this cohort were lost due 
to data being incompatible with EpiPGX definitions. Table 31 summarises the total 
number of cases by cohort, as well as the number of cases each cohort contributed to 
the logistic and Cox regression analyses. 
 
 
 137 
 
Table  30. Number of subjects included and excluded from the logistic and Cox 
regressions 
Cohort 
Total Included in analysis 
n % n % out of total 
UCL 36 1.9 31 86.11 
ULB 29 1.5 16 65.52 
EKUT 247 13.0 232 93.93 
RCSI 73 3.8 69 94.52 
Glasgow 462 24.2 413 89.39 
ULIV 53 2.8 53 100.00 
Australia 228 12.0 161 70.61 
SANAD  778 9.5 748 96.14 
Entire Cohort 1906 100.0 1723 100.00 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
4.4.2. Effect of method of case ascertainment 
The complete research cohort contained a mixture of prospective and retrospectively 
ascertained cases. Out of 1906 cases, 1006 (52.8%) were prospectively ascertained. For 
an assessment of the effect of case ascertainment, only cases with complete 
information were used (n = 1723). The reasons for excluding cases were exactly the 
same as those described in this chapter for the logistic regression. Out of these 1723 
cases, 909 (52.8%) were prospective. Only the SANAD and Australian cohorts were 
prospective. To assess the effect of the method of case ascertainment ,the final model 
of previously described logistic regression was refitted with an additional co-variate, 
“prospective v. retrospective”. Identical selection parameters as described in the logistic 
regression chapter were utilised. 
The method of case ascertainment was statistically significantly (p < 0.000) associated 
with the occurrence of a 12-month remission. Similarly to the previously described 
logistic regression model, epilepsy type, abnormal neurological examination, presence 
of generalised tonic-clonic seizure only, pre-treatment seizure count, age at diagnosis, 
EEG, CT, MRI, follow-up length and origin of cohort were significantly associated with 
the treatment outcome. Prospectively recruited cases were more likely to experience 
remission (odds ratio 1.054, 95% CI 1.023 – 1.085).  
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4.4.3. Period of observation 
Period of observation is an important methodological aspect as too short observation 
period would risk of failure to capture events of interest, on the other hand too long is 
associated with higher cost and logistic difficulties. Hence it is important to establish the 
minimal period required to capture most of the events of interest. Speed et al has 
assessed in their epilepsy pharmacogentic study and reported that 90% of patients with 
newly diagnosed epilepsy will experience remission within first 2 years after starting 
treatment (Speed et al., 2014a). This chapter will explore not only time required to a 
observe remission but a broader role of duration of whole follow up period. 
To assess the effect of length of the period of observation on the treatment outcome   
three variables – time to onset of 12 month remission, follow-up length and length of 
remission were used. 
Data on follow-up length were available in 1905 cases; it was only unavailable in one 
case. Its distribution is negatively skewed with an early peak and relatively steep fall off. 
The histogram is presented in Figure 18. Median follow-up length was 3.39 years (SD = 
4.87; IQR =2.06 - 5.57), highlighting relatively good data capture and the probability of 
observing events of interest. 
There were noticeable differences between cohorts in the period of observation, with 
the Australian cohort having the shortest median follow-up length (1.94 years) and ULIV 
(14.42 years) and RCSI (13.76 years) the longest. This was probably due to the fact that 
the Australian cohort is relatively recent compared to ULIV. ULIV and RCSI utilised direct 
retrospective phenotyping based on clinical notes and were able to trace back to the 
first anticonvulsant, hence they potentially had longer overall follow-up information. 
The SANAD study, was a pragmatic clinical trial and involved systematic data collection 
for a fixed time period but still individual follow up periods varied in-between patients.. 
The follow-up length stratified by the cohort are further summarised in Table 32. 
The length of the follow-up was also assessed in the logistic regression model for a 
relationship with the 12-month period of remission. It was statistically significantly (p < 
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0.000, Exp(B) = 1.054, 95% CI 1.023 – 1.085) associated with remission. A longer length 
of follow-up was associated with a higher probability of remission. 
 
Figure 18. Histogram of distribution (frequency of cases) for follow-up length in years 
(n = 1905)  
Table  31. Length of follow-up period in years stratified by cohort. IQR – interquartile 
range. 
Cohort 
Follow-up length (years) 
Mean 
Standard 
deviation 
Median IQR 
 
UCL 8.25 7.06 7.36 1.68 - 12.92 
ULB 3.87 3.50 3.08 1.28 - 5.30 
EKUT 5.86 5.37 4.44 2.36 - 7.41 
RCSI 13.76 8.15 13.62 7.68 - 18.57 
Glasgow 5.63 4.62 4.37 2.41 - 7.62 
ULIV 14.42 8.64 13.18 8.23 - 18.76 
Australia 1.98 1.14 1.94 1.06 - 2.46 
SANAD 3.32 1.52 3.06 2.09 - 4.48 
Entire Cohort 4.86 4.87 3.39 2.06 - 5.57 
UCL – University College London; ULB - Hôpital Erasme, Université Libre de Bruxelles; EKUT -  Eberhard-Karls-
Universität Tübingen; RCSI - Royal College of Surgeons in Ireland; University of Liverpool; SANAD - Standard and New 
Antiepileptic Drugs Study. 
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Data on time to onset of 12 month remission was available for all of the 982 patients 
experiencing remission; the median time to onset of remission was 0.0 years (mean = 
0.35; SD = 1.07; IQR = 0 – 0.25, range 0 – 13.97), indicating immediate onset of 
remission. 
A histogram (figure 19) illustrating frequency percentage distribution for time to 
onset of 12 month remission in years after application of the first well tolerated 
anticonvulsant shows a very steep drop after the first year followed by a tail lasting for 
several years. Ninety-five per cent of all remissions occurred within the 1.58 years from 
the onset of the treatment. The full range of time to remission in percentiles is 
presented in Table 33. 
 
Figure 19. Histogram (n = 982) demonstrates frequency percentage distribution of 
patients over time who achieved 12 month remission after application of the first well 
tolerated anticonvulsant. Bin size is equal to one year. For majority of patients onset of 
remission was within a first year after application of anticonvulsant. 
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Table 32. Time to 12 month remission (years) separated into percentiles 
 
Percentile 
05 
Percentile 
25 
Percentile 
50 
Percentile 
75 
Percentile 
90 
Percentile 
95 
Percentile 
99 
Time to 
remission 
(days) 
0 0 0 0.25 0.92 1.58 4.53 
 
4.4.4. Duration of remission 
It has already been shown that around 16% of patients with newly diagnosed 
epilepsy will have relapsing remitting course of disease with most of them experiencing 
30 months long remission before relapse (Brodie et al., 2012). Those patients potentially 
represent a different phenotype and potentially different genetic association, 
particularly in pharmacogenomics research as those cases might not represent the 
effect of drug. Hence it is important to assess duration of remission as a separate 
methodological aspect to establish how long patients in remission should be observed 
for.  
In total, 982 (56.3%) subjects experienced a 12-month remission after starting their 
first well-tolerated anticonvulsant. The median duration of remission on the first well-
tolerated AED was 28.04 months (mean = 37.47; SD = 28.19; IQR = 18.92 - 46.52). There 
were differences between cohorts in the duration of remission, with UCL (mean = 84.06; 
median 68.60 months) and EKUT (mean = 53.91; median 42.48 months) having the 
longest, while Australian (mean = 27.71; median 24.90 months), ULIV (mean = 47.62; 
median = 24.97 months) and ULB (mean = 34.55, median = 25.94 months) had the 
shortest duration of remission. For 670 (68.2%) of the 982 patients with remission, the 
remission lasted for the entire duration of the follow-up period of observation, while 
312 (31.8%) had a relapse. Subjects with continuous remission had the shortest period 
of follow up, whereas patients with initial remission but with subsequent relapse had 
the longest follow up period (median follow-up length in years for no remission = 3.66 
years, remission with relapse = 5.20 and remission without recorded relapse 2.97). 
Duration of remission demonstrated a statistically significant difference between the 
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remission subgroups. Patients with initial remission but a relapse later, had a 
significantly shorter period of remission than those with sustained remission 
(independent sample median test p < 0.001, median length of remission in months for 
remission without a recorded relapse = 29.55 months and for 12 months remission with 
relapse = 24.80 months). 
4.4.5. Assessment of effect of definition of remission 
The application of an increased length of time of seizure freedom required for a  case 
to be counted as being in remission resulted in a progressively reduced proportion of 
patients experiencing remission (1YR = 56.3%; 2YR = 43.5%; 5YR = 25.2%; 10YR = 12.2% 
and remission lasting for a whole period of observation = 38.4%). There were 197 
patients who had follow-up for at least 10 years; 47.2% (n = 93) experienced seizure 
freedom for at least of 12 months. Only 12.2% (n = 24) experienced a 10-year seizure 
freedom. Data on the effect of changes in the length of seizure freedom on the 
proportion of patients classified as in remission are summarised in Table 34. 
Table 34. Proportion of subjects with newly diagnosed epilepsy classified as 
experiencing remission after application of different periods of seizure freedom 
adjusted by the length of the follow up. 
Length of 
follow up 
Length of remission n % 95% CI 
Whole cohort 
No remission 762 43.7% 41.4% - 46.0% 
1 year remission 982 56.3% 54.0% - 58.6% 
At least 2 year 
follow up 
No 2 year remission 792 56.5% 53.9% - 59.1% 
2 year remission 610 43.5% 40.9% - 46.1% 
At least 5 year 
follow up 
No 5 year remission 419 74.8% 71.1% - 78.3% 
5 year remission 141 25.2% 21.7% - 28.9% 
At least 10 
year follow up 
No 10 year remission 173 87.8% 82.7% - 91.8% 
10 year remission 24 12.2% 8.2% - 17.3% 
Whole cohort 
No remission 762 43.7% 41.4% - 46.0% 
Remission till last 
follow up date 
670 38.4% 36.2% - 40.7% 
Remission but not for 
whole observation 
period 
312 17.9% 16.1% - 19.7% 
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4.4.6. Impact of data transformation and upload 
Data transfer between various digital databases is a potential source of systematic 
errors. Recording of data in particular is a potentially source of systematic errors 
especially if the approach in collecting parameters differs between datasets. This is a 
particularly important issue when multiple different digital sources are used. Often 
initial data after collection is further processed to create a specific derivation reflecting 
phenotype of interest. In some cases genetic studies are a continuation of previous 
older research hence differences in data handling at all levels (including phenotype 
derivation) can add some further complexity when interpreting results.  
A comparison was made between 711 identical cases present in the EpiPGX and 
SANAD genetic study datasets. The results of this assessment have been summarised in 
Table 35. Absolute concordance was observed between the data sets for the basic 
demographic (age and gender) data and for epilepsy type, and for most of the binary co-
variates a very good concordance were observed. Two variables describing seizure types 
(GTC only and other seizures) showed poor concordance between the data sets. Time to 
remission had a Lin’s concordance coefficient of 0.6409, indicating poor concordance; 
this was due to a difference in how time to remission was calculated. In EpiPGX it was 
calculated as a time span from the first date of starting AED to the onset of the 12-
month remission. In the SANAD study, the time to remission was calculated as a time 
span from the date of randomization to the last day of the 12-month period of seizure 
freedom. 
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Table  33. Concordance between compared data sets (SANAD original genetic derivation 
and EpiPGX) WP2 task 1 phenotype derivation 
Binary co-variates 
Covariate Kappa value Significance 
Abnormal neurological 
examination 
1.000 0.000 
Generalised epilepsy 0.962 0.000 
Unclassified epilepsy 0.943 0.000 
Gender 1.000 0.000 
Generalised tonic-clonic seizures 
only 
-0.136 0.000 
Partial seizures only 0.986 0.000 
Other seizures -0.008 0.619 
Absences or myoclonic seizures 
with GTC 
0.721 0.000 
CT abnormal 0.721 0.000 
EEG abnormal 0.930 0.000 
Continuous co-variates 
 
Lin’s 
Concordance 
Coefficient 
95% CI 
Time to remission 0.6409 0.6037 – 0.6753 
Age at the onset 0.9996 0.9995 – 0.9997 
 
A good concordance (kappa = 0.738, p = 0.000) for the treatment outcome (status of 
12-month remission) was observed, with 86.8% (n = 617) of cases matching each other. 
Fifty (7.03%) had no remission in EpiPGx, but were marked as a remission in the SANAD 
original genetic derivation. In 27 (3.8%) cases there were no treatment outcomes in 
EpiPGx, whilst there were recorded outcomes in the SANAD genetic derivation; the 
opposite was observed in 17 (2.4%) patients. There were no discordant cases with 
patients recorded as no remission in SANAD but as a remission in EpiPGX. As some of 
the statistical methods rely on proportions, a comparison between the proportions of 
patients experiencing remission was also performed. Remission was observed in 56.8% 
of EpiPGx cases and 63.9% of the SANAD genetic dataset, whereas there was no 
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remission in 39.2% versus 33.6% subjects respectively, and no outcome available in 3.9% 
and 2.5% of cases respectively. 
4.5. Genome-wide association analysis 
4.5.1. Description of GWAS 
 
Localisation-related or focal epilepsy is the commonest form of epilepsy. The aim of 
this genome-wide association study was to investigate genomic biomarkers associated 
with treatment outcomes after the application of the first appropriate and adequate 
anticonvulsant in those with focal epilepsy. The description of methods related to 
genotyping, imputation, QC and research cohort assembly have been provided 
separately in the methods section. 
This GWAS was not in the EpiPGX initial analysis plan, hence only cases with locally held 
genotyping results were included. There were 935 cases included in this analysis. 
Remission was defined as at least 12 months of continuous seizure freedom after 
exposure to the first anticonvulsant.  
4.5.2. Sample size calculation 
To assess the power of GWAS, a retrospective sample size calculation was performed 
using several different scenarios (Skol et al., 2006). 
The following parameters were used for the power calculation: 
 Number of subjects experiencing 12 months remission = 524 
 Number of subjects with no remission = 411 
 Significance level = 0.0000001 
 β = 0.8 
 Prevalence = 0.44 
 MAF = 0.05 or 0.1 
 Genotype relative risk = 1.5; 2.0; 3.0; 4.0 
As can be seen from table 36 the GWAS was underpowered to detect association in 
the case of low genetic relative risk for both additive and dominant model. For relative 
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risk = 2, 3 and 4 (MAF = 0.05) in the additive model and 3 and 4 (MAF = 0.05) for the 
dominant model combination of prevalence, RR and MAF failed to correspond to a 
possible genetic model. The same result was observed for RR = 2, 3, and 4 (MFA =0.1) 
under additive model and 4 (MAF= 0.1) under dominant model.  
The GWAS was adequately powered to detect association under dominant model 
with RR 2 (MAF = 0.05 and 0.1) and RR 3 (MAF = 0.1). 
Table  34. Results of power calculation for GWAS for focal newly diagnosed epilepsy 
applying both additive and dominant models of inheritance 
MAF RR Power Model 
0.05 1.5 5.0% Additive 
0.05 2 NA Additive 
0.05 3 NA Additive 
0.05 4 NA Additive 
0.05 1.5 3.0% Dominant 
0.05 2 96% Dominant 
0.05 3 NA Dominant 
0.05 4 NA Dominant 
0.1 1.5 39% Additive 
0.1 2 NA Additive 
0.1 3 NA Additive 
0.1 4 NA Additive 
0.1 1.5 22% Dominant 
0.1 2 100% Dominant 
0.1 3 100% Dominant 
0.1 4 NA Dominant 
 
A further retrospective power calculation for was performed for EpiPGX WP2 task 2 
GWAS, using the same scenarios, except the number of subjects experiencing 12 months 
remission was 850 and no remission 664. EpiPGX WP2 task 1 GWAS  for a binary 
treatment outcome (remission v. failure) had 31% power (MAF = 0.05; RR 1.5;) to detect 
association with an additive one-stage model, and 23% power for a dominant 
inheritance model. The model assuming dominant inheritance mode with RR 2.0 (MAF= 
0.05) had 100% power to detect association in a one-stage design. The additive model 
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with MAF = 0.1 and with a genetic relative risk of 1.5 had an 88% power to detect 
association. The same calculation was performed for the model with dominant mode of 
inheritance. For RR of 1.5 there was 71% power to detect association; for the RR = 2 and 
3 model the power was 100%.  
4.5.3. Results of GWAS 
4.5.3.1. Clinical covariate analysis 
 
There were 524 patients (56.0%) with at least a 12-month remission and 411 patients 
(44.0%) who had not experienced a remission. 928 cases were included in the logistic 
regression model; 6 cases were excluded due to lack of information in terms of time 
from first seizure to first AED. 
The demographic data for cases included in the logistic regression model and 
subsequent GWAS are presented in Table 37. The following clinical factors had a 
significant association (p<0.05) with treatment outcome: neurological examination, 
generalised tonic-clonic seizures only, EEG, MRI, CT and age at onset. 
The final model after backward selection using Wald statistics was applied included 
the following co-variates: neurological examination results, generalised tonic-clonic 
seizures only, EEG, MRI, CT results and pre-treatment seizure count. Results from the 
logistic regression are presented in Table 38. The variable ‘prospective v. retrospective’ 
was also included in the GWAS model, although it was not statistically significant in the 
final logistic regression model. It did however demonstrate significance in the full model 
and was retained in this model. 
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Table 35. The demographic data for cases included in the logistic regression model for 
12 month remission after application of first AED in newly diagnosed focal epilepsy (n = 
928) and subsequently GWAS. 
Categorical variables  n % 
Gender 
Males 482 52.0 
Females 446 48.0 
Positive family history Present 154 16.6 
Abnormal neurological examination Abnormal 67 7.2 
Febrile seizures Present 32 3.5 
Simple or complex partial only Yes 275 29.6 
Generalised tonic-clonic seizures 
only 
Yes 279 30.1 
Unclassified tonic-clonic seizures Yes 131 14.1 
Other seizures Yes 2 0.2 
EEG Normal (baseline)  388 41.8 
EEG Epileptiform abnormalities  159 17.1 
EEG Abnormal non-specific  220 23.7 
EEG Not known / Not done  161 17.3 
MRI Normal (baseline)  443 47.7 
MRI Focal abnormalities  169 18.2 
MRI Abnormal non-specific  84 9.1 
MRI Not known / not done  232 25.0 
CT Normal (baseline)  393 42.3 
CT Focal abnormalities  104 11.2 
CT Abnormal non-specific  28 3.0 
CT Not known / not done  403 43.4 
1 – 2 Seizures before treatment 
(baseline) 
 166 17.9 
3 – 5 seizures before treatment  210 22.6 
6 - 10 seizures before treatment  124 13.4 
11 - 20 seizures before treatment  87 9.4 
21 + seizures before treatment  258 27.8 
Pre – treatment seizure count 
unknown 
 83 8.9 
Prospective v. retrospective Prospective 584 62.9 
Continuous variables Median IQR 
Age at diagnosis Years 41.72 29.01 - 56.16 
Time from first seizure to first AED Years(log) 2.61 2.20 - 3.11 
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Table  36. Multivariable logistic regression model for 12-month seizures remission in 
newly diagnosed focal epilepsy (n = 928). Normal EEG, CT, MRI and 1 – 2 seizure before 
the treatment were used as baseline variables (n = 928) 
Co – variates 
p 
value 
Odds 
ratio 
95% C.I.for Odds Ratio 
Lower Upper 
Abnormal neurological 
examination 
0.005 0.426 0.235 0.774 
Generalised tonic-clonic seizures 
only 
0.068 1.421 0.974 2.073 
EEG 
EEG Epileptiform 
0.00 
1.355 0.878 2.092 
EEG Abnormal non-specific 0.778 0.531 1.141 
EEG Not done/not known 0.422 0.275 0.648 
MRI 
MRI Abnormal focal 
0.008 
0.448 0.278 0.723 
MRI Abnormal non-specific 1.005 0.570 1.773 
MRI Not done/not known 0.812 0.551 1.195 
CT 
CT Abnormal focal 
0.004 
1.759 0.968 3.197 
CT Abnormal non-specific 0.512 0.208 1.263 
CT Not done/not known 1.646 1.179 2.297 
Pre-treatment seizure frequency 
3 – 5 seizures before treatment 
0.000 
0.747 0.459 1.217 
6 – 10 seizures before treatment 0.374 0.211 0.666 
11 – 20 seizures before treatment 0.507 0.265 0.971 
21 + seizures before treatment 0.272 0.153 0.484 
Pre-treatment seizure count 
unknown 
0.284 0.145 0.554 
Age at diagnosis 0.000 1.025 1.016 1.034 
Prospective v. retrospective 0.056 1.398 0.991 1.973 
 
4.5.3.2. Genetic analysis 
Figures 20 and 21 show the Manhattan plot and qq plot for the GWAS (not adjusted 
for clinical factors). The genomic inflation factor (λgc) was 1.019. There were no SNPs 
with genome-wide significant association (p <5x10-8). There were 45 SNPs that had a p-
value of less than 5x10-5. Genes within 50kb of SNPs with genome-wide p-values less 
than 5 x 10-5 are presented in Table 39. There were no SNPs with significant association 
in the exon regions of genes, and none with clear biological significance. 
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Figure 21. A qq plot for binary GWAS, not adjusted for clinical factors, for the 12 
month remission on the first well-tolerated anticonvulsant in newly diagnosed focal 
epilepsy. The red line represents the null hypothesis of no association, whereas 
observed p-values (negative logarithm) are plotted on the y axis and expected p-values 
(negative logarithm) are plotted on the x axis. Deviation is only observed in the upper 
tail area indicating sufficient control of population stratification (genomic inflation factor 
= 1.019). The GWAS was adjusted for the first five principal components. 
Figure 20. Manhattan plot for binary GWAS analysis for remission on the first well-
tolerated anticonvulsant in newly diagnosed focal epilepsy, without adjustment for clinical 
factors 
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Table 37. SNPs with p-value less than 5x10-5 from binary unadjusted GWAS for 12 
month remission on the first well-tolerated anticonvulsant in newly diagnosed focal 
epilepsy together with corresponding genes within 50 kb 
SNP Chromosome MAF P- value 
Genes within 50 kb 
from SNP 
rs76100028 3 0.077 1.47E-06 C3orf70, VPS8 
rs10166451 2 0.371 1.83E-06 EFHD1, EIF4E2 
rs114442102 2 0.372 2.06E-06 EFHD1, EIF4E2 
rs59264451 3 0.074 3.22E-06 C3orf70, VPS8 
chr11:10798
2503:D 
11 0.193 3.36E-06 ACAT1, CUL5, NPAT 
chr3:184791
599:D 
3 0.078 3.53E-06 C3orf70, VPS8 
rs4687016 3 0.078 3.53E-06 C3orf70, VPS8 
rs55882333 1 0.469 3.64E-06 
HPDL, MUTYH, TOE1, 
ZSWIM5 
rs744306 3 0.078 3.96E-06 C3orf70,VPS8 
rs747507 3 0.078 3.96E-06 C3orf70, VPS8 
rs7607256 2 0.371 4.08E-06 EFHD1, EIF4E2 
rs2004208 3 0.078 4.33E-06 C3orf70, VPS8 
rs2004207 3 0.078 4.33E-06 C3orf70, VPS8 
rs17204959 15 0.414 6.83E-06 RORA 
rs35219733 11 0.209 7.39E-06 ACAT1, CUL5, NPAT 
rs2390716 7 0.166 8.66E-06 IL6, TOMM7 
rs7624642 3 0.082 8.90E-06 VPS8 
rs753796 10 0.360 9.13E-06 
CDHR1, LRIT1, LRIT2, 
RGR 
rs9460589 6 0.273 9.53E-06 CDKAL1 
rs11727253 4 0.203 9.73E-06 SEL1L3 
rs144267602 11 0.306 9.89E-06 C11orf65, KDELC2 
 
Figures 22 and 23 show the Manhattan plot and qq plot for the GWAS adjusted for 
clinical factors. The genomic inflation factor was 1.061. Similar to the unadjusted 
analysis, there were no genome- wide significant hits (p < 5x10-8). There were 37 SNPs 
that gave a p-value of less than 5 x 10-5. Genes within 50kb of SNPs with genome-wide 
suggestive p-values from the GWAS (adjusted by clinical co-variates) have been 
presented in Table 40. 
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Figure 22. Manhattan plot for binary GWAS analysis for 12 month remission on the first 
well-tolerated anticonvulsant in newly diagnosed focal epilepsy, after adjustment for 
significant clinical factors 
 
Figure 23. A qq plot for binary GWAS adjusted for significant clinical factors for 12 
month remission on the first well-tolerated anticonvulsant in newly diagnosed focal 
epilepsy. The red line represents the null hypothesis of no association, whereas 
observed p-values (negative logarithm) are plotted on the y axis and expected p-values 
(negative logarithm) are plotted on the x axis. Deviation is only observed in the upper 
tail area indicating sufficient control of population stratification (genomic inflation 
factor = 1.061). The GWAS was adjusted for the first five principal components.  
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Table 40. SNPs with p-value less than 5x10-5 from binary GWAS for 12 month 
remission on first well-tolerated anticonvulsant in newly diagnosed focal epilepsy after 
adjustment for significant clinical factors. 
SNP Chromosome MAF P-value Genes within 50 kb from SNP 
rs11096544 2 0.334 9.89E-07 NT5C1B, RDH14 
rs10828664 10 0.444 1.89E-06 KIAA1217 
rs72835240 10 0.121 1.99E-06 NPS 
rs12268215 10 0.450 2.01E-06 KIAA1217 
rs1874438 12 0.489 2.79E-06 MAP1LC3B2 
rs7968805 12 0.489 2.79E-06 MAP1LC3B2 
rs11068100 12 0.495 2.86E-06 MAP1LC3B2 
rs12725494 1 0.134 2.87E-06 PPFIA4, TMEM183A, TMEM183B 
rs11014141 10 0.440 3.00E-06 KIAA1217 
rs753796 10 0.360 3.56E-06 CDHR1, LRIT1, LRIT2, RGR 
rs9400994 6 0.341 3.59E-06 ROS1, VGLL2 
rs11068099 12 0.490 3.98E-06 MAP1LC3B2 
rs11584217 1 0.136 3.98E-06 
CYB5R1, PPFIA4, TMEM183A, 
TMEM183B 
rs11068101 12 0.487 4.04E-06 MAP1LC3B2 
rs713601 3 0.144 4.48E-06 FAM43A 
rs7137033 12 0.488 5.33E-06 MAP1LC3B2 
rs4508149 10 0.359 5.45E-06 LRIT1, LRIT2, RGR 
rs12747999 1 0.088 5.56E-06 
DUSP5P, RN5S1, RN5S2, RN5S3, RN5S4, 
RN5S5, RN5S6, RN5S7, RN5S8, RN5S9, 
RN5S10, RN5S11, RN5S12, RN5S13, 
RN5S14, RN5S15, RN5S16, RN5S17 
rs73053778 3 0.095 5.94E-06 
CHRD, CLCN2, EIF2B5, EIF4G1, 
FAM131A, POLR2H, PSMD2, SNORD66, 
THPO 
rs753795 10 0.360 6.06E-06 CDHR1, LRIT1, LRIT2, RGR 
rs7899757 10 0.360 6.06E-06 CDHR1, LRIT1, LRIT2, RGR 
rs7904309 10 0.360 6.06E-06 CDHR1, LRIT1, LRIT2, RGR 
rs7911510 10 0.476 6.29E-06 RPS3AP5 
rs140775682 16 0.096 6.37E-06 ITGAM 
rs11160087 14 0.122 6.88E-06 LGMN, RIN3 
rs1530632 2 0.281 8.40E-06 EPAS1 
rs7314617 12 0.486 8.71E-06 MAP1LC3B2 
rs4412590 1 0.178 9.28E-06 
RN5S1, RN5S2, RN5S3, RN5S4, RN5S5, 
RN5S6, RN5S7, RN5S8, RN5S9, RN5S10, 
RN5S11, RN5S12, RN5S13, RN5S14, 
RN5S15, RN5S16, RN5S17, RNF187 
rs72835241 10 0.118 9.28E-06 NPS 
rs10033588 4 0.200 9.43E-06 SEL1L3 
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SNPs with a p-value of less than 5 x 10-5 were re-tested for association with the 12 
months remission under a dominant inheritance model, both with and without 
adjustment for significant clinical factors. Similarly to the initial analysis, both univariate 
and adjusted GWAS was adjusted for the first five principal components. Full results for 
the SNPs included in the GWAS with the dominant inheritance model have been 
summarised in table available in appendix 4 on page 238. SNPs with a p-value of less 
than 5 x 10-5 in both the adjusted and unadjusted analysis using dominant inheritance 
are presented in Table 41. 
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Table 38. Results of re-testing SNPs with a p-value of less than 5 x 10-5 from the additive model for association with outcome under a 
dominant inheritance model. On a left side of the table values from univariate analysis are presented whereas those adjusted for 
significant clinical factors are shown on the right. 
CHR rsid position info 
p-value 
univariate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHR rsid Position info 
p-value 
adjusted 
  
13 chr13:85111634:D 85111634 0.993656 5.66E-07 13 chr13:85111634:D 85111634 0.993656 1.63E-06 
14 rs11160087 93129982 0.964623 6.92E-06 14 rs11160087 93129982 0.964623 6.76E-06 
13 rs12855432 85111586 0.998517 7.33E-07 13 rs12855432 85111586 0.998517 2.18E-06 
11 rs144267602 108319016 0.991432 5.10E-07 11 rs144267602 108000000 0.991432 8.15E-06 
13 rs1446766 85112660 0.992194 8.18E-07 13 rs1446766 85112660 0.992194 2.46E-06 
13 rs1446767 85110202 0.999908 7.33E-07 13 rs1446767 85110202 0.999908 2.18E-06 
13 rs1446768 85110189 0.999913 7.33E-07 13 rs1446768 85110189 0.999913 2.18E-06 
13 rs1446770 85108206 1.000000 7.33E-07 13 rs1446770 85108206 1.000000 2.18E-06 
13 rs1446782 85075320 0.999171 7.08E-07 13 rs1446782 85075320 0.999171 3.07E-06 
10 rs4077084 86420972 0.989580 8.34E-06 10 rs4077084 86420972 0.98958 6.65E-06 
3 rs59264451 184787463 0.997319 9.64E-07 3 rs59264451 185000000 0.997319 6.23E-06 
13 rs7337244 85108915 0.999995 7.33E-07 13 rs7337244 85108915 0.999995 2.18E-06 
13 rs7337326 85109087 0.999991 7.33E-07 13 rs7337326 85109087 0.999991 2.18E-06 
13 rs7337490 85109106 0.999991 7.33E-07 13 rs7337490 85109106 0.999991 2.18E-06 
13 rs7338700 85109002 0.999995 7.33E-07 13 rs7338700 85109002 0.999995 2.18E-06 
13 rs7339022 85109110 0.999991 7.33E-07 13 rs7339022 85109110 0.999991 2.18E-06 
3 rs76100028 184789338 0.997140 4.21E-07 3 rs76100028 185000000 0.997140 3.92E-06 
13 rs7991045 85080910 0.998700 7.40E-07 13 rs7991045 85080910 0.998700 2.83E-06 
13 rs7996369 85111713 0.997633 7.33E-07 13 rs7996369 85111713 0.997633 2.18E-06 
13 rs7997475 85112098 0.995518 8.18E-07 13 rs7997475 85112098 0.995518 2.46E-06 
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13 rs9319058 85108979 0.999995 7.33E-07 13 rs9319058 85108979 0.999995 2.18E-06 
13 rs9531612 85109868 0.999940 7.33E-07 13 rs9531612 85109868 0.999940 2.18E-06 
13 rs9531613 85110793 0.999867 7.33E-07 13 rs9531613 85110793 0.999867 2.18E-06 
13 rs9531615 85111407 0.999803 7.33E-07 13 rs9531615 85111407 0.999803 2.18E-06 
13 rs9546751 85109272 0.999500 6.06E-07 13 rs9546751 85109272 0.999500 1.81E-06 
13 rs9602496 85108738 1.000000 7.33E-07 13 rs9602496 85108738 1.000000 2.18E-06 
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The rs4077084 SNP retained significance in all of the analyses performed (both using 
the additive and dominant inheritance model, with and without adjustment for 
significant clinical factors). It is located in the intergenic region of chromosome 10 (BP = 
86420972) with a minor allele frequency of 0.061. In our analysis it was not genotyped 
directly, but rather imputed and had an imputation INFO score of 0.989 suggesting 
reliable imputation accuracy. A plot of the region surrounding this SNP, using the 
software package ‘Locuszoom’ (Pruim et al., 2010), plot showed that other SNPs with a 
reasonable degree of linkage disequilibrium with it did not have similarly low p-values. 
This, together with its relatively low minor allele frequency, may suggest a spurious 
result. The Locuszoom plot is presented as Figure 24. 
 
Figure 24. “Locuszoom” plot for the rs4077084 based on results of univariate GWAS 
analysis 
The rs753796 SNP had a GWAS suggestive p-value in both univariate and adjusted 
GWAS with an additive inheritance model, but no significance in the dominant model. It 
is located in chromosome 10 (BP = 86028463), MAF = 0.360277 and its INFO score = 
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0.997041. It is an intergenic SNP located within 50kb from the following genes – CDHR1, 
LRIT1, LRIT2, and RGR. The Locuszoom plot is presented in Figure 25. There is no clear 
biological significance for this SNP. 
 
Figure 25. “Locuszoom” plot for the rs753796 based on results of GWAS analysis 
adjusted for significant clinical covariates 
The rs73053778 SNP (BP = 184068305; MAF = 0.0951807; INFO score = 0.982405) had 
a low p-value in adjusted GWAS with the additive (p = 5.94E-06) and dominant (p = 
7.51E-06) inheritance model, but not in either unadjusted analyses. This SNP is 500B 
downstream intron variant for a chloride voltage-gated channel 2 (CLCN2) gene. The 
Locuszoom plot for this SNP is presented in Figure 26.  
In the additive model, unadjusted GWAS there were several SNPs located in close 
proximity to each other on chromosome 3, with a p-value of less than 5 x 10-5. Their 
data are summarised in Table 42. The rs76100028 SNP had also a p-value of 3.92E-06 in 
the additive model with adjustment for significant clinical factors. 
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Figure 26. “Locuszoom” plot for the rs73053776 based on results of GWAS analysis 
adjusted for significant clinical covariates 
Table  39. List of SNPs with a p-value of less than 5 x 10-5 clustering on chromosome 3 
in close proximity to each other 
CHR SNP BP P INFO MAF 
3 rs76100028 184789338 1.47E-06 0.997140 0.077367 
3 rs4687016 184792444 3.53E-06 1.000000 0.077803 
3 rs744306 184789748 3.96E-06 0.998469 0.078341 
3 rs747507 184790127 3.96E-06 0.998684 0.078341 
3 rs2004207 184790414 4.33E-06 0.997468 0.078161 
3 rs2004208 184790407 4.33E-06 0.997456 0.078161 
3 rs7624642 184561541  8.9E-06 0.994769 0.081797 
 
All SNPs retained suggestive p-values in the dominant unadjusted analysis, but only 
rs76100028 retained a suggestive p-value in the dominant adjusted analysis. The 
Locuszoom plot for the SNP (rs76100028) with the smallest p-value is presented in 
Figure 27. All those SNPs are either in proximity or located in VPS8 (vacuolar protein 
sorting-associated protein 8 homolog) gene. In mammals there is in limited information 
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about biological function of this protein, current evidence is suggestive that it might be 
related to CORVET complex have a role in endosomal trafficking (Perini et al., 2014).   
 
Figure 27. “Locuszoom” plot for the rs76100028 based on results of GWAS analysis 
without an adjustment for significant clinical covariates 
A SEL1L family member 3 (SEL1L3) gene had intronic hits in both unadjusted and 
adjusted GWAS. Suggestive SNPs were not overlapping between analyses. The SNP 
rs11727253 was flagged up in an unadjusted analysis (p = 9.72784E-06; BP = 25770524; 
INFO score = 0.987954; MAF = 0.203088); it failed to retain significance in analysis with 
the dominant model. In the adjusted additive model, rs10033588 (p = 9.43009E-06; BP = 
25754026; INFO score = 0.989671; MAF = 0.199519) retained a suggestive p-value in the 
dominant adjusted model but not in the dominant univariate model. Both SNPs are 
presented as locuszoom plots in figures 28 and 29. 
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   Figure 28. “Locuszoom” plot for the rs11727253 based on results of GWAS analysis 
without an adjustment for significant clinical covariates. 
 
Figure 29. “Locuszoom” plot for the rs10033588 based on results of GWAS analysis 
adjustment for significant clinical covariates. 
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 Locuszoom plots for all SNPs are available in the appendix 5 (univariate) and 6 (after 
adjustment for significant clinical factors) on pages 253 and 264 respectively. 
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5.0. Discussion 
 
The work described in this thesis comprised three principal analyses, investigation of 
clinical factors associated with outcome in newly-diagnosed epilepsy, issues of 
methodology and their impact on results of studies that amalgamate existing data from 
multiple sites, and a genome wide association study that provisionally explored genetic 
contribution to the likelihood of 12-month remission in people with focal epilepsy. The 
general discussion will tackle each of these areas in turn. 
5.1. Study of clinical factors 
 
This work assessed the association between 12-month remission after application of 
the first well-tolerated anticonvulsant in newly diagnosed epilepsy, and multiple routine 
clinical factors. A significant association was demonstrated between remission and 
several clinically important factors, which are discussed more in detail below. 
5.1.1. Remission 
 
Our study reported a remission rate for the first well-tolerated AED in patients with 
newly diagnosed epilepsy to be 56.3%. This result is in line with previous work on newly 
diagnosed epilepsy which has reported the remission rate for the first AED to be slightly 
above 50% (Cockerell et al., 1995, Brodie et al., 2012, Collaborative Group for the Study 
of, 1992). Lack of deviation from previously published research adds validity to our 
results and suggests that our data are representative of newly diagnosed epilepsy; from 
a clinical perspective our data replicate previous knowledge of relatively good prognosis 
in regards of seizure control.  
From the point of view of reliability, a significant proportion of cases (54.3%) in our 
cohort was transcribed directly from existing databases rather than be manually re-
phenotyped. Thus, there would be a reasonable question as to whether there was any 
impact of data transfer and whether it introduced any significant bias during this 
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process. This was assessed using the SANAD dataset as it was the largest of our cohorts 
and we had access to the original study data. Reassuringly, remission in SANAD patients 
showed only minimal and insignificant discordance between original and transcribed 
data and no cases of no remission were turned into remission. The effect of data 
transfer is discussed in more detail in further sections. 
Our overall research cohort was created by amalgamation of several different 
existing cohorts, and further analysis showed that there were statistically significant 
differences in proportions of patients experiencing remission.  
Cohorts from UCL (81.8%), ULB (76.5%) and ULIV (84.9%) showed relatively high no 
remission rates; in contrast, the cohort from Australia (72.5%) had a noticeably higher 
rate of remission. A higher rate of no remission is likely related to the method of case 
ascertainment and the nature of the cohort.  
The difference in proportion of remissions between some of the cohorts (i.e. SANAD, 
Glasgow, Australia) comprising the EpiPGX research cohort has previously been 
described (Shazadi et al., 2014). Several potential causes of this difference were already 
highlighted by the authors of that study, including factors such as a difference in 
recruitment and environment of the study (randomised trials vs. observational studies) 
or differences in local policies, drug selection and diagnostic approach. The same 
conclusions can be applied to our research cohort, plus differences in background of the 
population sampled can also be added. These differences illustrate the importance and 
the impact of case ascertainment and local clinical factors, and justify the adjustment for 
different origins of cohorts in the analysis of association.  
Treatment response were assessed after application of the first well tolerated AED 
hence there were no cases in a cohort which would have been censored due to failure 
due to adverse reactions. Furthermore cases where the minimal effective dose were 
achieved but no further up titration had been undertaken due to ADRs but patients still 
had seizures were classified as no remission. This was due to fact that according to the 
EpiPGX definitions ADR had to occur within the first 6 months and lead to a dose 
reduction or drug withdrawal. For this analysis if patient experienced adverse effects 
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this AED were not classified as well tolerated. This created a situation where cases for 
survival analysis were only censored due to failure to achieve remission. 
Both the analysis of association (logistic and Cox regression) as well as the genome 
wide association study relied on a 12-month remission as an outcome, hence they were 
specifically adjusted for origin of cohort. Furthermore, separate versions of the Cox 
regression stratified by origin of cohort were performed. 
In summary, we demonstrated heterogeneity in distribution of the primary outcome 
(12-month remission) between research cohorts, lending support to the need to account 
for differences between centres in large multinational pharmacogenetic research 
initiatives. 
5.1.2. Age at diagnosis 
 
Previously published epidemiological observations have indicated two peaks of onset 
of epilepsy; one occurring in the early years of life and the other in elderly patients 
(Kotsopoulos et al., 2002, Neligan et al., 2012). In our cohort, we observed only a single 
relatively early peak around adolescence which is probably due to fact that most cohorts 
primarily recruited adults, but not children or geriatric population. Median age at 
diagnosis observed in our cohort was 33.57 years (mean 36.03), which is not too 
different to the age observed in other clinical trials for newly diagnosed epilepsy 
(Steinhoff et al., 2005, Bill et al., 1997, Christe et al., 1997, Rosenow et al., 2012, Kwan et 
al., 2011). 
The cohort from Australia had the highest age at diagnosis, whereas the EKUT cohort 
had the lowest. The lower age for diagnosis at EKUT cohort probably reflects a research 
interest in genetic background of generalised epilepsy. The biggest single contributor to 
our research cohort was the SANAD study, which similarly observed a single peak of age 
distribution (Marson et al., 2007), probably reflecting that it was a clinical trial. 
Age at diagnosis was significantly associated with likelihood of remission and time to 
12-month remission in logistic and Cox regression models respectively. Furthermore, it 
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retained significance in sensitivity analysis when SANAD cases were excluded. It was also 
significantly associated with 12-month remission in the logistic regression model 
performed on focal epilepsy cases before GWAS. Direction of effect in all analyses of 
association was the same, indicating that older age at diagnosis was associated with 
higher probability of 12-month remission. Our observation would be in line with 
previous studies that have already shown that elderly patients have a more favourable 
prognosis (Stephen et al., 2006). From a data quality point of view, age at diagnosis 
showed high concordance when transcribed cases from SANAD were compared to the 
original genetic dataset.  
In summary, age at diagnosis was robustly associated with a higher likelihood of 12-
month remission in newly diagnosed epilepsy. 
5.1.3. Gender 
 
Previous epidemiological observations have shown a trend towards a higher 
incidence of epilepsy in males than females (Kotsopoulos et al., 2002, Hauser et al., 
1993). In our study, there were marginally more males than females, which is consistent 
with previous reports. In addition, epidemiological studies have observed gender 
differences in some epilepsy syndromes, with generalised epilepsy being more 
commonly observed in females and symptomatic localisation-related epilepsy more 
common in males (Christensen et al., 2005). In our cohort, we also observed a higher 
proportion of females than males in the generalised epilepsy group. In both the logistic 
and Cox regression models for 12-month remission and time to remission after 
application of the first AED, gender approached the threshold for statistical significance, 
but failed to reach it. 
 
5.1.4. Epilepsy type 
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The majority of patients (70.6%) in our cohort had focal epilepsy, followed by 17.9% 
with generalised epilepsy and 11.5% with unclassfied epilepsy. Those observations are 
consistent with already published epiedemiological data from Europe, where the 
majority of patients experience focal seizures/epilepsy (33–65%), followed by 
generalised (17-60%) and unclassifiable (2-8%) seizures (Forsgren et al., 2005). The 
combined research cohort is comprised of data taken from several studies conducted by 
various centres. The majority of the large cohorts, like SANAD (both arms), Glasgow, and 
Australia did not have specific exclusion criteria based on epilepsy type, but the EKUT 
cohort and a portion of the ULIV cohort, specifically those from the ReJuMEC study 
(Thomas et al., 2014), were originally enrolled to investigate specific epilepsy types. 
Assessment of the reliability of data transfer showed almost perfect (the kappa value 
for generalised epilepsy = 0.962 and for unclassified epilepsy = 0.943) concordance for 
epilepsy type (McHugh, 2012). A limitation of this assessment is that in both the SANAD 
genetic derivation and EpiPGX phenotype derivation, epileptic syndromes were split into 
just three basic categories. Thus, potentially, data transfer for more elaborate syndromic 
categories might not have achieved such good concordance. 
Epilepsy type was significantly associated with both likelihood of remission and time 
to 12-month remission in logistic and Cox regression, with a direction of effect favouring 
a more positive association for generalised epilepsy. This observation contradicts 
previously published studies (Collaborative Group for the Study of, 1992, Park et al., 
2014) which reported no association of epilepsy type with treatment outcome. Arm B 
from the SANAD study provided 32.8% of all cases with generalised epilepsy, which was 
surpassed only by the EKUT cohort (34%). In a sensitivity analysis after removal of all 
SANAD cases, this association remained significant, indicating that it is not observed due 
to the SANAD study. 
5.1.5. Neurological examination / sequelae 
 
Abnormal neurological examination in cases of newly diagnosed epilepsy has been 
reported in around 15% of cases (Del Felice et al., 2010, Heller et al., 1995, Collaborative 
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Group for the Study of, 1992). It was observed in 8% of cases in our study, which is 
slightly lower than in previously reported data. There is a wide range between cohorts 
going from 4.4% in the Australian cohort to 24.1% in the ULB cohort. This probably 
represents differences in sampling population and case ascertainment. Of note, cases 
with progressive neurological conditions were excluded from EpiPGX. Abnormal 
neurological examination was statistically significantly associated with a lower 
probability of attaining 12-month remission in newly diagnosed epilepsy in both logistic 
and Cox regression.  
5.1.6. Time from first seizure to first AED 
 
Median time from the first seizure to first AED was 11.5 months. This observation is 
similar to previously published data from the CAROLE study, which showed that the 
majority of patients were diagnosed with epilepsy within seven months from the first 
seizure (range 1.5-30 months) (Jallon et al., 2001). This clinical factor failed to reach 
statistical significance in logistic and Cox regression for 12-month remission.  
5.1.7. Investigations 
 
There was noticeable variability between centres with respect to investigations, for 
example the proportion of patients with an abnormal focal MRI would range from as 
high as 69.0% to only 12.3%.  Such a variability likely reflects diversity in the populations 
sampled, routine clinical practice, and data collection. For example, the Australian data 
was imported from a research database, and their CRF collected data from MRI but not 
CT results. Similarly, the higher proportion of abnormal epileptiform EEG results in the 
EKUT data could simply reflect a higher proportion of generalised epilepsy in this cohort. 
Those differences demonstrate the extent of variability between cohorts. 
From a clinical perspective, results showed that CT and MRI had reasonably good 
concordance for focal abnormalities but were poor for non-specific abnormalities. 
However, it should be noted that this study was not designed to evaluate this particular 
issue. Furthermore, as we utilised only the initial imaging studies, the result is 
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potentially biased toward significant acute changes rather than specific epileptiform 
abnormalities that are often quite subtle. Previous modelling work carried out by 
colleagues in Liverpool (Bonnett et al., 2012) on arm A of the SANAD study indicated a 
potential association between abnormal imaging studies and time to 12-month 
remission. We were able not only to replicate this, but also to demonstrate the direction 
of effect for a lower likelihood of 12-month remission in cases with an abnormal focal 
MRI. This result was confirmed in the sensitivity analysis after removal of the SANAD 
cases. In a Cox regression stratified by cohort, MRI lost statistical significance but was 
still retained in a final model. Our assessment of imaging studies for newly diagnosed 
epilepsy was limited by the fact that we excluded all cases with progressive neurological 
conditions. A significant proportion of those cases likely would have abnormal imaging 
studies (e.g. brain tumours). 
As for EEG, we showed that it is significant and that the direction of effect would be 
towards a lower probability of 12-month remission in cases where EEG was not done. 
This observation could be potentially explained by the fact that patients with higher 
seizure frequency and worse prognosis are not referred for EEG as there are fewer 
diagnostic doubts.  Alternatively patients with poorer prognosis in general or those with 
focal epilepsy are not referred routinely for EEG by their doctors.   
In summary, we showed that MRI results are a prognostic factor for 12 month 
remission for patients with newly diagnosed epilepsy after the application of a first well 
tolerated AED. As MRI is now considered as the routine imaging modality this result has 
the potential to influence daily clinical care. Observed differences between cohorts 
would support the introduction of a more standardised approach to the collection and 
interpretation of imaging studies in large pharmacogenetic cohorts, particularly as it 
might be a routinely used clinical marker that is significantly associated with treatment 
outcomes or in future employed in creation of endophenotypes.  
5.1.8. Pre – treatment seizure count  
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The majority of patients (43.8%) experienced between one and five seizures before 
starting their treatment; this is consistent with previously published research (Del Felice 
et al., 2010, Collaborative Group for the Study of, 1992, MacDonald et al., 2000).  
We observed a relatively high proportion of cases with unknown seizure number 
before starting treatment (15.8%). This could be explained by several factors related to 
clinical presentation, data collection, or transfer. As EpiPGX relied on the retrospective 
collection of data based on clinical records, it was impossible to resolve the problem of 
unknown data thus illustrating some of the limitations of this approach.  
From a clinical point of view, certain seizure types have a higher propensity to be 
underreported. Myoclonic and absence seizures had a higher proportion of unknown 
pre-treatment seizure count. This probably reflects the higher frequency and minimal 
intrusiveness of those seizure types. Conversely, complex partial and simple partial 
seizures have a high proportion of 21 or more definite seizures before treatment, but a 
relatively low unknown seizure count. As expected, primarily generalised tonic-clonic 
and secondarily generalised tonic-clonic seizures have a lower unknown seizure count 
than any other seizure type.  
For logistic and Cox regression analyses assessing associations with 12-month 
remission, pre-treatment seizure count is statistically significantly associated with the 
likelihood of remission. This observation is in line with previous work based both on the 
SANAD study and NGPSE (MacDonald et al., 2000, Bonnett et al., 2014b, Bonnett et al., 
2012). In a sensitivity analysis after exclusion of the SANAD cases, significance was lost; 
this implies a degree of uncertainty about this association. NGPSE suggested seizure 
density (number of seizures within six months of the index seizure leading to inclusion in 
study) as a significant factor associated with treatment response in newly diagnosed 
epilepsy (MacDonald et al., 2000), although this factor was not collected in EpiPGX or 
assessed in this analysis. 
5.1.9. Seizure type 
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Both logistic and Cox regression showed that presence of generalised tonic-clonic 
seizures only is positively associated with both likelihood of remission and time to 
remission. This seizure type was derived from cases with either secondarily generalised 
tonic-clonic seizures, primarily generalised tonic-clonic seizures, or unclassified 
generalised tonic-clonic seizures, without any other seizure types reported. There is an 
obvious question of whether the effect observed was potentially due to an underlying 
better prognosis of generalised epilepsy. In the final model of logistic and Cox 
regression, generalised tonic-clonic seizures only was significant along with epilepsy type 
indicating that the generalised tonic-clonic only seizure type has additional explanatory 
value itself. 
Generalised tonic-clonic seizures only were one of the variables that were assessed 
for concordance between the original SANAD genetic derivation and the EpiPGX 
derivation. It produced a kappa value of -0.136 indicating more disagreement than 
agreement (McHugh, 2012). This is probably due to a difference in how seizure types 
were derived in SANAD and EpiPGX, as we included not only primary generalised tonic-
clonic seizures, but also secondarily generalised tonic-clonic seizures in this category. 
Reassuringly, the generalised tonic-clonic only seizure type retained its significance after 
removal of the SANAD cases in the sensitivity analysis, indicating that the association is 
not affected by data transfer.  
5.1.10. First well-tolerated antiepileptic drug 
 
The most commonly prescribed anticonvulsants were lamotrigine, valproate and 
carbamazepine. This reflects both the setting up of the study (involving multiple 
historical studies) as well as the fact that those anticonvulsants are widely available 
throughout Europe (Baftiu et al., 2015). Furthermore all of them are established first-
line treatments for newly diagnosed epilepsy and both valproate and lamotrigine can be 
used for both focal and generalised epilepsy. 
Our study was not expressly designed to investigate the specific efficacy of any 
particular anticonvulsant, nor at this moment in time has EpiPGx interrogated data 
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regarding genetic biomarkers for treatment response to a specific drug. Nevertheless, 
EpiPGx as a consortium has aimed to assess certain aspects related to individual drugs, 
but that is outside of the scope of this thesis.  
Treatment efficacy of anticonvulsants has not improved since the introduction of new 
drugs over last two decades (Schmidt and Sillanpää, 2012, Shorvon and Luciano, 2007). 
It is arguable that treatment response is rather a broad phenomenon which is either 
partially or fully unrelated to drug selection. Furthermore, it has been shown that the 
strongest predictor for a treatment outcome is failure of the first anticonvulsant itself 
(Kwan and Brodie, 2000). Hence it made sense to look into a broad treatment response 
rather than to narrow it down to an individual drug. 
5.2. Logistic and Cox regression 
Logistic regression was applied as a model with a dichotomous outcome for 12-
month remission after the application of the first well-tolerated AED in newly diagnosed 
epilepsy. The Cox regression model was applied to time to onset of remission after 
application of the first well-tolerated anticonvulsant.  
Reassuringly, most of the significant covariates overlapped between logistic and Cox 
regression, providing a degree of confidence that the observed associations are true. 
Only follow up length and results of CT head were significant in logistic but not in Cox 
regression. When the Cox regression was stratified by cohort, MRI lost its significance 
but was still retained in the model and gender became statistically significant. The 
direction of effects for all covariates was the same, providing an additional degree of 
reassurance.  
Our study represents one of the largest research cohorts of newly diagnosed 
epilepsy. Only analysis based on the SANAD trial has had more combined cases. 
However, our study included only treatment naïve patients, whereas between 10% and 
18% of patients recruited in SANAD had previous exposure to AEDs (Bonnett et al., 
2014b, Bonnett et al., 2012). Furthermore, we were able to add an extra layer of 
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information about the impact of imaging studies by extracting additional information 
from the original trial data. 
From a practical point of view, we were able to confirm previously observed 
associations with important clinical factors. As can be seen from table 43 below, most of 
the significant clinical factors have already been separately described by various 
previous research studies.  
Table 40. Covariates significantly associated with 12-month remission after 
application of the first well-tolerated anticonvulsant in newly diagnosed epilepsy and 
their direction of effect based on logistic and Cox regression results. 
Covariate Logistic regression Cox regression 
Previously 
reported in 
literature 
Reference 
Male Not significant Not significant Yes 
(Bonnett et al., 2012, 
Annegers et al., 1979) 
Age at 
diagnosis 
Positive association 
Shorter time to 
onset of remission 
Yes 
(Mohanraj and Brodie, 
2006, Bonnett et al., 
2012) 
Abnormal 
neurological 
examination 
Negative 
association 
Longer time to 
onset of remission 
Yes 
(Okuma and 
Kumashiro, 1981, Elwes 
et al., 1984, Sillanpää, 
1993, Bonnett et al., 
2014b, Bonnett et al., 
2012) 
Generalised 
tonic-clonic 
seizures only 
Positive association 
Shorter time to 
onset of remission 
Yes (Mattson et al., 1996) 
Epilepsy type 
Generalised 
epilepsy – positive 
direction 
Generalised 
epilepsy -  positive 
direction 
Yes 
(Mohanraj and Brodie, 
2006) 
Pre-treatment 
seizure count 
1 -2 seizures before 
treatment - 
positive direction 
1 -2 seizures before 
treatment – 
positive direction 
Yes 
MacDonald et al., 
2000 
Cohort 
The same direction of effect in both Cox 
and logistic regression 
  
EEG 
EEG not done - 
negative direction 
EEG not done - 
negative direction 
Yes 
(Shafer et al., 1988, 
Bonnett et al., 2014b, 
Bonnett et al., 2012) 
CT 
CT abnormal focal 
positive direction 
Not significant in 
Cox regression 
Yes 
(Elwes et al., 1984, 
Bonnett et al., 2012) 
MRI 
Focal abnormality - 
negative direction 
Focal abnormality - 
negative direction 
Yes 
(Bonnett et al., 2012, 
Spooner et al., 2006) 
Follow up 
length 
Positive association 
Not significant in 
Cox regression 
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Sophisticated statistical predictive modelling based on SANAD has previously 
demonstrated that maximal discriminatory capacity for models is 70% (Bonnett et al., 
2014b, Bonnett et al., 2012), indicating that there are other factors predictive of the 
outcome which at the moment are not known. 
Our sample size (n = 1723) of logistic and Cox regressions was relatively large and 
provides a degree of confidence that they are not underpowered (Hosmer et al., 2013, 
Peduzzi et al., 1996, Peduzzi et al., 1995). One specific limitation of the Cox regression 
was that it failed to uphold the assumption of proportionality of hazards over time. 
Another limitation of our study is that our research cohort was largely comprised of 
cases from Glasgow and SANAD; hence potentially observed associations would be due 
to the effect of initial cohort. To assess this, we did a sensitivity analysis by excluding 
SANAD (the largest contributor) in which all clinical factors except pre-treatment seizure 
number and CT retained significance. Regression as a method also allowed adjustment 
for observed significant differences between cohorts. 
In summary, logistic and Cox regression analysis confirmed previously described 
clinical factors associated with treatment outcome in newly diagnosed epilepsy after the 
start of the first well-tolerated anticonvulsant. It also showed the direction of effect for 
abnormal focal MRI towards worse treatment prognosis in newly diagnosed epilepsy.  
5.3. Methodology 
Case ascertainment and the length of the period of observation are influenced by 
factors related to the initial aims and methodology applied to the original cohort. In our 
research, we had a limited ability to influence these factors as we relied on historically 
assembled cohorts.  
5.3.1. Origin of cohort and method of case ascertainment  
 
Our research showed that the origin of the cohort was highly statistically significantly 
associated with 12-month remission. This variable reflects local factors, methods, and 
aims of the original study. Often, genetic cohorts are assembled to answer an initial 
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question and then later re-used for a variety of different purposes. Our study 
demonstrated that it is feasible to create a large multi-national research cohort based 
on old and very different historical studies. Nevertheless, this is potentially at the 
expense of introducing of bias and researchers should account for this. We have 
demonstrated that the method of case ascertainment is associated with the measured 
outcome and, as expected, the prospective method of follow up was linked to a higher 
chance of observing a 12 month remission. This effect probably arises from the SANAD 
study (a randomised clinical trial) and the Australian cohort. All cohorts with a higher 
failure rate are based in tertiary care centres with an epilepsy surgery programme. 
Institutions like UCL, the Walton Centre (Liverpool), and ULB serve as tertiary referral 
centres thus creating a recruitment bias. In addition, in all of those cohorts, a 
retrospective design was used. Furthermore, they were initially developed for the 
research of treatment-resistant epilepsy. For example, the cohort from the University of 
Liverpool was composed of the Epilepsy Biobank (which is a random sample of patients 
attending out-patient clinics), ReJuMEC (Refractory Juvenile Myoclonic Epilepsy Cohort), 
and the so-called “Department of Health” study exploring the pharmacogenetics of 
clobazam and vigabatrin. ReJuMEC and Department of Health studies primarily targeted 
drug-resistant epilepsy; hence using retrospective phenotyping allowed the tracing back 
of cases to the time of diagnosis and first AED (Thomas et al., 2014, EU Clinical trial 
register accessed 24/04/2016 2004). Such an approach invariably introduced a selection 
bias. 
Future genetic studies of newly diagnosed epilepsy should aim to avoid selection bias 
and employ prospective recruitment methods only. The effect of case ascertainment in 
epilepsy research has previously been demonstrated. Abimbola and colleagues assessed 
the effect of methodological aspects on remission and intractability in cohorts of newly 
diagnosed epilepsy (Abimbola et al., 2011). The authors showed that a convenience 
sample can introduce bias into the study and preferably a prospective population-based 
incident cohort should be used. They also suggested that the exclusion of patients with 
progressive neurological conditions leads to an increased proportion of immediate 
remission. Our research excluded cases with progressive neurological conditions and 
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had a lower proportion (8.0%) of patients with neurological deficit than in other studies 
(13.0% - 15.7%) of newly diagnosed epilepsy (Heller et al., 1995, Collaborative Group for 
the Study of, 1992). On the other hand but not unexpectedly our cohort had the same 
proportion as SANAD study arm A (Marson et al., 2007).  
Our research cohort was a mixture of patients from observational studies and clinical 
trials. In cases of established epilepsy, it has already been demonstrated that 
observational studies are prone to various biases as well as possessing a bigger and 
more varied treatment effect size compared to randomised controlled trials (Maguire et 
al., 2008). 
In summary, our research confirmed that the origin of the cohort and the method of 
case ascertainment are significantly associated with the probability to observe 
measured outcomes, and hence should be adjusted for. 
5.3.2. Length of observation 
 
Length of observation is also an important methodological aspect. It has been shown 
in the past that it takes time for those patients included in research to enter into 
sustained terminal remission (Abimbola et al., 2011). Our study also showed that a 
longer follow up period is associated with a higher probability of observing a 12-month 
remission. To capture more than 95% of all first 12-month remissions in newly 
diagnosed epilepsy cases, the observation period should be a minimum of two years. 
Out of 982 patients experiencing 12-month remission, 312 of them later relapsed; this 
raises questions around the significance of non-sustained remission. To further 
strengthen the argument about a minimal period of observation, the median time to 
relapse was 29.3 months; thus indicating that a very short period of observation could 
potentially miss it.  
Most of the patients in our cohort started their treatment after the year 2000, but 
almost one quarter (23.3%) of the patients started their treatment earlier than that, 
with the earliest commencing their AED in the 1960s. During this period, treatment 
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strategies have changed significantly and a lot of new AEDs have entered into daily 
practice. However, there has been no major improvement in treatment efficacy 
(Shorvon and Luciano, 2007, Schmidt and Sillanpää, 2012). This issue could be a 
potential problem when adjusting for relevant clinical factors (particularly imaging 
studies) which tend to see technical advancement over the time. Furthermore, a period 
of recruitment can become an issue for studies assessing selective drug response as 
anticonvulsant usage changes over time, although this is not applicable to our work. 
5.3.3. Duration of remission 
 
Our definition of remission required at least 12 months of seizure freedom. However, 
there is no clear consensus in the case of newly diagnosed epilepsy about the duration 
of seizure freedom that is considered to constitute ‘remission’.  
Drug-responsive epilepsy has been defined by the ILAE task force as seizure freedom 
of 12 months, or three times the longest pre-treatment inter-seizure interval, whichever 
is longer (Kwan et al., 2010). The requirement for exactly 12 months of seizure freedom 
is rather arbitrary from a biological point of view, and based on evidence related to 
patients’ quality of life (Kwan et al., 2010) and statutory limits on driving. On the other 
hand, using the longest inter-seizure interval might not be practical for retrospective 
studies as data is often limited. We assessed the effect on a proportion of subjects 
experiencing remission after applying different definitions of remission. Applying longer 
durations of seizure freedom resulted in a lower proportion of patients being counted as 
in remission (1yr = 56.3%; 2yr = 43.5%). The limitation of this approach is that not all 
patients were followed up for the same period of time. Arguably, some patients who 
entered into sustained remission were not followed up in the long term, hence skewing 
longitudinal data towards treatment-resistant cases. The median follow up period in our 
cohort was 3.39 years (IQR = 2.06 - 5.57) meaning that most of the subjects were 
followed up for at least two years. 
In summary, our study demonstrates that methodological aspects can have a 
statistically significant association with the measured outcome. Future studies of newly 
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diagnosed epilepsy should account for those aspects and preferably utilise, where 
possible, a prospective community-based design and use a minimum period of 
observation. Whereas cautious assembly of large research consortiums utilising 
historical cohorts is feasible, it requires a careful approach. Results of short 
retrospective hospital-based genetic studies in newly diagnosed epilepsy should be 
interpreted with caution due to the propensity of introducing a whole spectrum of 
biases.  
5.3.4. Impact of data transfer 
Large scale genetic studies frequently rely on historical research cohorts. They have 
often been assembled for a different purpose and apply different phenotypes and 
measurement methods. During the process of assembly of a new research cohort, old 
cohorts are often transformed and fused together to form a new and much bigger one. 
To my knowledge, no previous large scale genetic study has assessed how this process 
affects the data. This step has the potential to introduce bias during the process of 
assembly, transformation, and fusion of the new cohort. Hence, it was decided to assess 
concordance between the original derivation of SANAD for a different genetic study and 
our phenotype derivation of SANAD cases in EpiPGX.  
Our assessment was limited by several factors, such as the original genetic dataset 
used for comparison containing only a limited number of variables that could be 
compared. Both datasets represent phenotype derivation rather than original raw data. 
On the other hand, the fact that those phenotype derivations were used for both GWAS 
and analysis of association means that it would make sense to compare them.  
The observed concordance for the binary treatment outcome of 12-month remission 
was very good, but not perfect (kappa = 0.738, p = 0.000). This is probably due to slight 
differences between definitions applied to different cohorts. Our research measured 
treatment response to the first well-tolerated anticonvulsant, whereas Speed et al. 
(2014) utilised the SANAD genetic dataset definition of remission which was not 
necessarily observed with the first well tolerated AED.  
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Another approach that could be used to assess how representative our sample is of 
the original cohort would be to assess proportions of patients being in remission to 
check if any significant deviation from the original cohort had occurred. Original publicly 
available data (Marson et al., 2007) from the SANAD study reported the proportion of 
treatment failures (SANAD arm A – 49%, arm B – 42%). As this is a binary outcome with 
minimal variability it can be compared between studies and datasets. The SANAD study 
did not collect DNA from all patients at the beginning, but from a selected population 
later during the study, potentially introducing a degree of selection bias. In the EpiPGx 
SANAD cohort,12 month remission was observed in 56.4%, failures were 39.7%, and no 
data was available in 3.9%. The SANAD study formed the UK cohort of the first large 
prospective GWAS in epilepsy (Speed et al., 2014a). The authors of the study reported 
the following treatment outcome proportions for their full UK cohort; remission in 
66.7% of subjects and failure in 33.3%. Those differences raise the question of whether 
selective recruitment (i.e. collection of DNA) of patients from old studies will not 
introduce a degree of bias, adding a further argument in favour of prospective genetic 
studies. 
Poor concordance (Lin’s concordance coefficient = 0.6409) was observed for the time 
to remission data (McBride, 2005). Discordance between cohorts was due to the 
difference in how time to remission was calculated in both studies. In the SANAD study 
it was calculated from the first date of AED randomisation and last day of the 12-month 
period of seizure freedom. In our study, the time span was taken from the first date of 
AED application to the first day of 12-month remission. Nevertheless, this situation 
demonstrates that there is potential scope for the introduction of systematic error if 
calculated data rather than raw data are imported without quality assurance. It also 
strengthens the case for not using multiple old historical cohorts as there is a risk of 
introducing systematic error if cohorts used different methods for calculation of 
continuous variables. 
Assessment of how data transfer affected seizure type was limited due to a small 
number of matched variables. It showed that there is a potential source of introduced 
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variability as two out of three assessed seizure types had a poor concordance between 
cohorts. Generalised tonic-clonic only and other seizures had poor concordance, 
whereas partial seizures only showed very good concordance. This was due to a 
difference in how seizure types were derived. This assessment demonstrates that even 
applying the same seizure types without directly applying the same code to derive them 
has the potential for introduction of bias, and should be monitored in large scale 
projects – particularly if they utilise a multi-stage, multi-centre design.  
In the SANAD study, investigation outcomes were coded as normal, abnormal, and 
not available; however in EpiPGX, abnormal was further separated into abnormal non-
specific and specific. Fortunately, the SANAD study collected imaging results separately 
hence during the data upload it was possible to classify the degree of abnormality. For 
EEG results, SANAD had a more elaborate classification separating various degrees of 
focal and generalised abnormalities, and for data transformation they were categorised 
and lumped together. In the original SANAD genetic dataset, investigation categories 
were also lumped together creating binary variables of abnormal EEG or CT. Abnormal 
CT had a kappa value of 0.721 (p < 0.00) and abnormal EEG was 0.930 (p < 0.00), 
indicating moderate and almost perfect concordance respectively between datasets for 
abnormal investigation results (McHugh, 2012). 
Basic demographic variables (gender, age, epilepsy type, and abnormal neurological 
examination) had almost perfect concordance, indicating safe data transfer. 
This analysis, in essence, shows that basic and robust demographic variables can be 
transformed and transferred between research studies. In contrast, more complex 
variables which have different definitions or classifications are at risk of introducing 
artificial variability during the process of transformation of data or derivation of new 
phenotypes.  
This assessment also underscores limitations direct comparison of our results with 
previous research. For example SANAD cases form a significant proportion of our cohort 
and co-variates were partially modelled according previous research (Bonnett et al., 
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2014b, Bonnett et al., 2012). Both impact of data transfer and fact that our cohort 
included only SANAD cases which contributed DNA (degree of selection bias) would raise 
a question about potential limitations for direct comparison of results. 
If a DNA sample is obtained only from a proportion of the original research cohort 
there is a potential sub-selection of the population; hence, DNA sampling should be 
representative of the baseline population. It can be concluded that there is a 
requirement for a quality and concordance assurance process in large scale studies, 
particularly utilising multiple historical cohorts and clinical databases. 
5.4. Genome based biomarkers for treatment response in newly 
diagnosed epilepsy 
 
5.4.1. Phenotypes 
 
In pharmacogenomic research, the phenotype requires not only presence of disease, 
but also exposure to the drug. The reaction of the subject is then observed and a 
potential genetic base for it is elucidated. Our phenotype definition was centred on the 
presence of a sustained 12-month period of seizure freedom after application of the first 
well-tolerated AED. It has been shown by previous research carried out in rural areas of 
developing countries that around 20-30% of patients with epilepsy experience 
spontaneous remission (Kwan and Sander, 2004, Placencia et al., 1994). This observation 
would imply that remission can occur in a significant proportion of patients irrespective 
of drug application, but as a part of the natural history of the illness. Hence, observed 
remission might not be a pharmacological effect. It is important to try to separate out 
patients who are truly responsive to treatment and without the benign natural course of 
the disease. One possible approach would be selecting patients who respond to the 
treatment, but have clinical factors associated with poorer prognosis. 
Several patterns of drug response in newly diagnosed epilepsy have been described 
which could potentially be turned into separate phenotypes, like delayed remission and 
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a remitting-relapsing course (Brodie et al., 2012). Hence, another option would be to 
define patients with delayed remission as cases on the assumption that if seizures are 
on-going until the right drug dose has been reached, seizure freedom would represent a 
true effect of the drug.  
Arguably, patients who relapse after an initial remission are not responsive to 
treatment or simply have more severe epilepsy. It is also possible that they were initially 
classified as in remission because they had infrequent seizures which were otherwise 
unaffected by AEDs. Alternatively, they might represent the development of progressive 
treatment intractability which would be in line with the “drug transporter” hypothesis of 
drug resistant epilepsy (Sisodiya et al., 2002). This subgroup also could potentially serve 
as a separate phenotype hence should be analysed separately. 
An alternative approach would be to actually define patients who potentially have a 
benign course of illness and interrogate their genome for biomarkers, as this group 
might be exposed unnecessarily to AEDs. 
In summary, future research is required to develop more nuanced phenotypes to 
effectively capture the underlying heterogeneity of epilepsy and treatment response. It 
has already been agreed within the pharmacogenomics field that with the development 
of genomic technologies and analytical methods, phenotypes have become the most 
complex part of the equation in the field as a whole (Relling and Evans, 2015). 
5.4.2. Role of adjustment for clinical and non-clinical factors in 
genomic studies 
 
It has already been argued by Speed et al. (2014) that epilepsy pharmacogenetic 
studies should be carried out as both unadjusted and adjusted for significant clinical 
factors (Speed et al., 2014a). We followed this trend and first performed a logistic 
regression of clinical factors associated with outcome in all cases included in the 
subsequent GWAS. Genetic analysis was then performed with and without adjustment 
for significant clinical factors. The prospective study design of pharmacogenomics is 
superior to retrospective design (Jorgensen and Williamson, 2008) and analyses of 
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association have demonstrated association of non-clinical factors with 12-month 
remission. Therefore, GWAS was also adjusted for non-clinical factors like mode of case 
ascertainment. 
5.4.3. Sample size 
The retrospective sample size calculation showed that the GWAS analysis on both 
EpiPGX WP2 task 1 and on newly diagnosed focal epilepsy was adequately powered to 
detect an association, assuming a dominant model of inheritance and relative risk of 
two; the additive model with similar parameters was incompatible with the statistical 
model. GWAS were adequately powered to detect SNPs with a high relative genotype 
risk, but studies were not designed to detect complex polygenetic traits. The GWAS of 
focal epilepsy was smaller than the original EpiPGX analysis on the newly diagnosed 
epilepsy cohort. The reason for a smaller sample size was that it was not planned at the 
beginning of the study, and hence we only included cases where genetic information 
was stored locally. Plus, it excluded all cases with generalised epilepsy (SANAD arm B). 
There was little active patient recruitments in the EpiPGX consortium; it relied on cases 
already collected, hence little possibility to increase the sample size. 
Nevertheless, the sample size of the GWAS was bigger than those in previously 
published work, but Speed et al. (2014) also included generalised epilepsy. Hence, the 
GWAS on focal epilepsy represents the biggest reported cohort in newly diagnosed focal 
epilepsy so far.  
5.4.4. Results of GWAS 
 
The GWAS analysis for remission of newly diagnosed focal epilepsy failed to detect 
any significant signal, but several SNPs demonstrated potential suggestive associations. 
Most of them did not possess any potential biological significance, except rs73053778 
which is an intronic variant 500bp downstream from chloride voltage-gated channel 2 
(CLCN-2). Animal studies have shown that CLCN-2 is widespread in the CNS and is 
involved in glial function, playing a role in ionic homeostasis (Blanz et al., 2007). 
Interestingly the authors of this study also been reported that CLCN-2 knockout mice 
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have a normal seizure threshold. In humans, mutations in this gene have been linked to 
autosomal recessive leukoencephalopathy, but interestingly the phenotype does not 
include seizures (van der Knaap et al., 2015, Depienne et al., Di Bella et al., 2014). It has 
also been controversially linked to idiopathic generalised epilepsy, although that 
association has not been confirmed and the original article was partially retracted 
(Niemeyer et al., 2010, Saint-Martin et al., 2009, Kleefusz-Lie et al., 2009). 
 
The other gene which had some signal is SEL1L3 which had intronic SNPs in the GWAS 
univariate and adjusted analysis, but they were not overlapping between analyses. This 
gene has not been implicated in epilepsy previously, although it has been shown to be 
up regulated in response to HIV-1 tat protein (Woollard et al., 2014). This association 
likely represents a spurious finding. 
 
Another important aspect is that our GWAS failed to replicate the results of any 
previous epilepsy pharmacogenomics study. It can be concluded that there is no single 
SNP with a strong effect size under the dominant inheritance model determining 
treatment outcomes in newly diagnosed focal epilepsy. 
5.5. Limitations of the study and suggestions regarding future 
research 
 
One of the limitations of this study was that the research cohort was comprised of a 
mixture of studies some with a prospective and some with retrospective design as well 
as some studies were created as genetic studies whereas some as randomized clinical 
trials (RCT). Significant heterogeneity was observed for treatment outcomes, implicating 
significant differences in the aims and ways in which the original historical studies were 
set up. To counteract this problem, cases were re-phenotyped where possible and a 
statistical analysis performed, were either adjusted or stratified to the origin of the 
cohort. Re-phenotyping of the cohort itself would not resolve issues related to selection 
bias as it merely dealt with individual data but had no effect on how the cases were 
 185 
 
selected. Selection bias is more pronounced in observational studies (Reeves et al., 
2005). In our cohort, RCTs constituted more than half of it. On the other hand, RCTs are 
prone to selective and narrow inclusion criteria which can raise problems related to the 
ability to generalise the results to a wider and less homogeneous population (Britton et 
al., 1999).  
Prognostic research is different from regulatory trials and epidemiological research. 
Prognostic factors can be either causally related to outcome or be only predictive in 
nature (Kamper et al., 2011). The best design for prognostic research is prospective 
cohort studies. RCTs can be used but, as they have fixed strict inclusion criteria, the 
results might not be generalizable (Moons et al., 2009). Furthermore, the usage of RCTs 
for the investigation of causational predictive factors would be unethical as it would 
require assigning people to variable degrees of causative factors (Kamper et al., 2011). 
The usage of a prospective design is preferable to a retrospective one (Riley et al., 2013). 
Our cohort was set up for the purpose of pharmacogenomics research and later adapted 
for the analysis of clinical markers for treatment outcome. Given the limited resources 
available, it would impossible to create a prospective cohort of the same size within the 
same time span; hence, we had to rely on historical data. Nevertheless, a significant 
proportion (52.7%) of patients were originally recruited into prospective studies.  
A further weakness of our research was the categorisation of the continuous 
variable of the pre-treatment seizure count. Such an approach has been discouraged in 
prognostic research; furthermore, it has been shown in newly diagnosed epilepsy that 
there is a non-linear relationship for this variable (MacDonald et al., 2000, Riley et al., 
2013). More than half (59.23%) of cases had categorical values; hence we would lose 
significant data by excluding them. To capture better the non-linear relationships, 
categories were created with relatively small steps. 
An additional limitation was that we only analysed predictors for binary outcomes 
that might not fully reflect the real-life clinical situations. If more than one mutually 
exclusive event can occur, methods using competing risk analysis might be preferred 
over Kaplan-Meier estimates (Koller et al., 2012). Competing risk analysis has already 
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been applied in the past on SANAD data (Williamson et al., 2008). Two mutually 
exclusive events can occur in the case of epilepsy. Patients can either withdraw from 
treatment due to adverse reactions or a lack of efficacy. An analysis of WP2 Task 1 
specifically interrogated the response to the first well tolerated AED; hence, competing 
risk analysis was not used. Such an approach makes more sense from the 
pharmacogenetic point of view rather than the clinical, as the genes that influence the 
probability of achieving remission may differ from those associated with the occurrence 
of ADR. Furthermore, WP2 Task 3 is planning to use a competing risk methodology for 
the analysis of treatment failure and the genetics of ADR were covered by a different 
work package.  
As discussed in the results section, the proportionality of hazards over time was not 
upheld for all covariates included in the Cox model. Previous work carried out by Dr 
Laura Bonnett on SANAD has shown that, when an accelerated failure time approach is 
added to the analysis, which does not rely on the assumption of proportionality, the 
results remain the same (personal communication Bonnett, 2016). It is not fully possible 
to apply that to this cohort as it did not solely comprise cases from SANAD. The non-
proportionality of hazards was also accounted for by stratifying the Cox regression by 
origin of the cohort. The stratified model that eliminated the CT Head and MRI results 
lost statistical significance but these were still retained in the model. In the meantime, 
gender gained statistical significance.  
As a part of the assessment of the methodological aspects, the length of remission 
was assessed. A limitation of this assessment is that it is only relevant to a subset of 
patients experiencing it, plus some of the patients have been discharged at the onset of 
the 12 month remission period. A more robust approach would be to analyse the time 
to a first seizure following the treatment. Unfortunately, these data were not collected, 
representing a limitation of this analysis. Future research should collect more time to 
event data. 
The effect of different definitions of remission was also assessed by applying 
different length criteria for remission. This approach has several limitations. There exists 
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selection bias, as not all patients in a cohort were followed for 5 - 10 years. There is a 
chance that patients who do not respond to treatment may be over represented when 
the sample is restricted to cases with long follow up periods. Patients in stable remission 
would be more likely to be discharged early compared to more complicated patients.  
The assessment of the quality of the SANAD data transfer demonstrated that 
certain co-variates have poor concordance when compared to an earlier genetic study 
carried out based on the same cohort. Reassuringly critically important co-variates like 
remission and basic demographic data had very high concordance. These results show 
some limitations of the approach when data are transferred from the existing database. 
A sensitivity analysis, which was performed by excluding SANAD cases returned similar 
results, with the exception that CT and the pre-treatment seizure count lost statistical 
significance. This has implications for future research, particularly the underlying 
importance of data quality checks immediately after transfer. 
The following practical conclusion can be drawn based on the EpiPGX experience 
which might be valuable for future epilepsy pharmacogenomics research: 
 Preferably, a prospective design should be utilized. Our research showed 
that the mode of case ascertainment is significantly associated with treatment outcome. 
 If a retrospective multi-centre design is used, researchers should account 
for and control for heterogeneity between centres or historical studies. Clinical practice 
varies between centres and countries and this includes the co-variates collected. This 
might affect the development of endophenotype later.   
 Continuous data should preferably be collected in an attempt to avoid 
unnecessary categorization. If data are collected as categorical, they should not mutually 
exclude the collection of continuous data. 
 The electronic transfer of existing clinical databases or historical studies 
should be planned well in advance and rigorous quality control procedures should be 
implemented before finalizing the transfer. 
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 If survival analysis is used time to event data should be collected. 
Results of GWAS performed as part of the EpiPGX study and this thesis did not 
produce any genome wide significant SNPs, furthermore they failed to replicate results 
of previous studies. This raises a question whether there is a requirement to change the 
approach. It has been previously suggested that complex diseases phenotypes results 
from the interaction of many alleles and environment, furthermore lot of identified 
genetic loci in common disease have only a modest effect (Civelek and Lusis, 2014). 
Systems genetics has been suggested as a potential approach to explore complex traits 
and has already been successfully applied to epilepsy (Civelek and Lusis, 2014, Johnson 
et al., 2015, Delahaye-Duriez et al., 2016). In epilepsy pharmacogenomics pathway 
analysis also has already been used and have demonstrated potentially utility (Speed et 
al., 2014a). Future epilepsy pharmacogenomics research should explore role of systems 
genetics and best methods of its application. 
Epilepsy pharmacogenomics future research lies with the large scale prospective 
multi-national consortia. It is unlikely that any single isolated centre will have the 
capacity to recruit sufficient patients on its own for adequately powered studies. With 
the digitalization of medicine, it might become feasible in future to interrogate routine 
clinical databases and electronic records in the case of common epilepsies. This would 
require quality control systems to be in place beforehand. Nevertheless, nuanced 
manual phenotyping likely may be required for phenotyping cases with suspected rare 
syndromes. Furthermore, the development and integration of electronic records have 
already paved the way for phenome-wide association studies which represent a 
reversion of the GWAS approach (Hebbring, 2014), although not yet in the epilepsy field.  
The reduction of costs and evolution of genomic technologies like next generation 
sequencing will provide more tools for pharmacogenomics research and translation into 
daily clinical practice (Goodwin et al., 2016). This will probably facilitate the further 
development of pharmacogenomics and prognostic research. With new genomic 
technologies, the most complex aspect of research will become the development of the 
phenotype of interest (Relling and Evans, 2015). 
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6.0. Conclusions  
 
This project explored three important aspects related to newly diagnosed epilepsy 
research. Routine clinical and genetic factors were assessed for an association with the 
remission after application of the first well tolerated anticonvulsant. Importantly 
methodological aspects related to creation large scale multinational epilepsy research 
project and data quality were also explored. 
As discussed in the introduction several studies including few very large already in 
past have investigated association and predictive role of routine clinical factors in the 
newly diagnosed epilepsy. Assessment of clinical factors and their relationship with 
remission from seizures after the application of the first well-tolerated anticonvulsant 
demonstrated that age at diagnosis, generalised tonic-clonic seizures only, epilepsy type, 
and the results of the first MRI and EEG were predictive factors and have the same 
direction of effect in both logistic and Cox regression. Those results in large part 
replicated previous observations hence confirming current knowledge in the field. 
 The MRI is becoming a more important tool in modern epileptology, for 
stratification of results of imaging studies we used a relatively simple classification, a 
future research should explore it in more details. Particularly as in past it has been 
demonstrated already that not all abnormalities have the same prognostic implications 
(Stephen et al., 2001, Mohanraj and Brodie, 2005a).  
Better knowledge about clinical factors and their association with treatment 
outcome might play an important in future epilepsy genetic research. It can be argued 
that some of clinical factors have a genetic background. Hence their in-depth 
exploration is not only beneficial for patient care, but in the process of creation of more 
nuanced phenotypes.  
In future epilepsy research collaboration between research groups and countries will 
take even more prominent role. It was an important part of this research to assess what 
is the effect for pulling together resources and patient cohorts and how does that affect 
quality of data. 
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Our research showed that there is significant heterogeneity between centres on the 
various parameters assessed. We demonstrated that the origin of cohort, method of 
case ascertainment, and follow up length are statistically significantly associated with 
the measured outcome. The change of duration for seizure freedom required for 
remission resulted in a progressive reduction in the proportion of subjects experiencing 
it. This provides support for the introduction of quality standards in epilepsy 
pharmacogenetics research. 
For the first time, we assessed the feasibility of using historical data cohorts, clinical 
databases, and data transfers. We demonstrated that robust demographic parameters 
are safe for data transfer, but complex variables have the potential to introduce 
systematic error during the data transfer process. Those results underline importance of 
internal quality assurance procedures during data transfers as well as during the process 
of derivation of a new phenotypes based on old historical data. Those aspects should be 
taken account during process assembly of future cohorts or perhaps giving a 
consideration of prospective multicentre recruitment.    
A GWAS performed on newly diagnosed focal epilepsy for a 12-month remission 
after application of the first well-tolerated anticonvulsant demonstrated that there is no 
single SNP with a strong effect size.  This finding does not conclude research in this field, 
but merely indicate requirement for a further large scale prospectively recruited genetic 
studies utilizing a careful selection of phenotype of interest. It has already been argued 
that GWAS-type approach might have a limited role in general in discovery of clinically 
useful predictors in pharmacogenetic field (Nelson et al., 2016). Furthermore in epilepsy 
pharmacogenetics there are already some arguments for application of pathway based 
analysis (Speed et al., 2014a).  
Future epilepsy pharmacogenomics research should continue developing our 
knowledge about relationship of clinical factors with disease and treatment results. 
There is a need for further large scale genetic studies both for epilepsy itself and 
phamracogenetics with integration of new genomic technologies while maintaining a 
sound study methodology and quality.  
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Appendix 1 
EpiPGX paper CRF final version as of 09/05/2012 (created by EpiPGX Consortium). 
 
 
EpiPGX 
        
Site Code:          
  
Date of CRF 
Completion: 
 DD/MM/YYYY  
  
Data Entered By:    
  
Data Source Medical 
records  
 
  
  
 Database 
(specify) 
 Spe
cify 
  
   Other  Spe
cify 
  
  
DNA nr:     
  DNA Source (tick only one) Blood  Sali
va 
 Brain 
tissue 
  
   Othe
r 
 Spe
cify 
  
  
Genotyped Yes  N
o 
  
  
 If ‘Yes’ Platform   
  
Imputed Yes  N
o 
  
  
 
C.I. 
Professor Sanjay M Sisodiya 
Department of Clinical & Experimental Epilepsy 
UCL Institute of Neurology 
Queen Square 
WC1N 3BG 
London 
United Kingdom  
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General Guidelines Regarding Completing The CRFS 
 
All forms should be completed in black ink in a clear manner. Any changes or corrections should be made 
by drawing a line through the data‚ making sure the amended script is still legible, entering the corrected 
information and initialling and dating the change.  
 
Note: Do not use Correction Fluid 
 
Following standard notation should be used in the event that values or answers cannot be provided: 
 
 NA: Not applicable 
 NK: Not known 
 ND: Not done 
 NR: Not retrievable/Not available 
 
 
 
 
 
Patient Enrolment - Notes 
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Patient Enrolment 
 
Patient Demographics 
  
  
Sex Mal
e 
 Female   
  
Date of Birth   DD/MM/YYYY  
  
 
Ethnic origin 
 
  
Please tick ethnic origin, as self 
reported by  
European  African   
Patient  
 Chinese  Japanese   
   
 Indian  Pakistani   
  
 Middle 
Eastern 
  
  
 Mixed race  Specify   
  
 Other  Specify   
  
  
Date of Recruitment / DNA 
Collection 
 DD/MM/YYYY  
  
Date of epilepsy diagnosis  DD/MM/YYYY  
  
Start date of contemporary 
medical records 
 DD/MM/YYYY  
  
Status at start of contemporary 
clinical records 
New epilepsy   
records (please tick all that apply)  
 Existing epilepsy on treatment   
  
 Existing epilepsy off treatment   
  
 Existing epilepsy, off treatment but previous AED 
treatment    <12 months   
   >12 months   
  
 Existing epilepsy on treatment   
  
Date of most recent update to   DD/MM/YYYY  
Contemporary medical records  
  
 
  
 215 
 
Epilepsy Diagnosis Notes 
 
   
Epilepsy Diagnosis 
    
Epilepsy syndrome according to  
1989 ILAE classification:  
  
Hippocampal sclerosis Y
e
s 
 N
o 
  
  
 If ‘Yes’ please state below 
 L
e
f
t 
 R
i
g
h
t 
  
  
Confirmed by: MRI   
  
 Histology   
  
 Unknown   
  
 
 
Known Progressive Neurological Disorder  
    
 Y
e
s 
 N
o 
 Unkno
wn 
  
  
 If ‘Yes’ please tick one 
  
Type  Neoplastic / 
paraneoplastic 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Metabolic   
  
 Infectious   
  
 Inflammatory   
  
 Degenerative  
  
 Genetic   
  
 O
th
er 
 Specify   
  
Onset Date  DD/MM/YYYY  
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Neurological Examination - Notes 
 
Neurological Examination 
    
 Nor
mal 
 Abnor
mal 
 N
/
A 
  
  
 If abnormal (please tick all that apply) 
 Higher cortical functions    
  
 Speech disturbance   
  
 Cranial nerve 
abnormalities 
  
  
 Motor abnormalities   
  
 Sensor abnormalities   
  
 Co-ordination   
  
 Other  Specif
y 
 
  
 
 
Seizures 
 
 
  
Seizures (please tick all that apply) Primary generalised tonic 
clonic 
  
  
 Absence    
  
 Clonic   
  
 Tonic   
  
 Atonic   
  
 Myoclonic   
  
 Simple partial   
  
 Secondarily GTCS   
  
 Unclassified partial   
  
 Unclassified GTCS   
  
 Uncertain epileptic   
  
 Non-epileptic   
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Seizure Frequency - Notes 
Seizure Frequency 
    
Date / Year of first ever seizure?  DD/MM/YYYY  
  
Total number of seizures prior to 
first ever AED 
Absolute number (if known):   
  
 
 
Total number of seizures prior to first ever AED 
 
 
  
GTC seizures Absolute number (if 
known) 
  
  
 1
-
2 
 3
-
5 
 6
-
1
0 
 1
1
-
2
0 
 2
1
+ 
 NK   
  
  
Non-GTC seizures (any type): Absolute number (if known)   
  
 1
-
2 
 3
-
5 
 6
-
1
0 
 1
1
-
2
0 
 2
1
+ 
 NK  
  
  
Combined (if type unknown) Absolute number (if known)   
  
 1
-
2 
 3
-
5 
 6
-
1
0 
 1
1
-
2
0 
 2
1
+ 
 NK 
U
n
k
n
o
w
n 
  
  
  
Any periods of remission Y
e
s 
 N
o 
 Unk
now
n 
  
  
  
Remission 1 Start date DD/MM/YYYY  
  
 Stop Date DD/MM/YYYY  
  
  
Remissions 2 Start date DD/MM/YYYY  
  
 Stop Date DD/MM/YYYY  
  
  
Remission 3 Start date DD/MM/YYYY  
  
 Stop Date DD/MM/YYYY  
  
  
Remission 4 Start date DD/MM/YYYY  
  
 Stop Date DD/MM/YYYY  
  
  
Total number of seizures in the 
last 12 months  
GTC seizures   
  
 Non-GTC seizures (any 
type): 
  
  
 Combined (if type 
unknown): 
  
  
  
Total number of seizures in the 
last 12 months 
GTC seizures   
prior to epilep y surgery (if 
applicable)  
 
 
 Non-GTC seizures (any 
type): 
  
  
Combined (if type 
unknown): 
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Non Medical Epilepsy Treatment – Notes  
 
 
Non Medical Epilepsy Treatment 
 
 
  
Date of Procedure  DD/MM/YYYY  
  
Type Specify  
  
  
  
  
  
  
  
  
 
 
AED History / General 
 
 
  
Non-epileptic seizures:  Y
e
s 
 N
o 
 NK   
  
  
Total number of appropriate and 
adequate 
specify 
 
AED trials 
  
  
Number of AEDS that failed due to 
lack of 
specify 
 
efficacy at minimum therapeutic 
dose   
  
Responder to VPA + LTG in 
combination only 
Yes  No  NK  NA   
  
  
 219 
 
Investigations (First Ever) - Notes 
 
   
Investigations (First Ever)  
    
EEG (please tick all that apply) Normal  Abnormal 
(Epileptiform) 
  
  
 Abnormal (non-specific)  Not done  Not known  
  
  
Imaging - MRI/CT (Please tick all that 
apply) 
Normal  Abnormal (focal)   
  
 Abnormal (non-specific)  Not 
done 
 Not known  
  
 
 
Investigations 2 (most relevant, if different from above) 
 
 
  
EEG (please tick all that apply) Normal  Abnormal 
(Epileptiform) 
  
  
 Abnormal (non specific)  Not done  Not known  
  
  
Imaging - MRI/CT (Please tick all that 
apply) 
Normal  Abnormal (focal)   
  
 Abnormal (non-specific)  Not done  Not known  
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AED History per AED - Notes 
 
[ 1 ] Reason for stopping: 
1. inadequate seizure control  
2. unacceptable adverse effects  
3. both inadequate seizure control and unacceptable adverse effects  
4. remission 
5. unknown 
 
[ 2 ] Outcome of this AED trial 
1. response 
2. failure 
3. extreme late response  
4. unclassified  
5. unknown 
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AED History per AED  
  
  
  
AED trial number specify   
  
AED generic name specify   
  
Start date  DD/MM/YYYY  
  
Stop date (NA if patient still on AED)  DD/MM/YYYY N/A   
  
Patient known to be non-adherent for 
this AED 
Yes  No  Unknown   
  
Initiated as (Tick all that apply) Monotherapy  Add-on   
  
Maximum dose reached Dose   
  
Average monthly seizure frequency 
during  
GTC seizures   
6 months before starting this AED  
 Non-GTC seizures (any type):  
 
  
  
 Combined (if type unknown):   
  
Average monthly seizure frequency on 
AED 
GTC seizures   
  
 Non-GTC seizures (any type):  
 
  
  
 Combined (if type unknown):   
  
Reason for stopping [ 1 ] 1  2  3  4  5 
  
 Other  Specify   
  
Can this AED trial be considered 
appropriate  
Yes  No  Unknown   
And adequate  
  
Outcome of this AED trial [ 2 ] 1  2  3  4  5   
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Adverse Drug Reactions 
  
  
  
Adverse drug reactions Yes  No  Unknown   
  
  
  
  
Behavioural disorder Agitation  Aggression   
  
 Irritability  Confusion   
  
Ascertained through: Prospective neuropsychological 
assessment 
 
  
  
 Retrospective contemporary data 
 
  
  
  
Cognitive impairment Amnesia  Forgetfulness   
  
 Concentratio
n difficulties 
 Slowed mentation   
  
  
Ascertained through: Prospective neuropsychological 
assessment 
 
  
  
 Retrospective contemporary data 
 
  
  
  
Hepatic dysfunction 
 
Highest GOT/AST (IU/l + reference 
values): 
  
  
  
 Highest GPT/ALT (IU/l + reference 
values):  
 
  
  
 Highest PT (seconds):  
 
  
  
  
Hyponatraemia / SIADH 
  
Lowest plasma Na+ (mEq/l):  
 
  
  
  
Neutropenia / agranulocytosis   
 
Lowest absolute neutrophil count ( /µl):  
 
  
  
  
Psychosis 
 
Psychosis according to ICD10 
definition  
 
  
  
 Confirmed by 
psychiatrist 
yes  no  NK   
  
  
Cutaneous adverse reactions 
 
Confirmed by lymphocyte transformation test: 
 Yes  No  Unknown   
  
 Confirmed by dermatologist 
 Yes  No  Unknown   
  
If ‘Yes’ please tick all that apply 
and label ADR 1, 2...etc 
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Type 
 
 
  
Maculopapular exanthema Hypersensitivity syndrome (please tick all that apply) 
  
 Prolonged recovery phase (despite AED 
withdrawal) 
 
 
  
 Fever 
 
 
  
 Internal organ involvement (tick & specify 
details):  
 
 
  
 Liver 
 
 Specify   
  
 Gastro-intestinal  Specify  
  
 Kidne
y 
 Specify   
  
 Lung  Specify   
  
 Central Nervous 
System 
 Specify  
  
 Heart  Specify   
  
 Muscle  Specify   
  
 Thyroid  Specify   
  
 Haematologica
l 
 Specify  
  
 Lymphoid 
system 
 Spec
ify 
 
  
 Stevens-Johnson syndrome 
 
  
  
 Toxic epidermal necrolysis 
 
  
  
  
  
Speech Disorder Speech difficulties witnessed by physician 
  Yes  No  Unknown   
  
  
Tremor 
 
Mild  Modera
te 
 S
e
v
e
r
e 
  
  
 Family History of tremor 
 Yes  No  Unknown   
  
  
Visual field constriction 
 
Confirmed 
by: 
Goldmann  Humphrey  OCT 
  
  
Weight change  
 
Weight before 
AED:  
KG  
  
 Weight after 
AED:  
 
KG  
  
 Weight change: KG  
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Type (Continued) - Notes 
 
Type (Continued) 
  
  
  
Miscellaneous (please tick all that 
apply) 
 
Arthralgia 
 
  
 . 
 Cardiac conduction 
abnormality 
 Syncope  
 
 Depressed mood  Depression  
  
 Encephalopathy   
  
 Erectile dysfunction  Impotence  
  
 Gastrointestinal symptoms 
 
  
  
 Gum hypertrophy  Gingivitis  
  
 Hair loss 
 
  
  
 Headache 
 
  
  
 Hirsutism 
 
  
  
 Insomnia 
 
  
  
 Osteoporosis 
 
  
  
 Paraesthesia 
 
  
  
 Polycystic ovaries  polycystic ovary syndrome  
  
 Renal stones 
 
  
  
 Sleepine
ss 
 Somnolence  Sedation  
  
 Fatigue  Lethargy   
  
 Thrombocytopenia 
 
  
  
 Unsteadiness  Dizziness  Vertigo  Ataxia  
  
 Urinary retention 
 
  
  
 Other  Specify  
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Summary - Notes 
 
Summary  
  
Patient can be included in WP02 Has newly diagnosed epilepsy   
  
 Immediate remission   
  
 Deferred remission   
  
 No remission   
  
 First AED failed due to 
inefficacy 
  
  
 First AED failed due to ADRs   
  
Patient can be included in WP03 Is drug resistant    
  
 Is drug responsive   
  
 Is extremely drug resistant   
  
 Is control for extremely drug 
resistant 
  
  
Patient can be included in WP04  
  
1. Specify 
AED’s 
  
  
 Response  Failure  Extreme late response 
  
  
2. Specify 
AED’s 
 
  
 Response  Failure  Extreme late response 
  
  
3.. Specify 
AED’s 
 
  
 Respo
nse 
 Failure  Extreme late response 
  
  
4. Specify 
AED’s 
 
  
 Respo
nse 
 Failure  Extreme late response 
  
  
5. Specify 
AED’s 
 
  
 Respo
nse 
 Failure  Extreme late response 
  
  
6. Specify 
AED’s 
 
  
 Respo
nse 
 Failure  Extreme late response 
  
  
7. Specify 
AED’s 
 
  
 Respo
nse 
 Failure  Extreme late response 
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Summary (Continued) 
  
8. Specify AED’s   
  
 Response  Failure  Extreme late response 
  
  
9. Specify AED’s   
  
 Response  Failure  Extreme late response 
  
  
10. Specify AED’s   
  
 Response  Failure  Extreme late response 
  
  
Patient can be included in WP05  
  
1. AED 
name 
 ADR  
  
2. AED 
name 
 ADR  
.  
3. AED 
name 
 ADR  
.  
4. AED 
name 
 ADR  
.  
5. AED 
name 
 ADR  
  
6. AED 
name 
 ADR  
  
7. AED 
name 
 ADR  
  
8. AED 
name 
 ADR  
  
9. AED 
name 
 ADR  
  
10. AED 
name 
 ADR  
  
  
Patient can be included in WP06  
  
1. AED 
name 
 case  control  
  
2. AED 
name 
 case  control  
  
3. AED 
name 
 case  control  
  
4. AED 
name 
 case  control  
  
5. AED 
name 
 case  control  
  
6. AED 
name 
 case  control  
  
7. AED 
name 
 case  control  
  
8. AED 
name 
 case  control  
  
9. AED 
name 
 case  control  
  
10. AED 
name 
 case  control  
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Appendices 
  
ADR’s - Notes 
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ADR’s 
    
ADR __ __ ADR dosing at time of reaction 
(mg/d) 
  
  
 ADR start date DD/MM/YYYY  
  
 ADR stop date (N/A if 
ongoing) 
DD/MM
/YYYY 
N
/
A 
  
  
 Can ADR be reasonably attributed to AED 
   Yes  No  Unknow
n 
  
  
 Did ADR lead to dose reduction 
   Yes  No  Unknow
n 
  
  
 Did ADR lead to ADR withdrawal  
   Yes  No  Unknow
n 
  
  
  
ADR __ __ ADR dosing at time of reaction 
(mg/d) 
  
  
 ADR start date DD/MM/YYYY  
  
 ADR stop date (N/A if ongoing) DD/M
M/YYY
Y 
N
/
A 
  
  
 Can ADR be reasonably attributed to AED 
   Yes  No  Unknown   
  
 Did ADR lead to dose reduction 
   Yes  No  Unknown   
  
 Did ADR lead to ADR withdrawal  
   Yes  No  Unknown   
  
  
ADR __ __ ADR dosing at time of reaction 
(mg/d) 
  
  
 ADR start date DD/MM/YYYY  
  
 ADR stop date (N/A if ongoing) DD/MM
/YYYY 
N
/
A 
  
  
 Can ADR be reasonably attributed to AED 
   Yes  No  Unknown   
  
 Did ADR lead to dose reduction 
   Yes  No  Unknown   
  
 Did ADR lead to ADR withdrawal  
   Yes  No  Unknown   
  
 
  
 229 
 
 
Pregnancy - Notes 
Pregnancy 
    
Number of this 
pregnancy? 
Specify   
  
Personal 
history of 
major 
congenital  
Yes  No  Unknown  
Malformation   
 If ‘yes’ please specify 
   
  
  
  
 Classification of 
MCM 
 
  
Family history 
of MCM 
Yes  No  Unknown   
  
 If ‘yes’ please specify 
   
  
  
  
 Classification of MCM  
  
Folic acid 
taken? 
Yes  No  Unknown   
  
 If ‘yes’ please specify below 
  
 Preconceptual folic 
acid? 
Yes  No   
  
 Dose 
(mg/d) 
  
  
AEDs taken 
prior to 
conception 
and during  
Name  Dose  
First 3 months  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
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Pregnancy (Continued) - Notes 
 
[1]  Outcome  
 1 = Completed 
 2 = Miscarriage 
 3 = Induced abortion 
 4 = Still birth 
 5 = Ongoing 
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Pregnancy (Continued) 
 
 
  
Other 
drugs taken 
during 
pregnancy? 
Yes  No  Unknown   
  
 If ‘yes’ please specify drug (generic) names and doses below 
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
Other 
drugs taken 
in 3 
months 
before  
Yes  No  Unknown   
conception  
 If ‘yes’ please specify drug (generic) names and doses below 
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
 Name  Dose  
  
Alcohol use 
in first 
trimester? 
Yes  No  Unknown  
  
Smoking in 
pregnancy 
Yes  No  Unknown  
  
Gestational 
age at birth 
(weeks) 
   
  
Birth 
weight 
(grams) 
   
  
Sex Male  Female  Unknown 
  
Outcome 
[1] 
1  2  3  4  5 
  
  
 
 232 
 
Pregnancy Continued - Notes 
 
[ 1 ] Major congenital malformation 
 1 = Cardiac malfunction 
 2 = Cleft palate 
 3 = Facial dysmorphism (other than cleft palate) 
 4 = Gastro-intestinal tract defect 
 5 = Genito-urinary tract defect 
 6 = Neural tube defect 
 7 = Spina bifida 
 8 = Skeletal malfunction 
 9= unspecified 
  
 
Pregnancy Continued 
 
 
  
Major congenital malformation [ 1 
] 
Yes  No  Unknown   
 If ‘Yes’ tick all that apply 
  
 1  2  3  4  5   
  
 6  7  8  9   
  
 Other  Specify   
  
Neurodevelopmental delay Yes  No  Unknown   
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Appendix 2 
 
Full set of phenotype definitions developed and applied by the whole consortium as of 
10/09/2014. 
 
WP 02 – Genome-based biomarkers of early treatment response in newly-diagnosed 
epilepsy 
 
Only patients with newly diagnosed epilepsy will be included for this purpose.  
- Newly diagnosed epilepsy is defined as the occurrence of ≥2 clinically definite 
unprovoked epileptic seizures in the previous year, or the occurrence of one seizure and 
the clinician decides to start AEDs.  
- Prospective data are preferred, but retrospective data are allowed if based on 
contemporary evidence (i.e. continuous records from initiation of the first AED onwards 
from a specialist epilepsy centre). 
- Patients with known progressive neurological disorders at time of first AED initiation 
are excluded  
- Make a note of those patients with prior AED exposure or rescue treatment + the 
indication. 
- Focal & generalized epilepsy are defined as in the 1989 ILAE classification 
 
Task 1: Identifying genome-based biomarkers of remission with first well-tolerated 
drug. 
- Remission is defined as any continuous period of ≥12 months complete seizure 
freedom. A titration period of 2 months is taken into account.  
- Immediate remission is defined as remission within 14 months of starting the first 
well-tolerated AED.  
- Deferred remission is defined as remission that is first recorded later than 14 months 
after starting the first well-tolerated AED (and prior to initiation of another AED).  
- No remission is defined as continuing seizures after starting the first well-tolerated, 
adequately applied and appropriate AED (see Appendix for guidance).  
 
Task 2: Identifying genome-based biomarkers that distinguish general and selective 
drug responsiveness. 
No additional definitions needed here.  
 
Task 3: Identifying genomic biomarkers of first drug failure. 
- Treatment failure (withdrawal) due to lack of efficacy is defined as continuing 
seizures after the first appropriate AED has been adequately applied. Where seizure 
frequency data is not available, there should be clear written evidence that the AED was 
withdrawn specifically because it failed to control seizures.  
- Treatment failure due to ADRs: In order to be attributed to the AED in question, 
ADRs should (i) occur within 6 months of initiation of the AED (not applicable for visual 
field defects), (ii) lead to withdrawal of the AED, and (iii) not be attributed to another 
cause by the treating clinician or the phenotyping clinician.  
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ADRs are sub-classified into ‘on-target’ and ‘off-target’ reactions:  
- On-target : neurological in origin, related to dose or concentration, associated with 
dose increase, resolve on dose reduction or drug withdrawal. 
- Off-target: non-neurological, not necessarily related to dose or concentration, not 
necessarily associated with dose increase, do not necessarily resolve on dose reduction or 
drug withdrawal. 
 
 
WP 03 – Genome-based biomarker discovery for broad AED resistance 
 
Task 2: Undertaking GWAS for broad drug resistance 
- Broad AED resistance is defined as seizures recurring at a frequency of ≥4/year over 
the last year till latest recorded visit, despite adequate trials of ≥2 tolerated and 
appropriately chosen and used AED schedules, whether as monotherapies or in 
combination (see Appendix for guidance).  
- Drug responsiveness is defined as freedom from seizures for ≥12 months up to latest 
recorded visit.  
 
- Patients who have had epilepsy surgery and fulfilled the above criteria for broad AED 
resistance before surgery can also be included.  
- Patients who have had epilepsy surgery can never be classified as drug responsive 
thereafter  
- Patients known to be systematically non-adherent should be excluded.  
(1 seizure a year due to non-adherence may be disregarded) 
- Make a note of patients with a history of alternating remissions (≥12 months) and 
relapses on any AED + specify the number of remissions.   
- During its long and sometimes fluctuating course a person’s epilepsy may not fulfil the 
definition criteria for either drug resistant or drug-responsive epilepsy at certain time 
points. In such circumstances, drug responsiveness should be temporarily classified as 
‘‘undefined.’’ 
 
Task 3: Search for rare variants causing broad drug resistance 
- Extreme AED resistance is defined as:  
- Clearly identifiable (MRI- or histologically-confirmed), stable lesion 
- Follow-up of ≥5 years 
- Seizures recurring at a frequency of ≥4/year over the last year till latest data entry, 
despite adequate trials of ≥5 tolerated and appropriately chosen and used AED schedules 
(whether as monotherapies or in combination). 
- Never been seizure-free for ≥12 months 
- Patients who have had epilepsy surgery and fulfilled the above criteria before surgery 
can also be included 
- Drug responsiveness is defined as:  
- Clearly identifiable, stable lesion  
- Free from seizures for ≥5 years up to latest data entry 
- Patients cannot have had surgery for their epilepsy.   
 
WP 04 – Genome-based biomarker discovery for late response to specific AEDs 
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Only patients who have failed at least one AED trial due to lack of efficacy will be 
included for this purpose (although this AED does not necessarily have to be withdrawn).  
 
Task 1: Search for variants for late response to specific AEDs in focal epilepsies 
- AEDs to be included: any.  
- Response to specific AEDs is defined as freedom from seizures lasting for ≥12 months 
which according to the treating clinician and/or the phenotyper can be attributed to the 
AED, e.g. after an increase of dose (and prior to initiation of another treatment for 
epilepsy). 
- Failure of specific AEDs is defined as seizures recurring at >50% of the pretreatment 
seizure frequency after the appropriate AED has been adequately applied (see Appendix 
for guidance).  
- Patients known to be systematically non-adherent should be excluded.  
(1 seizure a year due to non-adherence may be disregarded) 
 
- Extreme late AED response is defined as:  
 - Patients who failed adequate trials of ≥2 tolerated and appropriately chosen and 
used AED schedules (whether as monotherapies or in combination). 
- Became seizure free for ≥12 months after reaching the minimum therapeutic dose of the 
AED ‘X’ (see Appendix 1) 
- Where appropriate, concomitant AEDs have been withdrawn to leave the patient on 
AED ‘X’ in monotherapy. 
- Patients cannot have had surgery for their epilepsy.   
 
NB: cases in which some details are missing (e.g. exact seizure frequencies, exact AED 
exposure duration) but a response can be derived from the clinical context can also be 
included. These are coded as follows:  
R1= response + all criteria fulfilled 
R2= response with details missing 
R3= extreme late response 
F1= failure + all criteria fulfilled 
F2= failure with details missing 
 
Task 2: Search for variants for late response to specific AEDs in generalised 
epilepsies 
 - AEDs to be included: LTG & VPA, maybe others (e.g. LEV) 
 - Same definitions as above 
- Make a note of patients responding to VPA+LTG combination therapy, when both 
AEDs alone have failed, and to those not responding to VPA+LTG 
 
WP 05 – Genome-based biomarker discovery for specific ADRs 
 
- In order to be attributed to the AED in question, ADRs should:  
-  Occur within 6 months of initiation of the AED (not applicable for visual field defects) 
and 
-  Where appropriate, lead to withdrawal or dose reduction of the AED and 
- Where appropriate, reverse or improve after withdrawal or dose reduction (e.g. not for 
visual field defects) and 
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- Not be attributed to another cause by the treating clinician or the phenotyping clinician.  
 
NB: fulfilment of all of the above criteria (as well as specific ADR definitions below) 
classifies a case as ‘strict’; fulfilment of only criterion 4 classifies a case as ‘loose’.  
 
- Specific ADR definitions:  
Rash/hypersensitivity:  
Maculopapular exanthema (MPE) is defined as mild rash  
Hypersensitivity syndrome (HSS) is defined as:  
Rash  
Involvement of ≥1 internal organs (see Appendix 3) 
Prolonged recovery phase (despite AED withdrawal) and/or fever 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are defined 
as skin detachment (1-30% for SJS and >30% for TEN) 
Weight change is defined as a >10% weight gain or loss  
The definitions of behavioural disorder and cognitive impairment are based on the 
prospective neuropsychological assessments developed by participant 07.  Retrospective 
cases can be included on the basis of contemporary evidence (i.e. improvement on 
neuropsychological testing after coming off TPM).  
Speech disorder on TPM at a dose of ≤100 mg/d and witnessed by a physician.  
Neutropenia is defined as a documented neutrophil count of <1000/µl.  
Hyponatremia is defined as a documented plasma sodium concentration of <125 mEq/l. 
Visual field defect is measured by optical coherence tomography according to the 
protocol established by participant 01.    
Tremor is defined as the appearance of a new-onset, severe tremor in patients <40 years 
old on VPA monotherapy at a dose of 1000 mg/d and without a family history of tremor.  
Hepatotoxicity is defined as A) ≥5-fold elevation above the ULN of ALT or AST or B) 
≥2-fold elevation above the ULN for ALP (when there is no bony cause for rise in ALP) 
or C) ≥3-fold elevation in ALT plus bilirubin elevation exceeding 2x ULN.  
Thrombocytopaenia is defined as a documented platelet count of <100 *10
9
/L 
(<100.000/µl). 
Psychotic reaction is defined as vivid hallucinations, misidentifications, delusions and/or 
ideas of reference (often of a paranoid or persecutory nature), psychomotor disturbances 
(excitement or stupor), and an abnormal affect, which may range from intense fear to 
ecstasy. The sensorium is usually clear but some degree of clouding of consciousness, 
though not severe confusion, may be present.  
The diagnosis is confirmed by a psychiatrist.  
In addition, any idiosyncratic reaction on any AED will be recorded. 
 
WP 06 – Genome-based biomarker discovery for valproate teratogenesis 
 
- Cases are women with epilepsy who were taking any AED (either in monotherapy or 
polytherapy) during a period including the first trimester of pregnancy where the infant 
was identified to have any major congenital malformation (MCM).  
- Controls are women with epilepsy who were taking any AED (either in monotherapy or 
polytherapy) during a period including the first trimester of pregnancy where the infant 
did not have a MCM.   
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- A MCM is defined as any structural abnormality with surgical, medical, functional or 
cosmetic importance 
- MCMs resulting in spontaneous or induced abortion are also included.   
- Make a note in case of siblings with MCM.  
 
Appendix to phenotypes defintions. 
 
Antiepileptic 
drug 
Focal 
seizures 
Primary 
generalised 
tonic-clonic 
seizures 
Absence 
seizures 
Other primary 
generalised / 
unclassified 
seizures 
Minimum 
therapeutic 
dose (mg) 
Defined 
daily dose 
(mg) 
Carbamazepine     600 1000 
Clobazam     10 20 
Clonazepam     4 8 
Eslicarbazepine     800 800 
Ethosuximide     1000 1250 
Felbamate     1200 2400 
Gabapentin     1200 1800 
Lacosamide     200 300 
Lamotrigine     150 300 
Levetiracetam     1000 1500 
Oxcarbazepine     900 1050 
Phenobarbital     60 100 
Phenytoin     200 300 
Pregabalin     300 300 
Primidone     750 1250 
Retigabine     600 900 
Rufinamide     1200 1400 
Tiagabine     30 30 
Topiramate     100 300 
Valproate     1000 1500 
Vigabatrin     1000 2000 
Zonisamide     150 200 
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-  Adequate: the AED has been administered during an adequate time period and at an 
adequate dose (see also Tables 1 & 2 below).  
- Appropriate: previously shown to be effective, preferably in randomized controlled 
studies (e.g. ethosuximide for focal seizures is considered inappropriate and therefore 
does not count). Please note that some patients may ‘‘fail’’ several AEDs before they fail 
one that is ‘‘appropriate’’ and in a way that is ‘‘informative.’’ 
 
Table 1. AEDs, appropriate seizure types, minimum and defined daily doses for 
AED monotherapy in adult patients 
 
The above doses are given for guidance only. Final judgment of adequacy of any AED 
trial is left to the discretion of the treating clinician and/or phenotyper. 
 
  Kwan P. et al, Epilepsia 2010 (http://www.ncbi.nlm.nih.gov/pubmed/19889013) 
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Appendix 3 
 SANAD to EpiPGX data transfer dictionary (created by Dr Ben Francis, University of Liverpool). 
Dictionary was based on EpiPGX CRF and corresponding numbers reflect item in SANAD CRF. 
General note:  use “NA” whenever data are not available 
 
1. General data 
 
- Site code (e.g. UCL, ULB…): ULIV 
- Date of CRF completion:  
- Person entering data:  Ben Francis 
- Data source (tick one):  
o medical records  
o database (specify): SANAD 
o other (specify): 
- DNA nr:  
- DNA source (tick one):  
o blood  
o saliva  
o brain tissue  
o other (specify): 
- Genotyped : yes  
If yes: -Platform:                
           -Imputed: yes  
- Gender: male / female 2A 
- DOB:  2A 
- Ethnicity: European, African, Asian, other (specify), mixed (specify), unclassified 
- Date of recruitment / DNA collection: 2B 
- Date of epilepsy diagnosis:  
- Start date of continuous contemporary clinical records: 2B 
- Status at start of continuous contemporary clinical records (tick one): 2A  
o new epilepsy  
o existing epilepsy, off treatment  
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o existing epilepsy, off treatment but previous AED treatment (<12 months / 
>12 months)  
o existing epilepsy, on treatment 
- Date of latest recorded visit: 4: Follow-up 
 
2. Epilepsy diagnosis 
 
- Epilepsy syndrome according to 1989 ILAE classification: 1.5 
- Hippocampal sclerosis: yes / no 
 - If yes: - left / right 
   - confirmed by: MRI / histology / unknown 
 
  3.  Known progressive neurological disorder 
 
      - Yes / no 1.2 
      - If yes: - Type (tick one):  
o   Neoplastic/paraneoplastic 
o   Metabolic 
o   Infectious 
o   Inflammatory 
o   Degenerative 
o   Genetic 
o   Other 
       - Details:  
       - Onset date:  
 
4. Neurological examination 
 
- Normal / abnormal / NA 1.1 
- If abnormal: tick one or more:  
o Higher cortical functions  
o Speech disturbance  
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o Cranial nerve abnormalities  
o Motor abnormalities  
o Sensory abnormalities  
o Coordination  
o Other  
   - Details: 1.1 
 
5.   Seizures  
 
- Seizure types (tick any that apply): 1.4 
o primary generalized tonic clonic (GTC) 
o absence 
o clonic 
o tonic 
o atonic 
o myoclonic 
o simple partial 
o complex partial 
o secondarily GTC 
o unclassified partial 
o unclassified GTC 
o uncertain epileptic 
o non-epileptic  
 
6.   Seizure frequency 
 
- Date/year of first ever seizure: 1.4 
- Total number of seizures prior to first ever AED  
 1) GTC seizures: 1.4 
  - Absolute number (if known): 
  - Categorical: 1-2, 3-5, 6-10, 11-20, 21+, unknown 
 2) Non-GTC seizures (any type):  
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  - Absolute number (if known): 
  - Categorical: 1-2, 3-5, 6-10, 11-20, 21+, unknown 
 3) Combined (if type unknown): 1.4 
  - Absolute number (if known): 
  - Categorical: 1-2, 3-5, 6-10, 11-20, 21+, unknown 
- Did the patient experience at least one seizure in the 12 months prior to starting the first 
AED?  Yes / No / Unknown 1.4 
 
- Any periods of remission: unknown  
- Total number of seizures in the last 12 months prior to latest recorded visit  
1) GTC seizures: 1.4 
  - Absolute number (if known): 
  - Categorical: 1-3, ≥4, unknown 
 2) Non-GTC seizures (any type): 1.4  
  - Absolute number (if known): 
  - Categorical: 1-3, ≥4, unknown 
 3) Combined (if type unknown): 1.4 
  - Absolute number (if known): 
  - Categorical: 1-3, ≥4, unknown 
 
8. Investigations 1 (first ever)  
 
- EEG: 3B1 
o normal  
o abnormal (epileptiform)  
o abnormal (non-specific)  
o not done  
o not known  
- Imaging (MRI / CT – delete as appropriate): 3C 
o normal  
o abnormal (focal)  
o abnormal (non-specific)  
o not done  
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o not known  
 
9. Investigations 2 (most relevant, if different from above)  
 
- EEG: 3B1 
o normal  
o abnormal (epileptiform)  
o abnormal (non-specific)  
o not done  
o not known  
 
- Imaging (MRI / CT – delete as appropriate): 3C 
o normal  
o abnormal (focal)  
o abnormal (non-specific)  
o not done  
o not known  
 
 
10. AED history per AED (Fill out 1 form per AED tried, in chronological order) 
 
- AED generic name: 2A 
- Start date: 2B 
- Stop date (NA if patient still on AED): 4.3 
- Patient adherent for this AED: unknown  
- Initiated as monotherapy / add-on / unknown (delete as appropriate) 4.2 
- Maximum dose reached (mg/d): 2B 
- Average monthly seizure frequency during ≥3 months before starting this AED  
1) GTC seizures: 1.4 
                2) Non-GTC seizures (any type): 1.4 
      3) Combined (if type unknown): 1.4 
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- Average monthly seizure frequency while on this AED (and prior to any subsequent 
change in epilepsy treatment) 
1) GTC seizures: 4.1 
                2) Non-GTC seizures (any type): 4.1 
      3) Combined (if type unknown): 4.1 
- Reason for stopping: 4.6 
o inadequate seizure control  
o unacceptable adverse effects  
o both inadequate seizure control and unacceptable adverse effects  
o remission 
o other (specify): 
o unknown 
o NA 
- Can this AED trial be considered appropriate and adequate: yes / no / unknown  4.3 
- Outcome of this AED trial: response / failure / extreme late response / unclassified / 
unknown 4.3/4.6 
 
- Adverse drug reactions: yes / no / unknown 4.6 
      If yes (tick any, label “ADR1, 2 …” and fill out details below for each ADR):  
o Behavioural disorder (agitation / aggression / irritability / confusion). 
Ascertained through: 4.6 
o Prospective neuropsychological assessment 
o Retrospective contemporary data 4.6 
o Cognitive impairment (amnesia / forgetfulness / concentration difficulties / 
slowed mentation). Ascertained through: 4.6 
o Prospective neuropsychological assessment 
o Retrospective contemporary data 4.6 
o Hepatic dysfunction 4.6 
o Highest GOT/AST (IU/l + reference values):  
o Highest GPT/ALT (IU/l + reference values):  
o First elevated AP (IU/l + reference values): 
o Highest AP (IU/l + reference values): 
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o First elevated bilirubin (mg/dl + reference values): 
o Highest bilirubin (mg/dl + reference values): 
o Highest PT (seconds):  
o Hyponatraemia / SIADH 4.6 
o Lowest plasma Na+ (mEq/l):  
o Neutropenia / agranulocytosis 4.6   
o Lowest absolute neutrophil count ( /µl):  
o Psychosis 4.6 
o Psychosis according to ICD10 definition  
o Confirmed by psychiatrist: yes / no / unknown 
o Cutaneous adverse reactions 4.6 
o Confirmed by lymphocyte transformation test: yes / no / unknown 
o Confirmed by dermatologist: yes / no / unknown 
Type:  
o Maculopapular exanthema 
o Hypersensitivity syndrome (tick any that apply):  
 Prolonged recovery phase (despite AED withdrawal) 
 Fever 
 Internal organ involvement (tick + give details):  
 Liver 
 Gastro-intestinal 
 Kidney 
 Lung 
 Central nervous system 
 Heart 
 Muscle 
 Thyroid 
 Haematological 
 Lymphoid system 
o Stevens-Johnson syndrome 
o Toxic epidermal necrolysis 
o Speech disorder 
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o Speech difficulties witnessed by physician 
o Thrombocytopenia 
o Lowest thrombocyte count  ( /µl):  
o Tremor 
o Mild / moderate / severe 
o Family history of tremor: yes / no / unknown 
o Visual field constriction 
o Confirmed by : Goldmann / Humphrey / OCT 
o Weight change  
o Weight before AED:           kg 
o Weight after AED:           kg 
o Weight change:           kg 
o Miscellaneous  
o Cardiac conduction abnormality / syncope 
o Depressed mood / depression 
o Encephalopathy 
o Other:  
 
Fill out details for each of the above ADRs:  
 
- ADR1 :  4.6 
- ADR dosing at time of reaction (mg/d):  
- ADR start date:  
- ADR stop date (NA if ongoing):  
- Can ADR be reasonably attributed to AED: yes / no / unknown 
- Did ADR lead to dose reduction: yes / no / unknown 
- Did ADR lead to ADR withdrawal: yes / no / unknown 
 
- ADR2 : 4.6 
- ADR dosing at time of reaction (mg/d):  
- ADR start date:  
- ADR stop date (NA if ongoing):  
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- Can ADR be reasonably attributed to AED: yes / no / unknown 
- Did ADR lead to dose reduction: yes / no / unknown 
- Did ADR lead to ADR withdrawal: yes / no / unknown 
 
- ADR3 : 4.6 
- ADR dosing at time of reaction (mg/d):  
- ADR start date:  
- ADR stop date (NA if ongoing):  
- Can ADR be reasonably attributed to AED: yes / no / unknown 
- Did ADR lead to dose reduction: yes / no / unknown 
- Did ADR lead to ADR withdrawal: yes / no / unknown 
 
- ADR4 : 4.6 
- ADR dosing at time of reaction (mg/d):  
- ADR start date:  
- ADR stop date (NA if ongoing):  
- Can ADR be reasonably attributed to AED: yes / no / unknown 
- Did ADR lead to dose reduction: yes / no / unknown 
- Did ADR lead to ADR withdrawal: yes / no / unknown 
 
 
 
 
 
12. Summary (tick any that apply) 
 
 Patient has generalized epilepsy 1.5 
 Patient has focal epilepsy  1.5/1.6 
 WP02: Patient has newly-diagnosed epilepsy: yes 
If yes: 4.1 
o Immediate remission 
o Deferred remission 
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o No remission 
o First AED failed due to inefficacy 4.3 
o First AED failed due to ADRs 4.3 
 Patient can be included in WP03: unknown 
o Is drug resistant 
     -   Total number of adequate, appropriate and tolerated AEDs: 
o Is drug responsive 4.1 
o Is extremely drug resistant 
o Is a control for extremely drug resistant 
 Patient can be included in WP04 (list AED names and outcome below): yes / no 
/ unknown 
Include only patients who have failed at least one AED trial due to lack of efficacy! 
1) ……………4.2………… : response / failure / extreme late response 
4.1/4.3 
2) ……………………………… : response / failure / extreme late response 
3) ……………………………… : response / failure / extreme late response 
4) ……………………………… : response / failure / extreme late response 
5) ……………………………… : response / failure / extreme late response 
6) ……………………………… : response / failure / extreme late response 
7) ……………………………… : response / failure / extreme late response 
8) ……………………………… : response / failure / extreme late response 
9) ……………………………… : response / failure / extreme late response 
10) ……………………………… : response / failure / extreme late response 
11) ……………………………… : response / failure / extreme late response 
12) ……………………………… : response / failure / extreme late response 
Responder to VPA + LTG in combination only: yes / no / unknown / NA 
 
 Patient can be included in WP05 (list AED names and ADRs below)  4.2 
 
AED name ADR 
  
 249 
 
Appendix 4 
Table with the full list and results of SNPs include in GWAS with dominant inheritance model. Left sided columns are univariate analysis whereas right 
sided are after adjustment for significant clinical factors. 
CHR rsid Position info P value 
univariate 
analysis 
 CHR rsid position info P value 
adjusted 
analysis 
11 chr11:107982503:D 107982503 0.993793 0.000187703   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
11 chr11:107982503:D 108000000 0.993793 0.00032 
13 chr13:85111634:D 85111634 0.993656 5.65715E-07 13 chr13:85111634:D 85111634 0.993656 1.63E-06 
2 chr2:12639256:D 12639256 0.998011 0.000063158 2 chr2:12639256:D 12639256 0.998011 0.0000411 
3 chr3:184791599:D 184791599 0.995788 1.15897E-06 3 chr3:184791599:D 184791599 0.995788 1.097E-05 
8 chr8:33952031:D 33952031 0.991777 0.000609636 8 chr8:33952031:D 33952031 0.991777 6.06E-06 
4 rs10033588 25754026 0.989671 0.000040116 4 rs10033588 25754026 0.989671 6.77E-06 
2 rs10166451 233479640 0.984334 0.000396878 2 rs10166451 233479640 0.984334 0.0028749 
10 rs10828664 24814503 1 0.00153067 10 rs10828664 24814503 1 0.000984 
10 rs11014141 24814223 0.991028 0.00227079 10 rs11014141 24814223 0.991028 0.001581 
12 rs11068099 117034918 0.996878 7.47441E-05 12 rs11068099 117000000 0.996878 0.0000816 
12 rs11068100 117035067 0.995765 0.000162272 12 rs11068100 117000000 0.995765 0.000189 
12 rs11068101 117036472 0.997107 0.000105591 12 rs11068101 117000000 0.997107 0.000106 
2 rs11096544 18767384 1 0.00451517 2 rs11096544 18767384 1 0.0001044 
14 rs11160087 93129982 0.964623 6.92383E-06 14 rs11160087 93129982 0.964623 6.76E-06 
2 rs114442102 233478687 0.978042 0.000448273 2 rs114442102 233478687 0.978042 0.0032818 
1 rs11584217 202982240 0.995155 0.00248646 1 rs11584217 202982240 0.995155 8.071E-05 
3 rs116415722 163130184 0.979521 1.52929E-05 3 rs116415722 163000000 0.979521 0.000486 
4 rs11727253 25770524 0.987954 1.21643E-05 4 rs11727253 25770524 0.987954 0.0000208 
10 rs12268215 24814142 0.988971 0.00169348 10 rs12268215 24814142 0.988971 0.001027 
8 rs12676472 33972141 0.979782 0.000342764 8 rs12676472 33972141 0.979782 0.0000125 
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1 rs12725494 202996589 0.984188 0.00151839   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
1 rs12725494 202996589 0.984188 6.298E-05 
1 rs12747999 228796705 0.991716 0.000316075 1 rs12747999 228796705 0.991716 1.389E-06 
13 rs12855432 85111586 0.998517 7.33108E-07 13 rs12855432 85111586 0.998517 2.18E-06 
16 rs140775682 31290557 0.983502 9.79997E-05 16 rs140775682 31290557 0.983502 0.0000148 
11 rs144267602 108319016 0.991432 5.0952E-07 11 rs144267602 108000000 0.991432 8.15E-06 
13 rs1446766 85112660 0.992194 8.1794E-07 13 rs1446766 85112660 0.992194 2.46E-06 
13 rs1446767 85110202 0.999908 7.33108E-07 13 rs1446767 85110202 0.999908 2.18E-06 
13 rs1446768 85110189 0.999913 7.33108E-07 13 rs1446768 85110189 0.999913 2.18E-06 
13 rs1446770 85108206 1 7.33108E-07 13 rs1446770 85108206 1 2.18E-06 
13 rs1446782 85075320 0.999171 7.08097E-07 13 rs1446782 85075320 0.999171 3.07E-06 
2 rs1530632 46590384 0.992424 0.00229165 2 rs1530632 46590384 0.992424 0.0001708 
15 rs17204959 61481102 0.998619 0.00045448 15 rs17204959 61481102 0.998619 0.002085 
12 rs1874438 117034544 0.998148 7.79997E-05 12 rs1874438 117000000 0.998148 0.0000803 
6 rs1876550 106213051 0.999807 0.00116238 6 rs1876550 106000000 0.999807 0.0000444 
10 rs1937818 122511887 0.991968 0.000031822 10 rs1937818 123000000 0.991968 4.02E-06 
3 rs2004207 184790414 0.997468 1.44048E-06 3 rs2004207 185000000 0.997468 0.0000143 
3 rs2004208 184790407 0.997456 1.44048E-06 3 rs2004208 185000000 0.997456 0.0000143 
7 rs2390716 22807922 0.997207 1.75423E-05 7 rs2390716 22807922 0.997207 0.0000628 
11 rs35219733 107989244 0.997716 0.00022103 11 rs35219733 108000000 0.997716 0.000778 
10 rs4077084 86420972 0.98958 8.33869E-06 10 rs4077084 86420972 0.98958 6.65E-06 
1 rs4412590 228720037 0.987423 0.148345 1 rs4412590 228720037 0.987423 0.12195 
10 rs4508149 86032370 0.99926 0.000575802 10 rs4508149 86032370 0.99926 0.000162 
3 rs4687016 184792444 1 1.15897E-06 3 rs4687016 185000000 1 0.000011 
3 rs526346 176210523 0.994518 0.000159524 3 rs526346 176000000 0.994518 0.001169 
1 rs55882333 45757393 0.953498 6.29281E-06 1 rs55882333 45757393 0.953498 NA 
3 rs59264451 184787463 0.997319 9.64284E-07 3 rs59264451 185000000 0.997319 6.23E-06 
3 rs713601 194459554 0.977859 0.0106843 3 rs713601 194000000 0.977859 0.016326 
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12 rs7137033 117035544 0.997265 0.000132653 12 rs7137033 117000000 0.997265 0.000132 
10 rs72835240 129359897 0.993357 2.97218E-05 10 rs72835240 129000000 0.993357 3.28E-06 
10 rs72835241 129360226 0.996921 9.55415E-05 10 rs72835241 129000000 0.996921 0.0000154 
3 rs73053778 184068305 0.982405 6.71075E-05 3 rs73053778 184000000 0.982405 7.51E-06 
12 rs7314617 117031946 1 0.000160505 12 rs7314617 117000000 1 0.000211 
13 rs7337244 85108915 0.999995 7.33108E-07 13 rs7337244 85108915 0.999995 2.18E-06 
13 rs7337326 85109087 0.999991 7.33108E-07 13 rs7337326 85109087 0.999991 2.18E-06 
13 rs7337490 85109106 0.999991 7.33108E-07 13 rs7337490 85109106 0.999991 2.18E-06 
13 rs7338700 85109002 0.999995 7.33108E-07 13 rs7338700 85109002 0.999995 2.18E-06 
13 rs7339022 85109110 0.999991 7.33108E-07 13 rs7339022 85109110 0.999991 2.18E-06 
3 rs744306 184789748 0.998469 1.30976E-06 3 rs744306 185000000 0.998469 0.0000138 
3 rs747507 184790127 0.998684 1.30976E-06 3 rs747507 185000000 0.998684 0.0000138 
10 rs753795 86028579 0.998618 0.0006652 10 rs753795 86028579 0.998618 0.000179 
10 rs753796 86028463 0.997041 0.000428384 10 rs753796 86028463 0.997041 0.000102 
2 rs7607256 233485696 1 0.000573714 2 rs7607256 233485696 1 0.0043705 
3 rs76100028 184789338 0.99714 4.20872E-07 3 rs76100028 185000000 0.99714 3.92E-06 
3 rs7624642 184561541 0.994769 3.48511E-06 3 rs7624642 185000000 0.994769 0.0000243 
10 rs7899757 86024199 0.998313 0.0006652 10 rs7899757 86024199 0.998313 0.000179 
10 rs7904309 86025310 0.998455 0.0006652 10 rs7904309 86025310 0.998455 0.000179 
10 rs7911510 86342382 0.999702 0.000324525 10 rs7911510 86342382 0.999702 0.00019 
12 rs7968805 117034246 0.998675 7.79997E-05 12 rs7968805 117000000 0.998675 0.0000803 
13 rs7991045 85080910 0.9987 7.3992E-07 13 rs7991045 85080910 0.9987 2.83E-06 
13 rs7996369 85111713 0.997633 7.33108E-07 13 rs7996369 85111713 0.997633 2.18E-06 
13 rs7997475 85112098 0.995518 8.1794E-07 13 rs7997475 85112098 0.995518 2.46E-06 
13 rs9319058 85108979 0.999995 7.33108E-07 13 rs9319058 85108979 0.999995 2.18E-06 
6 rs9320132 106246658 0.998851 0.00269345 6 rs9320132 106000000 0.998851 0.000189 
6 rs9400994 117565453 0.993985 0.00637079 6 rs9400994 118000000 0.993985 0.000121 
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6 rs9460589 21044895 0.997508 4.52763E-07 6 rs9460589 21044895 0.997508 0.000056 
13 rs9531612 85109868 0.99994 7.33108E-07 13 rs9531612 85109868 0.99994 2.18E-06 
13 rs9531613 85110793 0.999867 7.33108E-07 13 rs9531613 85110793 0.999867 2.18E-06 
13 rs9531615 85111407 0.999803 7.33108E-07 13 rs9531615 85111407 0.999803 2.18E-06 
13 rs9546751 85109272 0.9995 6.05683E-07 13 rs9546751 85109272 0.9995 1.81E-06 
13 rs9602496 85108738 1 7.33108E-07 13 rs9602496 85108738 1 2.18E-06 
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Appendix 5 
Full list of LocusZoom plots for all SNPs with p value less than 5x10-5 from univariate GWAS for 
newly diagnosed focal epilepsy after application of first well tolerated anticonvulsant. 
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Appendix 6 
Full list of LocusZoom plots for all SNPs with p value less than 5x10-5 from GWAS for newly 
diagnosed focal epilepsy after application of first well tolerated anticonvulsant after adjustment 
for significant clinical factors. 
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Appendix 7 
This appendix contain the final progress report created on behalf of EpiPGX WP2 by Dr Graeme 
Sills, it was submitted to relevant funding body. It was created on 01/12/2015. 
WP02: Genomic biomarkers of early treatment response in newly-diagnosed epilepsy 
 
Objectives  
To identify biomarkers of remission with the first well-tolerated antiepileptic drug in newly-diagnosed epilepsy 
To identify biomarkers that distinguish general and selective drug responsiveness in newly-diagnosed 
epilepsy 
To identify biomarkers of first drug failure in newly-diagnosed epilepsy 
 
Summary of progress towards objectives and details for each task 
 
Summary & progress update 
WP02 represents the combined interests and efforts of the Universities of Liverpool (ULIV) and Glasgow 
(UGLA) and Imperial College London (IMP), with work coordinated from ULIV and with contributions from all 
other EpiPGX partners. The principal objectives for WP02 are to identify genomic biomarkers of clinically-
relevant treatment outcomes following initial antiepileptic drug exposure in patients with newly-diagnosed 
epilepsy. During this final reporting period, we have made significant progress towards achieving those 
objectives, as detailed below. This has been achieved thanks to the commitment of staff supported by 
EpiPGX – Dr Ben Francis and Dr Pauls Auce at ULIV and Dr Sarah Langley and Dr Prashant Srivastava at 
IMP – and senior investigators (Jorgensen, Marson, Johnson, Sills) at both sites. The WP02 team has 
continued to meet face-to-face on a six-monthly basis during the final reporting period and our regular 
teleconferences have increased in frequency to fortnightly. This coordinated effort, together with a clear 
analysis plan (as described in the previous periodic report in Dec 2014), means that we have now met the 
majority of our intended milestones and have fully completed two of our three main tasks (and the 
associated deliverables) and have partially completed the remaining task (with an interim deliverable 
available). It was hoped that a short no-cost extension to EpiPGX would allow full completion of all WP02 
tasks and deliverables but this was not forthcoming. The remaining work – which will necessitate 
collaboration across investigators in WP02, WP03 and WP04 – will be completed in the first half of 2016. 
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Progress on specific tasks 
A key component of the intended analysis in WP02 was to first establish the relative influence of 
demographic (i.e. age, sex) and clinical (i.e. epilepsy type) factors in the variability in treatment outcomes in 
newly diagnosed epilepsy. Understanding and adjusting for these factors (or covariates) should allow a more 
sensitive investigation of the relative contribution of genomic variants in the subsequent genome-wide 
association analyses. This essential work was undertaken by Dr Pauls Auce at ULIV using a logistic 
regression method to identify significant non-genetic predictors of treatment outcome and to quantify the 
extent of their influence. Although this work was not associated with any specific task or deliverable, it 
contributed to all of the genomic analyses undertaken in WP02 and the main findings are accordingly 
reported in the ‘significant results’ section below. 
 
Task 1: Identifying genome-based biomarkers of remission with first well-tolerated drug 
All phenotype and genotype data for this analysis was assembled by end of 2014. Subsequent quality 
control checks were implemented in early 2015. These resulted in a loss of cases due to either missing 
phenotype information essential to the determination of treatment outcome or missing genotype information 
above a pre-determined ceiling for inclusion. The final genome-wide association study (GWAS) was 
undertaken in a population of 1,514 individuals with newly-diagnosed epilepsy, who had been followed-up 
prospectively at a single epilepsy centre from initial diagnosis and treatment initiation and until such time that 
they reached an efficacy end-point associated with their first well-tolerated antiepileptic drug (AED). Patients 
were stratified into those experiencing an immediate remission from seizures (n=604), those experiencing a 
later (or deferred) remission (n=248), and those who did not experience remission on their first AED 
(n=664). This population was then interrogated using a variety of statistical approaches in an effort to 
identify genomic variants associated with treatment outcome, using binary, multinomial and survival GWAS 
methods. The latter approach (survival GWAS) necessitated the development of novel statistical 
methodology – three-way mixed modelling GWAS – which was outlined in the previous periodic report and 
has been the subject of dissemination activities. The key findings from the Task 1 analysis are reported 
under ‘significant results’ below and are described in more detail, together with further information on the 
statistical model, in the corresponding deliverable (D2.3). This task is now completed. 
 
Task 2: Identifying genome-based biomarkers that distinguish general and selective drug responsiveness 
Chronologically, this was always intended as the final task for WP02. It was originally designed as a 
collaborative effort between WP02 and WP04 and reliant on the identification of genome-wide significant 
biomarkers of early and late remissions in WP02 Task 1 and WP04 Tasks 1 & 2, respectively. To date, no 
such biomarkers have been reliably identified in either WP. In a revised approach, the intention is now to 
undertake collaboration across WP02, WP03 and WP04 and to explore response versus non-response to 
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specific medications or classes of medication, with analyses adjusted according to whether response is early 
(first drug) or late (second or subsequent drugs). This will essentially achieve the same result but using a 
different approach. To this end, we have undertaken an initial GWAS of the patient cohort described above 
for Task 1 analyses but restricted to those individuals whose first well-tolerated AED was a drug targeting 
voltage-gated sodium channels as its primary mechanism of action. This group includes several first-line 
AEDs, including carbamazepine, lamotrigine, phenytoin and oxcarbazepine. This sub-population was then 
interrogated using a binary GWAS method comparing genotypes between individuals who experienced a 
remission from seizures on a sodium channel blocker as their first well-tolerated AED compared to those 
who failed to experience a remission despite adequate drug exposure. The key findings from this initial Task 
2 analysis are reported under ‘significant results’ below and are described in more detail in the 
corresponding deliverable (D2.6), which is submitted in (partial) fulfilment of this task. Additional analyses to 
further explore general versus selective drug responsiveness will continue in conjunction with WP03 and 
WP04 during the first half of 2016. 
 
Task 3: Identifying genomic biomarkers of first drug failure 
The patient cohort for this analysis is essentially identical to that for Task 1. As described above, all 
genotypes and phenotypes had been assembled by end of 2014 and subsequent quality control checks 
were implemented in early 2015. Cases were again lost due to missing phenotype and/or insufficient 
genotype data. For this analysis, the final GWAS drew on a population of individuals with newly-diagnosed 
epilepsy who had been followed-up prospectively at a single epilepsy centre from initial diagnosis and 
treatment initiation and until such time as their first ever AED failed. Failure was defined as withdrawal of the 
first drug and/or addition of a second drug. Patients who did not experience drug failure were censored at 
the time of last recorded clinical visit (n=437). Patients who experienced failure of the first drug were 
stratified into those failing due to unacceptable adverse events (UAE; n=340) and those failing due to 
inadequate seizure control (ISC; n=276). This population was then interrogated a novel two-way competing 
risks GWAS approach, which was developed specifically for EpiPGX. The original intention of using three-
way statistical methodology was later revised for several reasons; insurmountable difficulties in data 
handling within the statistical model, artificial distinction in sub-groups of UAE (i.e. on- and off-target adverse 
events), and a lower than anticipated number of available cases (there was an unexpectedly large group of 
patients for whom the reason for first drug failure was recorded as “unknown”). The key findings from the 
Task 3 analysis are reported under ‘significant results’ below and are described in more detail, together with 
further information on the statistical model, in the corresponding deliverable (joint report for D2.4 and D2.5). 
This task is now completed. 
 
Milestones and deliverables for WP02 
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The following milestones and deliverables were outstanding at the time of the previous periodic report (Dec 
2014). 
Type No. Title Due 
date 
Status 
Milestone M24 Association analysis for first well 
tolerated AED 
Feb 
2015* 
Milestone 
reached 
Milestone M25 Development of three-way 
competing risks approach for 
analysis of drug failure 
Jan 
2015 
Milestone 
reached 
Milestone M26 Association analysis for first drug 
failure 
Apr 
2015 
Milestone 
reached 
Milestone M27 Development of prediction models 
for response to specific AEDs 
Apr 
2015 
Milestone not 
reached 
(expected in first 
half of 2016) 
Deliverable D2.3 Validated genome-based 
biomarkers [of remission with first 
AED] 
Feb 
2015* 
Delivered 
Deliverable D2.4 List of discovery genome-based 
biomarkers of first drug failure 
Apr 
2015* 
Delivered (joint 
report for D2.4 
and D2.5) 
Deliverable D2.5 List of validated genome-based 
biomarkers of first drug failure 
Oct 
2015 
Delivered (joint 
report for D2.4 
and D2.5) 
Deliverable D2.6 List of validated genome-based 
biomarkers of general 
responsiveness to AEDs 
Oct 
2015 
Partially 
delivered (interim 
report available) 
*Original date revised as described in second periodic report (Dec 2014) 
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Significant results 
Clinical and demographic predictors of treatment outcome in newly diagnosed epilepsy 
A total of 1,906 newly-diagnosed epilepsy patients were identified in the EpiPGX eCRF as eligible for 
inclusion in WP02. Of those, key phenotype information was missing in 183 (9.6%), leaving 1,723 individuals 
in the logistic regression analysis of non-genetic influences on treatment outcome. Of those, 43.4% came 
from the SANAD trial (UK), 24.0% from the Western Infirmary, Glasgow, 13.5% from Tübingen, and 9.3% 
from Melbourne. Other centres contributed less than 5% of cases. Males comprised 51.5% of the cohort, 
mean age at diagnosis was 35.6 years and mean duration of follow-up was 5.1 years. Over 70% of the study 
population had focal epilepsy. Remission was achieved with the first well-tolerated AED in 56.2% of cases. 
Statistically significant positive predictors of remission included generalised epilepsy (OR=1.94, 
95%CI=1.39-2.73) and older age at diagnosis (OR=1.02, 95%CI=1.01-1.03). Negative predictors of 
remission included abnormal neurological exam (OR=0.44, 95%CI=0.29-0.67), high pre-treatment seizure 
count (OR=0.56, 95%CI=0.38-0.84), and abnormal focal MRI (OR=0.56, 95%CI=0.39-0.81). Other 
predictors included duration of follow-up (OR=1.05, 95%CI=1.02-1.09) and source cohort (figure 1).  
The data are entirely consistent with pre-existing knowledge on treatment outcomes in newly diagnosed 
epilepsy. This gives confidence that the EpiPGX cohort is representative of new-onset epilepsy. In addition, 
this analysis has identified several key covariates that need to be adjusted for in subsequent GWAS 
analyses. 
Genomic biomarkers of remission with the first well-tolerated antiepileptic drug in newly-diagnosed epilepsy 
The first ever AED to which a patient with newly-diagnosed epilepsy is exposed is often discontinued due to 
Figure 1: Forest plot (including 
odds ratios and 95% confidence 
intervals) for association between 
source cohort and duration of 
clinical follow-up and the likelihood 
of remission with first well-
tolerated antiepileptic drug in 
newly-diagnosed epilepsy. Baseline 
comparator for cohort analysis was 
SANAD trial (UK). 
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adverse effects before a satisfactory evaluation of its efficacy can be made. As a result, we chose to explore 
the first well-tolerated AED which is the same as the first ever AED in most patients but can be the second 
or even third medication to which a patient is exposed in cases where tolerability is an initial problem. 
Treatment outcome on the first well-tolerated AED was stratified into immediate remission (12 months 
seizure freedom commencing within the first 2 months since diagnosis), deferred remission (12 months 
seizure freedom commencing at some point beyond 2 months from diagnosis) and no remission (no 12 
month period of seizure period at any point during exposure to the first well tolerated drug). We used binary 
(comparison of remission vs no remission), multinomial (3-way comparison) and survival (time to achieve 
remission) analyses to interrogate the data. An example of the output from this analysis is shown below 
(figure 2 and table 1). Full results are provided in accompanying deliverable D2.3. 
Table 1: Top 5 loci for binary GWAS of deferred vs no remission (unadjusted for clinical covariates) 
SNP Imp Gene Chr Pos (bp) 
Test 
allele 
Ref 
allele 
MAF P-value Adj P-value 
rs72996844 yes CNTN5 11 99916286 C T 0.06 4.56E-08 4.78E-08 
rs12791153 yes - 11 80685181 T A 0.08 1.16E-07 1.21E-07 
rs770584 yes CNTN5 11 99902569 G A 0.06 2.98E-07 3.10E-07 
rs6715132 yes - 2 208141163 C G 0.26 4.19E-07 4.36E-07 
rs11603610 yes - 11 80668994 G T 0.08 4.40E-07 4.58E-07 
 
In this analysis, a single SNP (rs72996844) on chr11 and located in the CNTN5 gene, which encodes 
contactin-5 was marginally genome-wide significant in a binary analysis of patients with deferred vs no 
remission but only when clinical covariates were excluded from the analysis. This SNP is of potential 
biological significance, having been reported to harbour de novo epilepsy-causing mutations in a recent 
exome-sequencing analysis by the Epi4K group. Other than this single SNP in CNTN5, none of the other 
binary, multinomial or survival analyses undertaken as part of WP02 Task 1 revealed any association that 
achieved genome-wide significance. This would suggest that there are no strong genomic influences on 
response to treatment with the first well-tolerated AED in newly-diagnosed epilepsy.  
 
Genomic biomarkers distinguishing general and selective drug responsiveness in newly-diagnosed epilepsy 
This analysis represent the first step in an attempt to distinguish between patients are who are essentially 
responsive to whatever AED they first receive and those who require a very specific drug or drug from a 
specific class in order to control their seizures. In this case, we chose to focus on patients who received a 
sodium channel blocking AED (i.e. carbamazepine, lamotrigine, phenytoin, oxcarbazepine) as their first well-
tolerated drug. Treatment outcome was stratified into remission (12 months seizure freedom occurring at 
any point during follow-up) and no remission (no 12 month period of seizure period at any point during 
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exposure to the first well tolerated drug) and we used a binary GWAS to interrogate the data. An example of 
the output from this analysis is shown below (figure 3 and table 2). Full results are provided in 
accompanying deliverable D2.6. 
 
 
Table 2: Top 5 loci for binary GWAS of remission vs no remission in patients treated with sodium channel blocking AEDs 
SNP Imp Gene Chr Pos (bp) 
Test 
allele 
Ref allele MAF P-value Adj P-value 
rs1967394 yes - 7 149681561 G C 0.06 4.08E-08 - 
rs7235163 no DLGAP1 18 3725553 G A 0.46 4.99E-07 - 
chr12:130642445:D yes 
FZD10-
AS1 
12 130642445 ATAC - 0.13 8.76E-07 - 
rs144402785 yes - 21 46245856 T A 0.10 1.28E-06 - 
rs883987 yes CNKSR3 6 154781155 G C 0.35 4.35E-06 - 
 
In this analysis, a single SNP (rs1967394) on chr7 was marginally genome-wide significant in a binary 
analysis of remission vs no remission in patients treated with sodium channel blocking AEDs. This SNP is 
located in an intergenic region, with no clear association with any particular gene. The analysis reported 
above was not adjusted for clinical and demographic factors known to influence treatment outcome, 
however this SNP remained significant (albeit not genome-wide) when the analysis was adjusted for such 
covariates. This lends weight to the role of rs1967394 in treatment response with sodium channel blocking 
agents. Further analysis is planned with these compounds, both individually and as a class of drugs, in 
conjunction with WP03 and WP04 as described above. 
 
Genomic biomarkers of first drug failure in newly-diagnosed epilepsy 
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The first ever AED to which people with newly-diagnosed epilepsy are exposed typically fails in up to 70% of 
cases. As discussed above, there are two key reasons for that failure – inadequate seizure control (ISC) or 
unacceptable adverse events (UAE). This analysis was undertaken to seek genomic biomarkers that might 
predict treatment failure and the reason for it. It required the development of a novel statistical methodology 
– two-way competing risks GWAS – which was then applied to a subset (n=799) of our newly-diagnosed 
epilepsy cohort who had a clear failure of their first ever AED recorded in the eCRF. Reason for first drug 
failure (ISC or UAE) was identified for all cases and a two-way competing risks GWAS used to interrogate 
the data. In this methodology, the hazard of failing from either cause is continually being calculated, which 
gives rise to two association plots and two sets of loci associated with outcome. A typical output from this 
analysis is shown below (figure 4 and tables 3 & 4). Full results are provided in corresponding deliverable 
(joint report for D2.4 and D2.5). 
 
 
 
Table 3: Top 5 loci for competing risks GWAS of first drug failure due to inadequate seizure control 
SNP Imp Gene Chr Pos (bp) Test allele Ref allele MAF P-value 
Adj P-
value 
rs6950012 yes GRM8 7 126668420 C T 0.23 2.20E-08 - 
rs9319547 yes - 16 80042084 T G 0.11 1.20E-06 - 
rs139820017 yes - 4 45027060 A/T - 0.19 1.20E-06 - 
rs12250166 yes SLK 10 105776055 T C 0.07 1.40E-06 - 
rs1821692 yes - 4 29279092 A C 0.20 1.60E-06 - 
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Table 4: Top 5 loci for competing risks GWAS of first drug failure due to unacceptable adverse events 
SNP Imp Gene Chr Pos (bp) Test allele Ref allele MAF P-value 
Adj P-
value 
rs139118386 yes - 11 54767936 A T 0.23 2.20E-16 - 
rs138964936 yes - 2 131208125 T A 0.05 8.90E-16 - 
rs140792738 yes - 9 97079046 C G 0.11 1.60E-15 - 
rs6487118 yes - 12 8594235 A T 0.06 1.60E-13 - 
rs9469157 yes - 6 32545390 C G 0.05 1.80E-13 - 
 
In this analysis, several SNPs were seen to achieve genome-wide significance, most notably in the analysis 
of failure due to UAE. The reason for such a large number of statistically significant associations is unclear 
but may be related to the relatively modest numbers of cases in each failure group. In the analysis of failure 
due to ISC, the most significant locus corresponded to a region on chr7 within the GRM8 gene, which 
encodes a specific sub-type of metabotropic glutamate receptor with strong plausibility for involvement in 
epilepsy and response to AED therapy. In contrast, the most significant loci associated with failure due to 
UAE fell within intergenic regions on various chromosomes. There was no clear association with any gene 
and no functional conclusions can be drawn. Further exploration of the data is merited, particularly in light of 
the large number of genome-wide significant signals. Identification of further cases for this analysis, via re-
evaluation of phenotypes and the method of phenotype derivation, would add to the robustness of the 
findings and their reliability. 
 
 
